New peptides
Bispecific polypeptides targeting CD40 and CEA in tumors enhance immune activation and reduce tumor growth by selectively activating CD40-expressing cells in tumor tissues, addressing the limitations of current immunotherapies for CEA-expressing cancers.
Patent Information
- Application Number
- JP2024526901
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-02
- Filing Date
- 2022-11-04
- Publication Date
- 2024-11-19
AI Technical Summary
Current immunotherapies for cancers expressing carcinoembryonic antigen (CEA) are limited in efficacy and safety, with immunocytokines showing unimpressive clinical results and bispecific antibodies lacking targeted tumor localization.
Development of bispecific polypeptides, specifically designed to bind CD40 and CEA, which activate tumor-specific immune responses by targeting CD40-expressing cells in tumor tissues while minimizing systemic toxicity.
The bispecific polypeptides enhance tumor-specific immune activation, reducing tumor growth by preferentially activating CD40-expressing cells in tumor tissues, thereby improving cancer treatment efficacy and safety.
Smart Images

Figure 2024543043000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancer, particularly cancers that express carcinoembryonic antigen (CEA). [Background technology]
[0002] Cancer immunotherapy Cancer is the leading cause of premature death in developed countries. The goal of cancer immunotherapy is to mount an effective immune response against tumor cells. This can be achieved, for example, by breaking tolerance to tumor antigens, enhancing antitumor immune responses, and stimulating local cytokine responses at the tumor site. The main effector cells of long-lasting antitumor immune responses are activated tumor-specific effector T cells. A strong expansion of activated tumor-specific effector T cells can redirect the immune response against the tumor. In this context, various immunosuppressive mechanisms induced by the tumor microenvironment suppress the activity of effector T cells. Several immunosuppressive mediators are expressed by tumor cells. Such mediators inhibit T cell activation either directly or indirectly, for example, by inducing regulatory T cells (Treg) or myeloid-derived suppressor cells. Thus, depleting, inhibiting, reversing, or inactivating such regulatory cells can provide an antitumor effect and reverse the immunosuppression in the tumor microenvironment. Furthermore, incomplete activation of effector T cells, for example by dendritic cells (DCs), can result in suboptimally activated or quiescent T cells, leading to inefficient antitumor responses. In contrast, proper induction by DCs can result in a strong expansion of activated effector T cells, redirecting and enhancing immune responses against tumors. In addition, natural killer (NK) cells play an important role in tumor immunology by expressing downregulated human leukocyte antigens (HLA) to attack tumor cells and by inducing antibody-dependent cellular cytotoxicity (ADCC). Therefore, stimulating NK cells can also reduce tumor growth.
[0003] CD40 CD40, a 48 kDa transmembrane cell surface glycoprotein, is a costimulatory receptor that belongs to the tumor necrosis factor receptor (TNFR) superfamily (Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994; 12: 881-922; Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40 / CD40L engagement in the immune system. Immunol Rev. 2009 May; 229(1): 152-72). CD40 is expressed on a variety of cell types and can be detected on antigen-presenting cells (APCs), including dendritic cells (DCs), B cells, and macrophages. In addition, CD40 is expressed on granulocytes, endothelial cells, smooth muscle cells, fibroblasts, and epithelial cells (Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922; Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40 / CD40L engagement in the immune system. Immunol Rev. 2009 May;229(1):152-72; Korniluk A, Kemona H, Dymicka-Piekarska V. Multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol. 2014 Oct;35(10):9447-57; Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol. 2009 Oct;21(5):293-300.).Consistent with its widespread expression on normal cells, CD40 is also present on the membrane of a wide range of malignant cells, including non-Hodgkin's and Hodgkin's lymphomas, myelomas, and certain types of carcinomas, including those of the nasopharynx, bladder, cervix, kidney, and ovary (Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40 / CD40L engagement in the immune system. Immunol Rev. 2009 May;229(1):152-72.; Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004 Aug;4(4):360-7).
[0004] CD40 interacts with a single ligand, CD40L (CD154), a transmembrane protein expressed by activated T cells but also by B cells, platelets, mast cells, macrophages, basophils, natural killer (NK) cells, and non-hematopoietic cells (smooth muscle cells, endothelial cells, and epithelial cells) (Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40 / CD40L engagement in the immune system. Immunol Rev. 2009 May;229(1):152-72.; Korniluk A, Kemona H, Dymicka-Piekarska V. Multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol. 2014 Oct;35(10):9447-57). Binding of CD40 to CD40L as part of cell-cell interactions activates intracellular signaling pathways that involve a series of adaptor molecules known as TNFR activators (TRAFs). To initiate this intracellular signaling, multiple CD40 receptor trimers must form higher-order clusters on the cell membrane (Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol. 2009 Oct;21(5):293-300; Werneburg BG, Zoog SJ, Dang TT, et al. Molecular characterization of CD40 signaling intermediates. J Biol Chem. 2001 Nov 16;276(46):43334-42).CD40 clustering forms a signaling complex that allows multiple TRAFs to assemble, which in turn leads to the activation of downstream transcription factors including NFκB (Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40 / CD40L engagement in the immune system. Immunol Rev. 2009 May;229(1):152-72; Kornbluth RS, Stempniak M, Stone GW. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. Int Rev Immunol. 2012 Aug;31(4):279-88).
[0005] The molecular outcome of CD40 signaling depends on the cell type expressing CD40 and their microenvironment (Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013 Mar 01; 19(5): 1035-43). "Licensing" of APCs, especially DCs, leads to upregulation of membrane costimulatory molecules and MHC, and the production of proinflammatory cytokines (Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994 Oct 1; 180(4): 1263-72; van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997 Jun; 9(3): 330-7). Thus, CD40 is involved in the functional maturation of APCs and, consequently, the activation of antigen-specific T cells (Ma DY, Clark EA. The role of CD40 and CD154 / CD40L in dendritic cells. Semin Immunol. 2009 Oct;21(5):265-72; Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol. 2013 Apr;25(2):230-7).CD40 also plays a role in humoral immunity by activating resting B cells and increasing their antigen-presenting function (Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013 Mar 01;19(5):1035-43; Zarnegar B, He JQ, Oganesyan G, et al. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci US A. 2004 May 25;101(21):8108-13). Furthermore, CD40 is involved in the induction of innate immunity through stimulation of cells such as macrophages, granulocytes, and NK cells (Rakhmilevich AL, Alderson KL, Sondel PM. T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol. 2012 Aug;31(4):267-78).
[0006] Monoclonal CD40 agonist antibodies are thought to exert antitumor effects through two distinct mechanisms: (i) tumor-specific immune activation and (ii) direct tumoricidal effects, e.g., via apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and / or complement-dependent cytotoxicity (CDC) (Khong A, Nelson DJ, Nowak AK, et al. The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol. 2012 Aug;31(4):246-66). Treatment with CD40 agonists induces the activation of several different immune cells that contribute to the antitumor immune response.T cells, especially cytotoxic T lymphocytes (CTLs), are essential for the antitumor effects induced by CD40 agonists, as demonstrated in a range of preclinical models (Byrne KT, Vonderheide RH.CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Cell Rep.2016 Jun 21;15(12):2719-32, Mangsbo SM, Broos S, Fletcher E,et al.The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.Clin Cancer Res.2015 Mar 01;21(5):1115-26, Tutt AL, O'Brien L, Hussain A,et al.T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody.The Journal of Immunology.2002;168(6):2720-2728, van Mierlo GJ, den Boer AT, Medema JP, et al.CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.Proc Natl Acad Sci US A.2002 Apr 16;99(8):5561-6).Activation of DCs and subsequent priming of T cells may play a central role as the presence of antigen-cross-presenting DCs is required for the antitumor efficacy of CD40 agonist therapy in T cell-dependent models (Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011 Mar 25; 331(6024): 1612-6; Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017 Feb; 17(2): 175-186; Long KB, Gladney WL, Tooker GM, et al. IFNgamma and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma.Cancer Discov.2016 Apr;6(4):400-413, Lum HD, Buhtoiarov IN, Schmidt BE, et al.In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.J Leukoc Biol.2006 Jun;79(6):1181-92).NK cells are also capable of cytotoxic killing of tumor cells and have been shown to contribute to the reduction in tumor growth in response to CD40 agonists (Turner JG, Rakhmilevich AL, Burdelya L, et al. Anti-CD40 Antibody Induces Antitumor and Antimetastatic Effects: The Role of NK Cells. The Journal of Immunology. 2001;166(1):89). B cells activated via CD40 can further add to the antitumor immune response by presenting antigens to T cells and producing tumor-targeting antibodies (Jackaman C, Cornwall S, Graham PT, et al. CD40-activated B cells contribute to mesothelioma tumor regression. Immunol Cell Biol. 2011 Feb;89(2):255-67; Liu M, Sun Q, Wang J, et al. A New Perspective: Exploring Future Therapeutic Strategies For Cancer By Understanding The Dual Role Of B Lymphocytes In Tumor Immunity. Int J Cancer. 2018 Sep 5).In addition, CD40 agonists have been found to convert tumor-associated macrophages (TAMs) into activated macrophages with anti-tumor properties that can promote tumor regression independent of T cells (Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011 Mar 25; 331(6024): 1612-6; Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017 Feb; 17(2): 175-186; Long KB, Gladney WL, Tooker GM, et al. IFNgamma and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma.Cancer Discov.2016 Apr;6(4):400-413, Lum HD, Buhtoiarov IN, Schmidt BE, et al.In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.J Leukoc Biol.2006 Jun;79(6):1181-92).
[0007] DCs are the most important APCs for the generation of antigen-specific T cell responses (Flamar AL, Xue Y, Zurawski SM, et al. Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+and CD8+T cells. AIDS. 2013 Aug 24; 27(13): 2041-51). Their central role in inducing antitumor immune responses has been shown in preclinical models lacking Batf3 and therefore cross-presenting DCs (cDC1s), which show impaired rejection of immunogenic tumors and do not respond to immunotherapy due to impaired priming of tumor-targeting CTLs (Hildner K, Edelson BT, Purtha WE, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008 Nov 14;322(5904):1097-100, Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, et al. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discov. 2016 Jan;6(1):71-9).According to these data, the presence of cross-presenting DCs in human tumors correlates with infiltration of CD8+ T cells and is associated with a better prognosis as well as superior response to immunotherapy (Broz ML, Binnewies M, Boldajipour B, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014 Nov 10; 26(5):638-52; Sanchez-Paulete AR, Teijeira A, Cueto FJ, et al. Antigen Cross-Presentation and T-Cell Cross-Priming In Cancer Immunology And Immunotherapy. Ann Oncol. 2017 Sep 01). Signaling through CD40 on DCs induces activation of the antigen-presenting machinery and upregulation of costimulatory molecules such as CD80 and CD86, thereby improving the ability of DCs to present antigen to and activate T cells (Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017 Feb;17(2):175-186; Gladue RP, Paradis T, Cole SH, et al. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother. 2011 Jul;60(7):1009-17) and produce cytokines, notably IL-12, that help shape T cell responses.
[0008] CD40 expression can be detected on all blood DCs, with the highest expression found in a subpopulation called cDC1 (Carenza C, Calcaterra F, Oriolo F, et al. Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells [Original Research]. Frontiers in Immunology. 2019 2019-June-11; 10(1325); MacDonald KP, Munster DJ, Clark GJ, et al. Characterization of human blood dendritic cell subsets. Blood. 2002 Dec 15; 100(13):4512-20). Recent studies have focused on the role of cDC1s in driving T cell responses against tumors, demonstrating the potential of CD40 agonists alone or in combination with other therapies in enhancing cDC1 priming of tumor-targeted T cells (Hegde S, Krisnawan VE, Herzog BH, et al. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Cancer Cell. 2020 Mar 16;37(3):289-307 e9, Morrison AH, Diamond MS, Hay CA, et al. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proc Natl Acad Sci US A. 2020 Mar 25, Zhang L, Li Z, Skrzypczynska KM, et al. Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer.Cell.2020;181(2):442-459.e29).Single-cell RNA sequencing studies confirm the presence of cDC1s with the potential to respond to CD40 agonists in primary tumor tissues (Chevrier S, Levine JH, Zanotelli VRT, et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 2017;169(4):736-749.e18; Zhang L, Li Z, Skrzypczynska KM, et al. Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer. Cell. 2020;181(2):442-459.e29; Zhang Q, He Y, Luo N, et al. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell. 2019;179(4):829-845.e20). Thus, targeting CD40 on DCs has the potential to expand the tumor-specific T cell pool, potentially representing a modality to treat immunologically "cold" tumors.
[0009] Carcinoembryonic antigen (CEA) Carcinoembryonic antigen (CEA) describes a family of highly related glycoproteins, some of which are cell surface-anchored glycosylphosphatidylinositol (GPI), involved in cellular functions such as cell adhesion, phagocytosis, proliferation, and signal transduction. CEA is generally characterized as a member of the CD66 family of molecules (with CEA including examples of CD66a, CD66b, CD66c, CD66d, CD66e, and CD66f molecules). Currently, 29 CEA family genes have been identified, which are commonly referred to as carcinoembryonic antigen-related cell adhesion molecules (CEACAMs). Examples of CEACAM genes are CEACAM1, CEACAM3, CEACAM4, CEACAM5, CEACAM6, CEACAM7, CEACAM8, CEACAM16, CEACAM18, CEACAM19, CEACAM20, and CEACAM21.
[0010] CEA (especially CEACAM5) is normally produced during fetal development and is present only at very low levels in the blood of healthy human adults.However, the level of CEA found in cancer increases, and in this context, it is characterized as a tumor-associated antigen (TAA).CEA is associated with many types of cancer and tumors, including gastric cancer, pancreatic cancer, lung cancer, breast cancer, and medullary thyroid cancer. Particularly associated with cancer and tumors are CEACAM1, CEACAM6, CEACAM7, and CEACAM5 (Zi-Wen Han, Zhi-Wu Lyv, Bin Cui, et al. The old CEACAMs find their new role in tumor immunotherapy. Invest New Drugs volume. 2020 38:1888-1898; Chaogu Zheng, Jing Feng1, Di Lu1, et al. A Novel Anti-CEACAM5 Monoclonal Antibody, CC4, Suppresses Colorectal Tumor Growth and Enhances NK Cells-Mediated Tumor Immunity. PLoS One. 2011;6(6):e21146).
[0011] Despite advances in the development of immunotherapies for the treatment of various cancers over the past decade, there remains a need for new effective agents to treat cancer, particularly those that express CEA.
[0012] Thus, the present invention seeks to provide improved polypeptide-based therapies for the treatment of cancer, particularly those cancers that express CEA. Summary of the Invention
[0013] In a first aspect, the present invention provides a bispecific polypeptide comprising a first binding domain, designated B1, capable of specifically binding to CD40, and a second binding domain, designated B2, capable of specifically binding to CEA.
[0014] Such bispecific compounds can be used to establish highly effective and safe cancer immunotherapy.
[0015] Various types of tumor-localized immunotherapeutic molecules, such as immunocytokines and bispecific antibodies, have shown beneficial immune activation and inhibition of tumor growth in preclinical trials as well as in the clinic (reviewed in Kiefer and Neri, 2016).
[0016] Clinical progress with immunocytokines has not been impressive so far, and side effects remain because tumor-binding entities only confer limited tumor localization, while most immunocytokines end up in other compartments. Bispecific antibodies that restrict their activity to tumors as described in the present invention would offer distinct advantages over immunocytokines, since they are inactive in the absence of cancer and / or tumors, especially those expressing CEA.
[0017] The design of molecular formats of CD40 agonists can be optimized to avoid affecting parts of the immune system that are not relevant to inducing tumor immunity, to avoid systemic toxicity caused by CD40 activators, and to obtain high efficacy in the tumor area. For example, a good efficacy / safety profile can be obtained with CD40-CEA bispecific antibody, which requires cross-linking by binding to CEA for CD40 activation to occur. Thus, CD40-expressing cells, such as dendritic cells, present in tumor tissues are preferentially activated, while CD40-expressing cells in other tissues, where CEA expression is low or absent, are not activated. This will allow for focused activation of CD40-expressing cells specifically in tumor tissues, while limiting the toxicity induced by general CD40 activation.
[0018] Structure of bispecific polypeptides "Polypeptide" is used herein in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or other peptidomimetics. Thus, the term "polypeptide" includes short peptide sequences, as well as longer polypeptides and proteins. As used herein, the term "amino acid" refers to any natural and / or unnatural or synthetic amino acid, including both D or L optical isomers, and amino acid analogs and peptidomimetics.
[0019] The term "bispecific" as used herein means that a polypeptide is capable of specifically binding to at least two target entities. Thus, bispecific as used herein can describe a polypeptide that is capable of specifically binding to more than two target entities, such as at least three, at least four, or at least five target entities. In a preferred embodiment, the bispecific polypeptide is capable of specifically binding to two target entities.
[0020] Thus, the first and / or second binding domain may be selected from the group consisting of antibodies and antigen-binding fragments thereof, and CD40 ligand.
[0021] "Antibody or antigen-binding fragment thereof" includes not only substantially intact antibody molecules, but also chimeric antibodies, humanized antibodies, isolated human antibodies, single chain antibodies, bispecific antibodies, antibody heavy chains, antibody light chains, homodimers and heterodimers of antibody heavy and / or light chains, and antigen-binding fragments and derivatives thereof. Suitable antigen-binding fragments and derivatives include Fv fragments (e.g., single chain Fvs and disulfide-linked Fvs), Fab-like fragments (e.g., Fab fragments, Fab' fragments and F(ab)2 fragments), single variable domains (e.g., VH and VL domains), and single domain antibodies (dAbs, including single and double formats [i.e., dAb-linker-dAbs], and nanobodies). The potential advantages of using antibody fragments rather than whole antibodies are several fold. The smaller size of the fragments may result in improved pharmacological properties, such as better penetration of solid tissue. Furthermore, antigen-binding fragments, such as Fab, Fv, ScFv and dAb antibody fragments, can be expressed in and secreted from E. coli, thus allowing the facile production of large amounts of the fragments.
[0022] In a preferred embodiment, the polypeptide is a bispecific antibody (numerous examples of which are described in detail below).
[0023] In one embodiment, the antigen-binding fragment is an Fv fragment (such as a single chain Fv fragment or a disulfide-linked Fv fragment), a Fab-like fragment (such as a Fab fragment, a Fab' fragment, or a F(ab) 2 fragments thereof), and single domain antibodies.
[0024] The term "antibody or antigen-binding fragment thereof" is also intended to encompass antibody mimetics (e.g., non-antibody scaffold structures that allow for the introduction of variability at specific positions while retaining high stability). Those skilled in the art of biochemistry will be familiar with many such molecules, such as those discussed in Gebauer & Skerra, 2009, the disclosure of which is incorporated herein by reference. Exemplary antibody mimetics include affibodies (also called trinectins, Nygren, 2008, FEBS J, 275, 2668-2676), CTLDs (also called tetranectins, Innovations Pharmac. Technol. (2006), 27-30), adnectins (also called monobodies, Meth. Mol. Biol., 352 (2007), 95-109), anticalins (Drug Discovery Today (2005), 10, 23-33), DARPins (ankyrins; Nat. Biotechnol. (2004), 22, 575-582), avimers (Nat. Biotechnol. (2005), 23, 1556-1561), microbodies (FEBS J, (2007), 274, 86-95), peptide aptamers (Expert. Opin. Biol. Ther. (2005), 5, 783-797); Kunitz domains (J. Pharmacol. Exp. Ther. (2006) 318, 803-809), affilins (Trends. Biotechnol. (2005), 23, 514-522), and affimers (Avacta Life Sciences, Wetherby, UK).
[0025] Also included within the scope of the present invention are chimeric T cell receptors (also known as chimeric immune receptors and chimeric antigen receptors or CARs) (see Pule et al., 2003, the disclosure of which is incorporated herein by reference). These are engineered receptors that graft any specificity onto immune effector cells. Typically, CARs are used to graft the specificity of a monoclonal antibody onto T cells, and the grafting of their coding sequence is facilitated by a retroviral vector. The most common form of such molecules is a fusion that contains a single chain variable fragment (scFv) from a monoclonal antibody fused to the transmembrane and endodomains of CD3-zeta. Upon expressing this fusion molecule, T cells recognize and kill target cells expressing the specificity of the transferred monoclonal antibody.
[0026] Those skilled in the art will further appreciate that the present invention also encompasses modified versions of antibodies and antigen-binding fragments thereof, whether existing now or in the future, which are modified, for example, by the covalent attachment of polyethylene glycol or other suitable polymers (see below).
[0027] Methods for producing antibodies and antibody fragments are well known in the art. For example, antibodies may be produced through any one of several methods using inducing in vivo production of antibody molecules, screening immunoglobulin libraries (Orlandi et al., 1989; Winter et al., 1991, the disclosures of which are incorporated herein by reference), or producing monoclonal antibody molecules by cell lines in culture. These include, but are not limited to, hybridoma techniques, human B-cell hybridoma techniques, and Epstein-Barr Virus (EBV)-hybridoma techniques (Kohler et al., 1975; Kozbor et al., 1985; Cote et al., 1983; Cole et al., 1984, the disclosures of which are incorporated herein by reference).
[0028] Suitable methods for the production of monoclonal antibodies are also disclosed in "Monoclonal Antibodies: A manual of techniques", H Zola (CRC Press, 1988, the disclosure of which is incorporated herein by reference) and "Monoclonal Hybridoma Antibodies: Techniques and Applications", JGR Hurrell (CRC Press, 1982, the disclosure of which is incorporated herein by reference).
[0029] Similarly, antibody fragments can be obtained using methods well known in the art (e.g., Harlow & Lane, 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory, New York, the disclosure of which is incorporated herein by reference). For example, antibody fragments according to the invention can be prepared by proteolytic hydrolysis of the antibody or by expression of DNA encoding the fragment in E. coli or mammalian cells (e.g., Chinese hamster ovary cell culture or other protein expression systems). Alternatively, antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods.
[0030] Those skilled in the art will understand that for human therapy or diagnosis, human or humanized antibodies are preferably used. Humanized forms of non-human (e.g., murine) antibodies are genetically engineered chimeric antibodies or antibody fragments, preferably with minimal portions derived from the non-human antibody. Humanized antibodies include antibodies in which the complementarity determining regions of a human antibody (recipient antibody) are replaced with residues from the complementarity determining regions of a non-human species (donor antibody) such as mouse, rat, or rabbit that have the desired function. In some cases, Fv framework residues of a human antibody are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues that are found neither in the recipient antibody nor in the imported complementarity determining regions or framework sequences. In general, humanized antibodies comprise substantially all of at least one, and typically two, variable domains, with all or substantially all of the complementarity determining regions corresponding to those of a non-human antibody and all or substantially all of the framework regions corresponding to those of the relevant human consensus sequence. A humanized antibody optimally will comprise at least a portion of an antibody constant region, such as an Fc region, typically from a human antibody (see, e.g., Jones et al., 1986; Riechmann et al., 1988; Presta, 1992, the disclosures of which are incorporated herein by reference).
[0031] Methods for humanizing non-human antibodies are well known in the art. In general, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as imported residues and are usually taken from an imported variable domain. Humanization can be performed essentially as described by substituting human complementarity determining regions with corresponding rodent complementarity determining regions (see, e.g., Jones et al., 1986; Reichmann et al., 1988; Verhoeyen et al., 1988; US 4,816,567, the disclosures of which are incorporated herein by reference). Thus, such humanized antibodies are chimeric antibodies in which substantially less than an intact human variable domain has been replaced by the corresponding sequence from a non-human species. In practice, humanized antibodies will typically be human antibodies in which some complementarity determining region residues, and possibly some framework residues, are replaced by residues from analogous sites in rodent antibodies.
[0032] Human antibodies can also be identified using a variety of techniques known in the art, including phage display libraries (see, e.g., Hoogenboom & Winter, 1991; Marks et al., 1991; Cole et al., 1985; Boerner et al., 1991, the disclosures of which are incorporated herein by reference).
[0033] It will be appreciated by those skilled in the art that the bispecific polypeptides, eg, antibodies, of the present invention may be in any suitable structural format.
[0034] Thus, in an exemplary embodiment of the bispecific antibody of the invention: (a) binding domain B1 and / or binding domain B2 are (or together form) an intact IgG antibody, (b) binding domain B1 and / or binding domain B2 are Fv fragments (e.g., scFv); (c) binding domain B1 and / or binding domain B2 are Fab fragments, and / or (d) binding domain B1 and / or binding domain B2 are single domain antibodies (e.g. domain antibodies and nanobodies).
[0035] It will be appreciated by those skilled in the art that the bispecific antibody may comprise a human Fc region, or a variant of said region, wherein the region is an IgG1 region, an IgG2 region, an IgG3 region, or an IgG4 region, preferably an IgG1 region or an IgG4 region.
[0036] Engineering the Fc region of therapeutic monoclonal antibodies or Fc fusion proteins allows for the generation of molecules that are better suited for their required pharmacological activity (Strohl, 2009, the disclosure of which is incorporated herein by reference).
[0037] "CD40 ligand" includes non-antibody molecules capable of binding to CD40, such as CD40L (CD154, e.g., GenBank: D31797.2), or fragments or variants of CD40L that retain their ability to bind to CD40.
[0038] (a) Engineered Fc region for increased half-life One approach to improving the efficacy of therapeutic antibodies is to increase their serum persistence, thereby allowing higher circulating levels, less frequent administration, and smaller doses.
[0039] The half-life of IgG depends on its pH-dependent binding to the neonatal receptor FcRn, which is expressed on the surface of endothelial cells and binds IgG in a pH-dependent manner, protecting it from degradation.
[0040] Some antibodies that selectively bind to FcRn at pH 6.0 but not at pH 7.4 exhibit higher (i.e., longer) half-lives in various animal models. In addition, some antibodies that bind to FcRn with higher affinity at pH 6.0 but remain with lower affinity at pH 7.4 exhibit longer half-lives.
[0041] Several mutations located at the interface between the CH2 and CH3 domains, such as T250Q / M428L (Hinton et al., 2004, the disclosure of which is incorporated herein by reference) and M252Y / S254T / T256E+H433K / N434F (Vaccaro et al., 2005, the disclosure of which is incorporated herein by reference), have been shown to increase the binding affinity to FcRn and the half-life of IgG1 in vivo.
[0042] (b) Engineered Fc regions for altered effector functions To ensure lack of CD40 activation in the absence of CEA, the Fc portion of the bispecific antibody should not bind FcγR or should bind with very low affinity, since FcγR-mediated cross-linking of CD40 antibodies may induce activation. "Very low affinity" includes that the Fc portion exhibits at least a 10-fold reduced affinity for FcγRI, FcγRII, and III compared to wild-type IgG1, as determined by the concentration at which half-maximal binding is achieved by flow cytometric analysis of FcγR-expressing cells (Hezareh et al., 2001) or FcγR ELISA (Shields et al., 2001).
[0043] Another factor to consider is that FcγR engagement can also induce antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) of antibody-coated cells. In one embodiment, the isotype of the CD40-CEA bispecific antibody should preferably be silent in order to enhance tumor-dependent CD40 activation and to avoid depletion of CD40-expressing cells.
[0044] The four human IgG isotypes bind with different affinities to activating Fcγ receptors (FcγRI, FcγRIIa, FcγRIIIa), inhibitory FcγRIIb receptors, and the first component of complement (C1q), resulting in very different effector functions (Bruhns et al., 2009, the disclosure of which is incorporated herein by reference). IgG1 molecules have the highest affinity and capacity to induce effector functions, while IgG2, IgG3, and IgG4 are less effective (Bruhns, 2012, Hogarth and Pietersz, 2012, Stewart et al., 2014) (Wang et al. 2015, Vidarson et al. 2014). In addition, certain mutations within the Fc region of IgG1 dramatically reduce FcγR affinity and effector function while retaining neonatal FcR (FcRn) interactions (Ju and Jung, 2014; Leabman et al., 2013; Oganesyan et al., 2008; Sazinsky et al., 2008).
[0045] The most widely used IgG1 mutants are mutations at positions L234 and L235, including N297A alone or in combination with D265A, and the so-called "LALA" double mutant L234A / L235A. Another position described to further silence IgG1 by mutation is P329 (see US2012 / 0251531).
[0046] Therefore, selecting a mutated IgG1 format with reduced effector function but retaining binding to FcRn may result in a bispecific antibody with CEA-dependent activation of CD40, exhibiting a favorable efficacy / safety profile and good PK properties.
[0047] Advantageously, the polypeptide is incapable of inducing antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and / or complement-dependent cytotoxicity (CDC). "Incapable" includes that the ability of the polypeptide to induce ADCC or the like is at least 10-fold reduced compared to wild-type IgG1, for example as shown by monocyte-dependent ADCC or CDC assays as reported by Hezareh et al. 2001.
[0048] In one embodiment, the Fc region comprises the following amino acids at the following positions: It may be a variant of the human IgG1 Fc region comprising a mutation at one or more of L234, L235, P239, D265, N297, and / or P329.
[0049] Advantageously, an alanine may be present at the mutated position(s).
[0050] Optionally, the IgG1 variant may be a variant of the human IgG1 Fc region comprising the mutations L234A and L235A (i.e. the LALA double mutant, see SEQ ID NO: 336).
[0051] Those skilled in the art will appreciate that the bispecific polypeptides of the present invention may be of a number of different structural formats (see, e.g., Chan & Carter, 2016, the disclosure of which is incorporated herein by reference).
[0052] In an exemplary embodiment, the bispecific antibody comprises: (a) bivalent bispecific antibodies, such as IgG-scFv bispecific antibodies (e.g. B1 is an intact IgG and B2 is an scFv linked to B1 at the N-terminus of the light chain and / or the C-terminus of the light chain and / or the N-terminus of the heavy chain and / or the C-terminus of the heavy chain of IgG, or vice versa); (b) monovalent bispecific antibodies such as DuoBody® (Genmab AS, Copenhagen, Denmark) or “knob-in-hole” bispecific antibodies (e.g., scFv-KIH, scFv-KIHr , BiTE-KIH or BiTE-KIH r (See Xu et al., 2015, mAbs 7(1):231-242) (c)scFv 2 -Fc bispecific antibodies (such as the ADAPTIR™ bispecific antibodies from Aptevo Therapeutics); (d) BiTE / scFv 2 bispecific antibodies, (e) DVD-Ig bispecific antibody, (f) DART-based bispecific antibodies (e.g., DART 2 -Fc or DART), (g)DNL-Fab 3 Bispecific antibodies, and (h) scFv-HSA-scFv bispecific antibody.
[0053] For example, the bispecific antibody may be an IgG-scFv antibody. The IgG-scFv antibody may be in either a VH-VL or VL-VH orientation. In one embodiment, the scFv may be stabilized by a SS bridge between the VH and VL.
[0054] In one embodiment, binding domain B1 and binding domain B2 are directly fused to each other.
[0055] In an alternative embodiment, binding domain B1 and binding domain B2 are linked via a polypeptide linker. For example, the polypeptide linker can be a short linker peptide of between about 10 and about 25 amino acids. The linker is usually rich in glycine for flexibility and serine or threonine for solubility and can connect the N-terminus of VH with the C-terminus of VL, or vice versa.
[0056] Thus, the linker may be selected from the group consisting of the amino acid sequences SGGGGSGGGGS (SEQ ID NO: 337), SGGGGSGGGGSAP (SEQ ID NO: 338), NFSQP (SEQ ID NO: 339), KRTVA (SEQ ID NO: 340), GGGSGGGG (SEQ ID NO: 341), GGGGSGGGGS (SEQ ID NO: 342), GGGSGGGGSGGGGGS (SEQ ID NO: 343), GSTSGSGKPGSGEGSTKG (SEQ ID NO: 344), THTCPPCPEPKSSDK (SEQ ID NO: 345), GGGS (SEQ ID NO: 346), EAAKEAAKGGGGS (SEQ ID NO: 347), EAAKEAAK (SEQ ID NO: 348), or (SG)m (wherein m = 1 to 7).
[0057] In preferred embodiments, the linker may be selected from the group consisting of SEQ ID NO: 341, SEQ ID NO: 342, and SEQ ID NO: 343. In particularly preferred embodiments, the linker is GGGGSGGGSGGGGS (SEQ ID NO: 343).
[0058] As used herein, the term "amino acid" includes the standard 20 genetically encoded amino acids and their corresponding "D" (as compared to the naturally occurring "L") stereoisomers, omega-amino acids, other naturally occurring amino acids, non-conventional amino acids (e.g., α,α-disubstituted amino acids, N-alkyl amino acids, etc.), and chemically derived amino acids (see below).
[0059] When an amino acid is specifically recited, such as "alanine," "Ala," "A," the term refers to both L-alanine and D-alanine unless expressly stated otherwise. Other non-conventional amino acids may also be suitable components for the polypeptides of the invention, so long as the desired functional property is retained by the polypeptide. For the peptides shown, where appropriate, each encoded amino acid residue is represented by a single letter designation that corresponds to the common name of the conventional amino acid.
[0060] In one embodiment, the polypeptides defined herein comprise or consist of L-amino acids.
[0061] It will be understood by those skilled in the art that the polypeptides of the present invention may comprise, or consist of, one or more amino acids which have been modified or derivatized.
[0062] Chemical derivatives of one or more amino acids can be achieved by reaction with a functional side group. Such derivatized molecules include, for example, molecules in which free amino groups are derivatized to form amine hydrochlorides, p-toluenesulfonyl groups, carboxybenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups, or formyl groups. Free carboxyl groups can be derivatized to form salts, methyl and ethyl esters, or other types of esters and hydrazides. Free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives. Chemical derivatives also include peptides that contain naturally occurring amino acid derivatives of the 20 standard amino acids. For example, 4-hydroxyproline can be replaced with proline, 5-hydroxylysine can be replaced with lysine, 3-methylhistidine can be replaced with histidine, homoserine can be replaced with serine, and ornithine can be replaced with lysine. Derivatives also include peptides that contain one or more additions or deletions, so long as the required activity is maintained. Other modifications included are amidation, amino terminal acylation (eg, acetylation or thioglycolic acid amidation), terminal carboxylamidation (eg, with ammonia or methylamine), and similar terminal modifications.
[0063] It will further be appreciated by those skilled in the art that peptidomimetic compounds may also be useful. The term "peptidomimetic" refers to a compound that mimics the conformation and desirable characteristics of a particular peptide as a therapeutic agent.
[0064] For example, the polypeptide includes not only molecules in which the amino acid residues are linked by peptide (-CO-NH-) bonds, but also molecules in which the peptide bonds are reversed. Such retro-inverso peptidomimetics can be made using methods known in the art, such as those described in Meziere et al. (1997), which is incorporated herein by reference. This approach involves making pseudopeptides that contain changes involving the backbone, but not the orientation of the side chains. Retro-inverso peptides that contain NH-CO bonds instead of CO-NH peptide bonds are much more resistant to proteolysis. Alternatively, the polypeptide can be made in which one or more of the amino acid residues are linked by -y(CH) bonds instead of the traditional amide bonds. 2 The compound may be a peptidomimetic compound linked by an N-H)- bond.
[0065] In a further alternative, the peptide bonds may be fully distributed, provided that appropriate linker moieties are used which preserve the spacing between the carbon atoms of the amino acid residues, and it may be advantageous for the linker moiety to have substantially the same charge distribution and substantially the same planarity as the peptide bonds.
[0066] It will also be appreciated that the polypeptide may be conveniently blocked at its N-terminus or C-terminus to serve to reduce susceptibility to exoproteolytic digestion.
[0067] A variety of non-encoded or modified amino acids, such as D-amino acids and N-methyl amino acids, have also been used to modify mammalian peptides. In addition, the predicted bioactive conformation can be stabilized by covalent modifications such as cyclization or by the incorporation of lactam or other types of bridges, see, e.g., Veber et al., 1978 and Thursell et al., 1983, which are incorporated herein by reference.
[0068] In one embodiment of the invention, one of binding domain B1 or binding domain B2 is an immunoglobulin molecule and one of binding domain B1 or binding domain B2 is a Fab fragment, which is fused via the light chain of the Fab fragment to the C-terminus of the heavy chain of the immunoglobulin.
[0069] For example, the polypeptide may have a format as shown in Figure 23. Such a format is referred to as the "RUBY™ format" (described in pending UK Patent Application No. 1820556.7 and PCT Application No. WO2020 / 127354). Antibodies in the "RUBY™ format" and "optimized RUBY™ format" described herein are particularly preferred for the bispecific polypeptides of the invention.
[0070] The bispecific polypeptide may contain one or more mutations to promote association of an immunoglobulin heavy chain polypeptide with an immunoglobulin light chain polypeptide and / or promote association of a Fab heavy chain polypeptide with a Fab light chain polypeptide.
[0071] In one embodiment, the one or more mutations prevent the formation of aggregates and Fab by-products.
[0072] It will be appreciated by those skilled in the art that in one embodiment, the mutations may prevent the formation of aggregates and / or Fab by-products by creating steric hindrance and / or charge incompatibility.
[0073] "Steric hindrance" refers to the retardation of reaction due to steric bulk, i.e., the size of the amino acid molecules, which prevents association of two protein surfaces that might otherwise occur when smaller amino acids are present.
[0074] "Incompatibility between charges" means that the charges are incompatible and prevent the product from being formed and not forming unwanted products, for example, the presence of two negatively charged moieties may repel and prevent the formation of unwanted products.
[0075] As discussed above, the mutations limit the formation of Fab by-products and / or aggregates, for example, by creating surfaces that limit the formation of aggregates or by-product Fab fragments. In one embodiment, the mutations prevent the formation of Fab by-products by creating steric hindrance and / or charge incompatibility (resulting in charge incompatibility of the incorrect chains). The mutations may also promote correct inter-chain (i.e., between a first heavy chain polypeptide and a first light chain polypeptide, and / or between a second heavy chain polypeptide and a second light chain polypeptide) interactions, for example, by creating salt or disulfide bridges.
[0076] Thus, the mutations may favor the formation of bispecific polypeptides.
[0077] In one embodiment, the percentage of aggregates formed during production is 25% or less. Optionally, the percentage of aggregates is 20%, 17.5%, 15%, 13.5%, or 10% or less. Preferably, the percentage of aggregates is less than 10%. Optionally, these measurements are performed when the chains of the bispecific polypeptide are transfected in equal ratios, for example, a 1:1:1 ratio when three chains are used during production.
[0078] Alternatively, the strand transfection ratio can be optimized. Optionally, the % of aggregates when the strand transfection ratio is optimized can be 3.5%, 3%, 2.5%, or 2% or less.
[0079] In one embodiment, the bispecific polypeptide comprises one or more pairs of mutations, each of which comprises two functionally compatible mutations.
[0080] By "functionally compatible mutations" is meant that the mutations have complementary functions, for example, one mutation of a pair (in one strand) can be a mutation that forms a positively charged region, and the other mutation (in the other strand) forms a negatively charged region. Together, these mutations act in a functionally compatible manner to promote association of the respective strands.
[0081] In one embodiment, the bispecific polypeptide comprises the following groups of regions: (a) the CH1 and Ckappa or Clamda regions of an immunoglobulin, and / or (b) the CH1 and Ckappa or Clamda regions of a Fab, and / or (c) the VL and VH regions of an immunoglobulin, and / or (d) one or more of the VL and VH regions of the Fab, comprising one or more pairs of mutations.
[0082] Thus, in one embodiment, the mutation pair is within the CH1 and Ckappa or Clamda regions of the Fab and / or immunoglobulin, and the mutation pair is (a) hollow and protruding surface variations (i.e., stereovariations), and / or (b) hydrophobic exchange mutations, and / or (c) charge mutations (i.e., salt mutations), and / or (d) a mutation that results in the formation of disulfide bridges.
[0083] The pair of mutations may alternatively or additionally be within the VH and VL regions of the Fab and / or immunoglobulin, and the pair of mutations within the VH and VL regions may be (a) charge mutations (i.e., salt mutations), and / or (b) a doubly charged mutation, and / or (c) a mutation that results in the formation of a disulfide bridge.
[0084] In one embodiment of the invention, the mutation is (a) one or more of the following positions in the CH1 domain: H168, F170, L145, S183, and T187 (according to the EU numbering system); and / or (b) at one or more of the following position ranges in the C kappa or C lambda domain: 132-138, 173-179, 130-136, 111-117, and 134-140 (according to the EU numbering system); and / or (c) a position selected from one or more of the following position ranges in the VL: 41-47, 117-123, and 46-52 (according to the IMGT numbering system); and / or (d) at a position selected from the group consisting of one or more of the following position ranges in VH: 41-47, 46-52, and 117-123 (according to the IMGT numbering system).
[0085] In one embodiment of the invention, the mutation is (a) one or more of the following positions in the CH1 domain: H168, F170, L145, S183, and T187 (according to the EU numbering system); and / or (b) at one or more of the following position ranges in a C kappa or C lambda domain: 132-138, 173-179, 130-136, 111-117, and 134-140 (according to the Kabat numbering system); and / or (c) a position selected from one or more of the following position ranges in the VL: 41-47, 117-123, and 46-52 (according to the IMGT numbering system); and / or (d) at a position selected from the group consisting of one or more of the following position ranges in VH: 41-47, 46-52, and 117-123 (according to the IMGT numbering system).
[0086] In one embodiment of the invention, the mutation is (a) one or more of the following positions in the CH1 domain: H168, F170, L145, S183, and T187 (according to the EU numbering system); and / or (b) at one or more of the following position ranges in the C kappa or C lambda domain: 132-138, 173-179, 130-136, 111-117, and 134-140 (according to the EU numbering system); and / or (c) a position selected from one or more of the following position ranges in the VL: 41-47, 117-123, and 46-52 (according to the IMGT numbering system); and / or (d) at a position selected from the group consisting of one or more of the following position ranges in VH: 41-47, 46-52, and 117-123 (according to the IMGT numbering system).
[0087] One mutation in each of the ranges shown above is a relevant functional mutation since it is a position that will contact amino acids in the corresponding domain / chain and thus the relevant interface between the chains.
[0088] Thus, it will be understood by one of skill in the art that mutations in the position ranges indicated above are preferred as the relevant functional characteristic is whether the position contacts the corresponding position on the other chain, i.e. the relevant position is a position in the VH chain that contacts a corresponding position in the VL chain, or a position in Clamda that contacts a position in the CH1 chain.
[0089] In one embodiment, the mutation is [Table 1]
[0090] The use of " / " in the context of discussing mutations is to illustrate possible alternative amino acids, for example, "X44R / E / D / K" indicates that R or E or D or K can be included at position 44 as an alternative to amino acid "X".
[0091] In one embodiment, the mutation is [Table 2]
[0092] In one embodiment of the invention, the mutation is (a) one or more of the following positions in the CH1 domain: H168, F170, L145, S183, and T187 (according to the EU numbering system); and / or (b) one or more of the following positions in the C kappa domain: L135, S176, V133, S114, and N137 (according to the EU numbering system), and / or one or more of the following positions in the C lambda domain: L135, S176, V133, T114, and S137 (according to the EU numbering system), and / or (c) one or more of the following positions in the VL: Q44, Q120, and A49 (according to the IMGT numbering system); and / or (d) at one or more of the following positions in VH: Q44, G49, and Q120 (according to the IMGT numbering system).
[0093] In one embodiment of the invention, the mutation is (a) one or more of the following positions in the CH1 domain: H168, F170, L145, S183, and T187 (according to the EU numbering system); and / or (b) one or more of the following positions in the C kappa domain: L135, S176, V133, S114, and N137 (according to the Kabat numbering system), and / or one or more of the following positions in the C lambda domain: L135, S176, V133, T114, and S137 (according to the Kabat numbering system), and / or (c) one or more of the following positions in the VL: Q44, Q120, and A49 (according to the IMGT numbering system); and / or (d) at one or more of the following positions in VH: Q44, G49, and Q120 (according to the IMGT numbering system).
[0094] For example, the mutation (a) one or more of the following mutations in the CH1 domain: H168A, F170G, L145Q, S183V, and T187E (according to the EU numbering system); and / or (b) one or more of the following mutations in the C kappa domain: L135Y, S176W, V133T, S176V, S114A, and N137K (according to the EU numbering system), and / or one or more of the following mutations in the C lambda domain: L135Y, S176W, V133T, S176V, T114A, and S137K (according to the EU numbering system), and / or (c) one or more of the following mutations in the VL: Q44R, Q44E, Q120C, Q44D, and A49D (according to the IMGT numbering system); and / or (d) one or more of the following mutations in VH: Q44E, Q44R, G49C, Q44K, and Q120K (according to the IMGT numbering system).
[0095] For example, the mutation (a) one or more of the following mutations in the CH1 domain: H168A, F170G, L145Q, S183V, and T187E (according to the EU numbering system); and / or (b) one or more of the following mutations in the C kappa domain: L135Y, S176W, V133T, S176V, S114A, and N137K (according to the Kabat numbering system), and / or one or more of the following mutations in the C lambda domain: L135Y, S176W, V133T, S176V, T114A, and S137K (according to the Kabat numbering system), and / or (c) one or more of the following mutations in the VL: Q44R, Q44E, Q120C, Q44D, and A49D (according to the IMGT numbering system); and / or (d) one or more of the following mutations in VH: Q44E, Q44R, G49C, Q44K, and Q120K (according to the IMGT numbering system).
[0096] The above mutations are in the "RUBY™ format."
[0097] In a further embodiment, the polypeptide may have the format shown in FIG. 23 with further optimized mutations, referred to as the "optimized RUBY™ format."
[0098] While bispecific polypeptides in the "RUBY™ format" can be reproducibly produced with excellent levels of purity, bispecific polypeptides in the "Optimized RUBY™ format" can be reproducibly produced with even higher levels of purity. Furthermore, bispecific polypeptides in the "Optimized RUBY™ format" have been engineered to have a reduced risk of eliciting an immunogenic response directed against the bispecific polypeptide itself.
[0099] The optimized mutations are described below as "optimized mutation set 1" and "optimized mutation set 2" - including "set 2a" and / or "set 2b". It will be appreciated by those skilled in the art that various combinations of these optimized mutations can be used in the bispecific polypeptides of the invention as well as in combination with any of the "RUBY™ format" mutations described above. Combinations of "RUBY™ format" mutations and "optimized RUBY™ format" mutations used in the same bispecific antibody are described below. It will also be understood that variations of these mutations described herein also function as part of the present invention. All mutations in the variable domain (VH or VL) are numbered according to the IMGT numbering system and all mutations in the constant domain are numbered according to the EU numbering system.
[0100] Mutation Set 1 - Mutations in the variable domain heavy (VH): T65E, T65A, T65I.
[0101] Mutation Set 2 - Any individual and / or any combination of the mutations listed in Set 2a and Set 2b. Mutations in Set 2a-CH1: Y180A, Y180G, Y180I, Y180N, Y180S, Y180T, Y180V, or Y180W, and / or S183N or S183T, and / or V188G, preferably Y180T. Set 2b-C Mutations in the kappa domain: A111R, A111T, A111W, or A111V, and / or T109P, preferably T109P and / or A111V, and / or mutations in the variable domain light (VL): I126A, I126G, I126H, I126N, I126P, I126Q, I126S, or I126T.
[0102] In one embodiment of the invention, the mutation is (a) position T65 in VH (according to the IMGT numbering system), and / or (b) one or more of the following positions in CH1: Y180, S183, and V188, preferably Y180 (according to the EU numbering system); and / or (c) one or more of the following positions in the C kappa domain: A111 and T109 (according to the EU or Kabat numbering system); and / or (d) position I126 in the VL (according to the IMGT numbering system).
[0103] In a particular embodiment, the mutation is at position T65 in the variable domain heavy (VH) (according to the IMGT numbering system).
[0104] In certain embodiments, the mutation is at one or more of the following positions in CH1: Y180, S183, and V188, preferably Y180 (according to the EU numbering system).
[0105] In certain embodiments, the mutations are at one or more of the following positions in the C kappa domain: A111 and T109 (according to the EU numbering system), and / or at position I126 in the VL (according to the IMGT numbering system).
[0106] In one embodiment of the invention, the mutation is (a) X65E / A / I (according to the IMGT numbering system) in VH, and / or (b) one or more of the following mutations in CH1: X180A / G / I / N / S / T / V / W, X183N / T, and X188G, preferably X180T (according to the EU numbering system); and / or (c) one or more of the following mutations in the C kappa domain: X111R / T / W / V, and X109P, preferably X111V and X109P (according to the EU or Kabat numbering system); and / or (d) X126A / G / H / N / P / Q / S / T in VL (according to the IMGT numbering system). *X stands for any amino acid
[0107] In a particular embodiment, the mutation is X65E / A / I (according to the IMGT numbering system) in VH. *X stands for any amino acid
[0108] In certain embodiments, the mutations are one or more of the following mutations in CH1: X180A / G / I / N / S / T / V / W, X183N / T, and X188G, preferably X180T (according to the EU numbering system). *X stands for any amino acid
[0109] In certain embodiments, the mutations are one or more of the following mutations in the C kappa domain: X111R / T / W / V, and X109P, preferably X111V and X109P (according to the EU or Kabat numbering system), and / or the mutations are X126A / G / H / N / P / Q / S / T in the VL (according to the IMGT numbering system). *X stands for any amino acid
[0110] For example, the mutation (a) one or more of the following mutations in VH: T65E, T65A, and T65I (according to the IMGT numbering system); and / or (b) one or more of the following mutations in CH1: Y180A, Y180G, Y180I, Y180N, Y180S, Y180T, Y180V, Y180W, S183N, S183T, V188G, preferably Y180T (according to the EU numbering system); and / or (c) one or more of the following mutations in the C kappa domain: A111R, A111T, A111W, A111V, and T109P, preferably T109P and A111V (according to the EU or Kabat numbering system); and / or (d) one or more of the following mutations in the VL: I126A, I126G, I126H, I126N, I126P, I126Q, I126S, and I126T (according to the IMGT numbering system).
[0111] In particular examples, the mutations are one or more of the following mutations in VH: T65E, T65A, and T65I (according to the IMGT numbering system).
[0112] In particular examples, the mutation is one or more of the following mutations in CH1: Y180A, Y180G, Y180I, Y180N, Y180S, Y180T, Y180V, Y180W, S183N, S183T, V188G, preferably Y180T (according to the EU numbering system).
[0113] In particular examples, the mutations are one or more of the following mutations in the C kappa domain: A111R, A111T, A111W, A111V, and T109P, preferably T109P and A111V (according to the EU or Kabat numbering system), and / or one or more of the following mutations in the VL: I126A, I126G, I126H, I126N, I126P, I126Q, I126S, and I126T (according to the IMGT numbering system).
[0114] As discussed above, any combination of "RUBY™ format" mutations and "optimized RUBY™ format" mutations can be used in the same bispecific polypeptide, such as any one or more of the following "RUBY™ format" mutations, or variations described herein, in (a)-(d), combined with any one or more of the following "optimized RUBY™ format" mutations, or variations described herein, in (e)-(g): (a) one or more of the following mutations in the CH1 domain: H168A, F170G, and / or T187E (according to the EU numbering system); (b) one or more of the following mutations in the C kappa domain: L135Y, S176W, S114A, and / or N137K (according to the EU or Kabat numbering system), and / or the following mutations in the C lambda domain: L135Y, S176W, T114A, and / or S137K (according to the Kabat numbering system); (c) mutation in VL: Q44R or Q44E (according to the IMGT numbering system), and (d) mutation in VH: Q44E or Q44R (according to the IMGT numbering system); (e) a mutation in VH: T65E, T65A, or T65I (according to the IMGT numbering system); (f) a mutation in CH1: Y180T (according to the EU numbering system); and / or (g) Mutations in C kappa: T109P and / or A111V (according to the EU or Kabat numbering system).
[0115] Thus, in certain embodiments, a bispecific antibody with combined "RUBY™ format" and "optimized RUBY™ format" mutations comprises the following mutations: one or more of the following mutations in the CH1 domain: H168A, F170G, Y180T, and / or T187E (according to the EU numbering system); one or more of the following mutations in the C kappa domain: T109P, A111V, L135Y, S176W, S114A, and / or N137K (according to the EU or Kabat numbering system), and / or one or more of the following mutations in the C lambda domain: L135Y, S176W, T114A, and / or S137K (according to the Kabat numbering system); Mutations in the VL: Q44R or Q44E (according to the IMGT numbering system), and / or It may include one or more of the following mutations in VH: Q44E or Q44R, and / or T65E, T65A, or T65I (according to the IMGT numbering system).
[0116] In one embodiment, one or more Fab fragments are linked to the C-terminus of the immunoglobulin via a linker.
[0117] In one embodiment of the first aspect of the invention, the bispecific polypeptide is tetravalent and capable of bivalent binding to each of two antigens.
[0118] In one embodiment, the bispecific polypeptide comprises an immunoglobulin arranged as an antibody with two arms, thus two binding sites for a first antigen, and two of the Fab fragments, each providing a binding site for a second antigen. Thus, there are two binding sites for the first antigen and two binding sites for the second antigen. The bispecific polypeptide of this embodiment may comprise three polypeptide chains: (1) a chain H1 comprising the heavy chain of IgG, a linker, and a light chain of Fab, (2) a chain L1 which is the light chain of IgG, and (3) a chain H2 which is the heavy chain of the attached (combined) Fab. In a preferred embodiment, the bispecific polypeptide may comprise six polypeptide chains: (a) two chains H1 comprising the heavy chain of IgG, a linker, and a light chain of Fab, (b) two chains L1 which are the light chain of IgG, and (c) two chains H2 which are the heavy chain of the attached (combined) Fab. This structure can be used for both "RUBY™ format" and "optimized RUBY™ format" antibodies.
[0119] In one embodiment, binding domain B1 is an immunoglobulin and binding domain B2 is a Fab. In an alternative embodiment, binding domain B1 is a Fab and binding domain B2 is an immunoglobulin.
[0120] In one embodiment, the bispecific polypeptide is capable of modulating and / or activating the activity of target immune system cells, said modulation being an increase or decrease in the activity of said cells. Such cells include T cells, dendritic cells, and natural killer cells.
[0121] In another embodiment, the bispecific polypeptide may modulate the activity and / or activate myeloid cells, such as macrophages, monocytes, and myeloid-derived suppressor cells.
[0122] Monocytes and macrophages also express CD40 and can promote immune responses against tumors. Indeed, it has been shown that the murine anti-CD40 surrogate antibody FGK45 can mediate antitumor activity involving macrophages, independent of T cell and NK cell function (Lum HD, Buhtoiarov IN, Schmidt BE, et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol. 2006 Jun; 79(6): 1181-92). However, the effect of CD40 agonists on macrophages and other myeloid cell populations also leads to increased production of IFN-γ and CCL5, promoting improved influx of T cells into tumors (Huffman AP, Lin JH, Kim SI, et al. CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. JCI Insight. 2020 May 21; 5(10)).
[0123] Several studies have shown that CD40 agonist antibodies can convert TAMs into activated macrophages with an anti-tumor phenotype. FGK45 interacts with TAMs after in vivo treatment, leading to their increased expression of MHCII and CD86 (Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011 Mar 25;331(6024):1612-6). A similar effect was observed in the CD11b + F4 / 80 +It has been observed in macrophages, spleen (Luheshi NM, Coates-Ulrichsen J, Harper J, et al. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget. 2016 Apr 5; 7(14): 18508-20), and liver, and the treatment may lead to hepatotoxicity due to its strong effect on macrophages (Byrne KT, Vonderheide RH. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep. 2016 Jun 21; 15(12): 2719-32, Medina-Echeverz J, Ma C, Duffy AG, et al. Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.Cancer Immunol Res.2015 May;3(5):557-66).Interestingly, aged and obese mice have been shown to be more susceptible to systemic toxicity following immunotherapy such as anti-CD40, further demonstrating that macrophages are the primary cells responsible for these effects (Bouchlaka MN, Schisel GD, Chen M, et al. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med. 2013 Oct 21; 210(11): 2223-37; Mirsoian A, Bouchlaka MN, Schisel GD, et al. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J Exp Med. 2014 Nov 17; 211(12): 2373-83). Macrophage-mediated hepatotoxicity after anti-CD40 treatment was later shown to be mitigated by combination treatment with an anti-CSF-1R antibody, blocking CSF-1R signaling that supports monocyte and macrophage differentiation, proliferation, and function (Byrne KT, Vonderheide RH. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep. 2016 Jun 21; 15(12): 2719-32). Combination therapy with anti-CD40 and anti-CSF-1R is currently being explored in clinical trials (Machiels JP, Gomez-Roca C, Michot JM, et al. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. J Immunother Cancer. 2020 Oct; 8(2)).
[0124] The immune system cells (e.g., target immune cells) are typically dendritic cells. For example, the bispecific polypeptide may be capable of inducing activation of dendritic cells, which can then internalize tumor-associated debris or extracellular vesicles containing CEA and tumor neo-antigens.
[0125] For example, the polypeptide may be (a) tumor-specific immune activation, and / or (b) dendritic cell activation, and / or (c) internalization of associated tumor debris and / or extracellular vesicles containing CEA as well as tumor neoantigens; and / or (d) cross-presentation of peptides derived from internalized tumor antigens on MHC; and / or (e) priming and activation of effector T cells; and / or (f) may be capable of inducing a direct tumoricidal effect selected from the list consisting of apoptosis, necroptosis, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).
[0126] It will be understood by those skilled in the art that said activation of dendritic cells may be an increase in the expression of the costimulatory molecules CD40, CD80, or CD86, or increased IL-12 production. Alternatively, activation of dendritic cells may be determined by an increased ability to cross-present antigens, e.g., tumor neo-antigens, with MHC class I or II to T cells, resulting in enhanced activation of T cells that recognize the antigen by the antigen presenting cells.
[0127] In one embodiment, the bispecific antibody induces an increase in the uptake of tumor debris or tumor extracellular vesicles by antigen presenting cells, such as dendritic cells. It will be understood by those skilled in the art that said increase in uptake can be measured by co-localization or internalization of tumor debris or tumor extracellular vesicles by antigen presenting cells.
[0128] The increased uptake of tumor debris or tumor extracellular vesicles by antigen-presenting cells subsequently results in the effective presentation of neo-antigens contained within the tumor debris or tumor extracellular vesicles in the context of MHC molecules, which in turn results in a broader tumor-specific T cell repertoire and therefore more effective T cell-mediated tumor eradication. Methods for determining the expansion of tumor antigen-specific T cells are well known and include, for example, the use of MHC-peptide multimers, such as tetramers or pentamers. Such expansion can be measured by inoculating mice with tumors expressing specific tumor antigens or tumors transfected with tumor model antigens (e.g., ovalbumin), or alternatively, by inoculating mice with the same cells that have been heat-shocked to induce necrosis, followed by measuring the expansion of tumor antigen-specific T cells by the use of various MHC-tumor (model) antigen peptide tetramers or pentamers by flow cytometry-based methods. Alternatively, such expansion can be measured by culturing dendritic cells with antigen-specific TCR transgenic T cells labeled with a proliferation dye, or with tumor debris or tumor-derived extracellular vesicles derived from tumors transfected with a model antigen (e.g., ovalbumin). Antigen-specific T cell expansion can be assessed by analyzing the dilution of the proliferation dye using flow cytometry.
[0129] The polypeptide or binding domain of the present invention can also be characterized and defined by its binding ability.Standard assays for evaluating the binding ability of a ligand to a target are well known in the art, and include, for example, ELISA, Western blot, RIA, and flow cytometry analysis.The binding rate (e.g., binding affinity) of a polypeptide can also be evaluated by standard assays known in the art, for example, by surface plasmon resonance analysis or biolayer interferometry.
[0130] The terms "binding activity" and "binding affinity" are intended to refer to the tendency of a polypeptide molecule to bind or not bind to a target. Binding affinity is determined by the dissociation constant (K D) can be quantified by determining the lower K D indicates a higher affinity for the target. Similarly, the specificity of binding of a polypeptide to its target can be determined by the comparative dissociation constant (K D ) can be defined in terms of
[0131] The value of this dissociation constant can be determined directly by well-known methods and can also be calculated for complex mixtures by methods such as those described in Caceci et al., 1984, the disclosure of which is incorporated herein by reference. For example, K D can be established using a double filter nitrocellulose filter binding assay such as that disclosed by Wong & Lohman, 1993. Other standard assays for evaluating the binding ability of a ligand such as an antibody to a target are known in the art, including, for example, ELISA, Western blot, RIA, and flow cytometry analysis. The binding rate (e.g., binding affinity) of a polypeptide can also be evaluated by standard assays known in the art, such as by surface plasmon resonance analysis (e.g., by using the Biacore™ system analysis) or by biolayer interferometry (e.g., by using the Octet® system analysis).
[0132] Competitive binding assays can be performed in which binding of a polypeptide to a target is compared to binding of the target by another known ligand of that target, such as another polypeptide. The concentration at which 50% inhibition occurs is known as the Ki. Under ideal conditions, Ki is: D The Ki value is equivalent to K D Since the measured value of Ki is K D can be conveniently substituted to provide an upper limit for
[0133] Alternative measures of binding affinity include EC50 or IC50. In this context, EC50 refers to the concentration at which a polypeptide achieves 50% of the maximum binding to a fixed amount of target. IC50 refers to the concentration at which a polypeptide inhibits 50% of the maximum binding of a fixed amount of competitor to a fixed amount of target. In either case, a lower level of EC50 or IC50 indicates a higher affinity for the target. Both the EC50 and IC50 values of a ligand for its target can be determined by well-known methods, such as ELISA. Suitable assays for evaluating the EC50 and IC50 of a polypeptide are described in the Examples.
[0134] A polypeptide of the invention is preferably capable of binding to its target with an affinity that is at least 2-fold, 10-fold, 50-fold, 100-fold or more than its affinity to bind to another non-target molecule.
[0135] In one embodiment, the bispecific polypeptide comprises: (a) activation of B cells in the presence of CEA (preferably CEACAM5); and / or (b) activation of dendritic cells in the presence of CEA (preferably CEACAM5), and / or (c) allowing increased dendritic cell cross-presentation of neo-antigens; and / or (d) It is possible to induce the proliferation of neoantigen-specific T cells.
[0136] In one embodiment, the bispecific polypeptide promotes uptake of tumor-derived material derived from tumor cells that overexpress CEA (preferably CEACAM5). In a particular embodiment, the uptake of tumor-derived material is by antigen-presenting cells.
[0137] It will be appreciated by those skilled in the art that such activation of B cell activation can be characterized by CD86 upregulation, as well as optionally other markers of B cell activation.
[0138] CD40-binding domain The bispecific polypeptides of the invention comprise a binding domain (B1) capable of specifically binding to CD40. Preferably, B1 is an agonistic CD40 binding domain.
[0139] Binding domain B1 specifically binds to CD40, i.e. it binds to CD40 but does not bind or binds with lower affinity to other molecules. The term CD40 as used herein typically refers to human CD40. The sequence of human CD40 is shown in GenBank:X60592.1. Binding domain B1 may have some binding affinity to CD40 from other mammals, such as CD40 from non-human primates (e.g. Macaca fascicularis (cynomolgus monkey), Macaca mulatta). Binding domain B1 preferably does not bind to murine CD40 and / or does not bind to other human TNFR superfamily members, such as human CD137 or OX40.
[0140] Advantageously, the binding domain B1 binds to human CD40 at a concentration of 2×10 -7 Less than M or 1.5 x 10 -7 Less than M or 8.5 x 10 -8 Less than M or 8 x 10 -8 Less than M or 7.5 x 10 -8 Less than M or 7 x 10 -8 Less than M or 9 x 10 -8 Less than M or 9 x 10 -9 Less than M or 5 x 10 -10 Less than M or 3 x 10 -10 Less than M, preferably 8.5 x 10 -8 Less than M, more preferably 5×10 -10 Less than M or 3 x 10 -10 K under M D Preferably, K D is measured in Octet and is described, for example, in the Examples.
[0141] For example, binding domain B1 preferably does not bind to murine CD40 or any other TNFR superfamily members, such as CD137 or OX40. Thus, typically, the K D K for other non-target molecules such as mouse CD40, other TNFR superfamily members, or any other unrelated or associated material in the environment. D More preferably, it will be less than 2 times, preferably less than 5 times, more preferably less than 10 times. D will be less than 50-fold, even more preferably less than 100-fold, and even more preferably less than 200-fold.
[0142] Binding domain B1 is preferably capable of binding to its target with an affinity that is at least 2-fold, 10-fold, 50-fold, 100-fold or more than its affinity to bind to another non-target molecule.
[0143] In summary, the binding domain B1 therefore preferably exhibits the following functional characteristics: a) 2 × 10 -7 Less than M, more preferably 5×10 -10 K is less than M D Join by value, b) does not bind to murine CD40; c) does not bind to other human TNFR superfamily members, such as human CD137 or OX40.
[0144] In one embodiment, binding domain B1 comprises one or more light chain CDR sequences selected from those in Table C(2) and / or one or more heavy chain CDR sequences selected from Table C(1). Thus, binding domain B1 comprises: (a) CD40 heavy chain CDRs, SEQ ID NOs: 73-89, and / or (b) It may comprise one or more CDR sequences selected from the group consisting of CD40 light chain CDRs, SEQ ID NOs: 90 to 104.
[0145] In one embodiment, binding domain B1 comprises one, two or three light chain CDR sequences from a particular row in the individual antibody reference in Table C(2) and / or one, two or three heavy chain CDR sequences from the corresponding row for the antibody with the same reference in Table C(1). For example, binding domain B1 may comprise one or more of the light chain CDR sequences in 1132 (SEQ ID NOs: 90, 91, and 92) and one or more of the heavy chain CDR sequences in 1132 (SEQ ID NOs: 73, 74, and 75), or binding domain B1 may comprise one or more of the light chain CDR sequences in 1132 (SEQ ID NOs: 96, 97, and 98) and one or more of the heavy chain CDR sequences in 1132 (SEQ ID NOs: 81, 82, and 83). Most preferably, B1 comprises the CDRs and / or the VL and VH of 1132. Also most preferably, B1 comprises the CDRs and / or VL and VH of G12 or G12-mut.
[0146] The CDRs of G12-mut are shared by ffAC_05337. Thus, in a preferred embodiment, B1 comprises the CDRs of ffAC_05337 and is SEQ ID NOs: 81-83 and 96-98.
[0147] A preferred CD40 binding domain may comprise at least a heavy chain CDR3 as defined in any individual row of Table C(1), and / or a light chain CDR3 as defined in any individual row of Table C(2).
[0148] Thus, in one embodiment, binding domain B1 comprises all six CDR sequences in a given antibody (VH / VL) reference, for example binding domain B1 may comprise all six CDR sequences of antibody 1132 or all six CDR sequences of antibody G12 (also present in G12_mut and ffAC_05337).
[0149] In one embodiment, binding domain B1 comprises the VH and / or VL amino acid sequence shown in Table A. In one embodiment, binding domain B1 comprises the VH and VL amino acid sequence shown in Table A for a particular antibody reference. For example, binding domain B1 may comprise the VH sequence of 1132 (SEQ ID NO:3) and / or the VL sequence of 1132 (SEQ ID NO:1), or the VH sequence of G12 (SEQ ID NO:19) and / or the VL sequence of G12 (SEQ ID NO:17), the VH sequence of G12-mut (SEQ ID NO:29) and / or the VL sequence of G12_mut (SEQ ID NO:17), the VH sequence of ffAC_05337 (SEQ ID NO:431) and / or the VL sequence of ffAC_05337 (SEQ ID NO:430).
[0150] In a preferred embodiment, B1 comprises the VL and VH of ffAC_05337 and is SEQ ID NOs: 430 and 431.
[0151] In one embodiment, the CD40 binding domain of B1 is selected from 1132, 1150, 1140, 1107, G12, APX005, and 21.4.1. Preferably, the CD40 binding domain of B1 is G12 and / or 1132. Most preferably, the CD40 binding domain of B1 is G12. In an alternative most preferred embodiment, the CD40 binding domain of B1 is G12_mut.
[0152] Thus, the CDR or VH and VL sequences of binding domain B1 are (a) 1132 (heavy chain CDR: SEQ ID NOs: 73, 74, and 75, light chain CDR: SEQ ID NOs: 90, 91, and 92, VL: SEQ ID NO: 1, VH: SEQ ID NO: 3) (b) 1150 (heavy chain CDRs: SEQ ID NOs: 73, 76, and 77, light chain CDRs: SEQ ID NOs: 90, 91, and 93, VL: SEQ ID NO: 5, VH: SEQ ID NO: 7) (c) 1140 (heavy chain CDRs: SEQ ID NOs: 73, 78, and 79, light chain CDRs: SEQ ID NOs: 90, 91, and 94, VL: SEQ ID NO: 9, VH: SEQ ID NO: 11) (d) 1107 (heavy chain CDRs: SEQ ID NOs: 73, 78, and 80, light chain CDRs: SEQ ID NOs: 90, 91, and 95, VL: SEQ ID NO: 13, VH: SEQ ID NO: 15) (e) G12 (heavy chain CDRs: SEQ ID NOs: 81, 82, and 83, light chain CDRs: SEQ ID NOs: 96, 97, and 98, VL: SEQ ID NO: 17, VH: SEQ ID NO: 19) (f) APX005 (heavy chain CDRs: SEQ ID NOs: 84, 85, and 86, light chain CDRs: SEQ ID NOs: 99, 100, and 101, VL: SEQ ID NO: 21, VH: SEQ ID NO: 23) (g) 21.4.1 (heavy chain CDRs: SEQ ID NOs: 87, 88, and 89, light chain CDRs: SEQ ID NOs: 102, 103, and 104, VL: SEQ ID NO: 25, VH: SEQ ID NO: 27) (h) G12_mut (heavy chain CDRs: SEQ ID NOs: 81, 82, and 83, light chain CDRs: SEQ ID NOs: 96, 97, and 98, VL: SEQ ID NO: 17, VH: SEQ ID NO: 29) (i) ffAC_05337 (heavy chain CDRs: SEQ ID NOs: 81, 82, and 83; light chain CDRs: SEQ ID NOs: 96, 97, and 98; VL: SEQ ID NO: 431; VH: SEQ ID NO: 430).
[0153] The numbering of an antibody (e.g., antibody X / Y) defines the heavy chain variable region (X) and the light chain variable region (Y), respectively (or if a single number is given, only the heavy chain variable region [X] is defined). As mentioned above, the sequence may be one or more CDR sequences, or a VH sequence and / or a VL sequence. As mentioned above, the sequence of the bispecific polypeptide may include certain mutations.
[0154] In one embodiment, binding domain B1 is specific for CD40, typically human CD40, and independently comprises: (a) a heavy chain CDR1 sequence consisting of the sequence "G, F, T, F, S, S, Y, A"; (b) a heavy chain CDR2 sequence that is 8 amino acids in length and includes the consensus sequence: "I, G / S, S / G, Y / S, G / S, G / S, G / Y / S, T"; (c) a heavy chain CDR3 sequence having a length of 9 to 12 amino acids and including the consensus sequence of "A, R, Y / R / G, Y / P / V / -, N / S / V, F / Y / W, G / H / S, - / S, - / V, M / F, D, Y"; (d) a light chain CDR1 sequence consisting of the sequence: "Q, S, I, S, S, Y"; (e) a light chain CDR2 sequence consisting of the sequence: "A, A, S"; (f) a light chain CDR3 sequence that is 9 amino acids in length and includes the consensus sequence: "Q, Q, Y / S, G / Y, R / S / V, N / A / Y / T, P, P / F / Y, T".
[0155] The use of "," in the context of discussing amino acid sequences is to illustrate the list of amino acids when further nomenclature such as " / " is included, for example "G,F,T,F,S,S,Y,A" indicates that the sequence of amino acids is GFTFSSYA, and "A,R,Y / R / G" indicates that the sequence of amino acids may be ARY or ARR or ARG. The use of "-" in the context of discussing amino acid sequences is to illustrate that there may be no amino acid present at that respective position, for example "- / V,M / F,D" indicates that the sequence of amino acids may be VMD or VFD or MD or FD.
[0156] Binding domain B1 may comprise at least the heavy chain CDR3 defined in (c) and / or the light chain CDR3 defined in (f). Binding domain B1 may comprise all three heavy chain CDR sequences of (a), (b), and (c), and / or all three light chain CDR sequences of (d), (e), and (f).
[0157] Exemplary complete heavy and light chain variable region amino acid sequences for binding domain B1 are shown in Table A. Exemplary nucleic acid sequences encoding each amino acid sequence are also shown. The numbering of the VH and VL regions in Table A corresponds to the numbering system used in Tables C(1) and C(2). Thus, for example, the amino acid sequence "1132, light chain VL (also known as 1133)" is an example of a complete VL region sequence containing all three CDRs of VL number 1132 (1133) shown in Table C(2), and the amino acid sequence "1132, heavy chain VH" is an example of a complete VH region sequence containing all three CDRs of VH number 1132 shown in Table C(1).
[0158] In an exemplary embodiment, binding domain B1 comprises: (a) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 1132 / 1133 (SEQ ID NOs: 73, 74, and 75, and / or SEQ ID NOs: 90, 91, and 92); (b) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 1150 / 1151 (SEQ ID NOs: 73, 76, and 77, and / or SEQ ID NOs: 90, 91, and 93); (c) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 1140 / 1135 (SEQ ID NOs: 73, 78, and 79, and / or SEQ ID NOs: 90, 91, and 94); (d) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 1107 / 1108 (SEQ ID NOs: 73, 78, and 80, and / or SEQ ID NOs: 90, 91, and 95); (e) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody G12 or G12_mut or ffAC_05337 (SEQ ID NOs: 81, 82, 83, and / or SEQ ID NOs: 96, 97, and 98); (f) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody APX005 (SEQ ID NOs: 84, 85, and 86, and / or SEQ ID NOs: 99, 100, and 101); or (g) comprises the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 21.4.1 (SEQ ID NOs: 87, 88, and 89, and / or SEQ ID NOs: 102, 103, and 104).
[0159] Thus, binding domain B1 is (a) the heavy chain variable region and / or the light chain variable region of antibody 1132 / 1133 (SEQ ID NO: 3 and / or SEQ ID NO: 1); (b) the heavy chain variable region and / or the light chain variable region of antibody 1150 / 1151 (SEQ ID NO: 7 and / or SEQ ID NO: 5); (c) the heavy chain variable region and / or the light chain variable region of antibody 1140 / 1135 (SEQ ID NO: 11 and / or SEQ ID NO: 9); (d) the heavy chain variable region and / or the light chain variable region of antibody 1107 / 1108 (SEQ ID NO: 15 and / or SEQ ID NO: 13); (e) the heavy chain variable region and / or light chain variable region of antibody G12 (SEQ ID NO: 19 and / or SEQ ID NO: 17); (f) the heavy chain variable region and / or light chain variable region of antibody APX005 (SEQ ID NO:23 and / or SEQ ID NO:21); (g) the heavy chain variable region and / or light chain variable region of antibody 21.4.1 (SEQ ID NO:27 and / or SEQ ID NO:25); (h) the heavy chain variable region and / or the light chain variable region of antibody G12_mut (SEQ ID NO: 29 and / or SEQ ID NO: 17), or (h) may comprise the heavy chain variable region and / or light chain variable region of antibody ffAC_05337 (sequence number 431 and / or sequence number 430).
[0160] In an exemplary embodiment, binding domain B1 comprises: The heavy and light antibody chains comprising the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 1132 / 1133 (SEQ ID NOs: 73, 74, and 75, and / or SEQ ID NOs: 90, 91, and 92), or exemplary heavy and light chain variable regions (SEQ ID NO: 3 and SEQ ID NO: 1), or as detailed above.
[0161] In a further exemplary embodiment, binding domain B1 comprises: The heavy and light antibody chains comprising the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody G12 (SEQ ID NOs: 81, 82, and 83, and / or SEQ ID NOs: 96, 97, and 98), or exemplary heavy and light chain variable regions (SEQ ID NO: 19 and SEQ ID NO: 17), or the heavy and light antibody chains comprising said CDRs as detailed above.
[0162] In a further exemplary embodiment, binding domain B1 comprises: The three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody G12_mut (SEQ ID NO: 81, 82, and 83, and / or SEQ ID NO: 96, 97, and 98), or exemplary heavy and light chain variable regions (SEQ ID NO: 29 and SEQ ID NO: 17), or heavy and light antibody chains comprising said CDRs as detailed above.
[0163] In a further preferred exemplary embodiment, binding domain B1 comprises The three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody ffAC_05337 (SEQ ID NO: 81, 82, and 83, and / or SEQ ID NO: 96, 97, and 98), or exemplary heavy and light chain variable regions (SEQ ID NO: 431 and SEQ ID NO: 430), or the heavy and light antibody chains comprising said CDRs as detailed above.
[0164] The numbering of an antibody (e.g., antibody X / Y) defines the heavy chain variable region (X) and light chain variable region (Y), respectively (or, if a single number is given, only the heavy chain variable region [X] is defined).
[0165] It will be appreciated by those skilled in the art that the bispecific polypeptides of the invention may alternatively comprise variants of the variable regions defined above (or variants of the CDR sequences of the B1 and / or B2 binding domains).
[0166] A variant of any one of the heavy or light chain amino acid sequences or CDR sequences listed herein may be a substitution, deletion, or addition variant of the sequence. A variant may include 1, 2, 3, 4, 5, up to 10, up to 20, up to 30 or more amino acid substitutions and / or deletions from the sequence. "Deletion" variants may include deletion of individual amino acids, deletion of small groups of amino acids, such as 2, 3, 4, or 5 amino acids, or deletion of larger amino acid regions, such as deletion of a particular amino acid domain or other feature. "Substitution" variants preferably involve replacing one or more amino acids with the same number of amino acids, making conservative amino acid substitutions. For example, an amino acid may be replaced with an alternative amino acid with similar properties, such as another basic amino acid, another acidic amino acid, another neutral amino acid, another charged amino acid, another hydrophilic amino acid, another hydrophobic amino acid, another polar amino acid, another aromatic amino acid, or another aliphatic amino acid. Some properties of the 20 main amino acids that can be used to select suitable replacements are as follows: [Table 3]
[0167] Amino acids herein may be referred to by their full name, their three letter code, or their one letter code.
[0168] Preferred "derivatives" or "variants" include those in which an amino acid that appears in the sequence instead of a naturally occurring amino acid is a structural analog thereof. The amino acids used in the sequence may also be derivatized or modified, e.g., labeled, so long as the function of the polypeptide is not significantly adversely affected.
[0169] The above-mentioned derivatives and variants may be prepared during the synthesis of the antibody or by post-production modification, or if the polypeptide is in recombinant form, using known techniques of site-directed mutagenesis, random mutagenesis, or enzymatic cleavage and / or ligation of nucleic acids.
[0170] Preferably, the variants have an amino acid sequence that has more than 60%, or more than 70%, such as 75 or 80%, preferably more than 85%, such as more than 90 or 95% amino acid identity to the sequences shown in the sequences disclosed herein. This level of amino acid identity can be found over the entire length of the sequence of the relevant SEQ ID NO, or over a portion of the sequence, such as over 20, 30, 50, 75, 100, 150, 200 or more amino acids, depending on the size of the full length polypeptide.
[0171] "Sequence identity," in the context of amino acid sequences, refers to sequences having the recited values when assessed using ClustalW (Thompson et al., 1994, the disclosure of which is incorporated herein by reference) with the following parameters: Pairwise alignment parameters- Method: Exact, Matrix: PAM, Gap open penalty: 10.00, Gap extension penalty; 0.10.
[0172] Multiple alignment parameters - matrix: PAM, gap open penalty: 10.00, % identity for delay: 30, end gap penalty: on, gap separation distance: 0, negative matrix: none, gap extension penalty: 0.20, residue specific gap penalty: on, hydrophilic gap penalty: on, hydrophilic residues: GPSNDQEKR. Sequence identity at specific residues is intended to include identical residues that have only been derivatized.
[0173] In one embodiment, binding domain B1 comprises the light chain of antibody 1132 / 1133 (SEQ ID NO: 372 or 379) and / or the heavy chain of antibody 1132 / 1133 (SEQ ID NO: 371 or 378).
[0174] In one embodiment, binding domain B1 comprises the light chain of antibody G12 (SEQ ID NO: 381) and / or the heavy chain of antibody G12 (SEQ ID NO: 380).
[0175] In one embodiment, binding domain B1 comprises the light chain of antibody G12_mut (SEQ ID NO: 383) and / or the heavy chain of antibody G12_mut (SEQ ID NO: 382).
[0176] It will be understood by those skilled in the art that the mutations described herein for the RUBY™ format and / or optimized RUBY™ format can be applied to the above light and / or heavy chain sequences of G12 and / or G12_mut, and are included herein.
[0177] Thus, in one embodiment, binding domain B1 may comprise one or more variants of the light chain variable region and / or said heavy chain variable region (and / or light chain and / or said heavy chain) as defined above having at least 90% sequence identity thereto, or 95% sequence identity thereto, or 99% sequence identity thereto. Binding domain B1 may also comprise variants of the CDR sequences specified herein, e.g. variants in which 1, 2, 3, 4 or up to 5 amino acid residues have been substituted, deleted or added compared to the specified reference sequences.
[0178] For reference, the antibody references used in this application, possible alternative names for the same antibody / binding domain, and the targets of the antibody / binding domain are expanded in Table I below. [Table 4]
[0179] The "G12_mut" antibody largely corresponds to the sequence of "G12", but G12_mut contains three mutations in the VH framework. The CDR and VL sequences of G12_mut are the same as G12.
[0180] Thus, in a further independent aspect of the invention there is provided a polypeptide capable of specifically binding to CD40 comprising a heavy chain variable region comprising SEQ ID NO:29 and / or a light chain variable region comprising SEQ ID NO:17, preferably the polypeptide is monospecific, more preferably the polypeptide is an agonistic CD40 polypeptide, more preferably the light chain comprises SEQ ID NO:383 and / or the heavy chain comprises SEQ ID NO:382, more preferably the polypeptide is the antibody G12_mut.
[0181] Embodiments of other aspects of the invention (such as aspect 1 and / or aspect 2) may be incorporated into this aspect of the invention and are of a polypeptide capable of specifically binding to CD40 comprising a heavy chain variable region comprising SEQ ID NO:29 and / or a light chain variable region comprising SEQ ID NO:17.
[0182] Carcinoembryonic antigen (CEA) binding agents The bispecific polypeptide of the invention further comprises a binding domain (B2) capable of specifically binding to carcinoembryonic antigen (CEA).
[0183] Binding domain B2 specifically binds to CEA, i.e., it binds to CEA but does not bind or binds with lower affinity to other molecules. The term CEA as used herein typically refers to human CEA. Binding domain B2 may have some binding affinity to CEA from other mammals, such as CEA from non-human primates (e.g., Macaca fascicularis (cynomolgus monkey), Macaca mulatta). Binding domain B2 preferably does not bind to non-target molecules, such as CTLA-4-Fc and / or human ubiquitin.
[0184] In one embodiment, the CEA is tumor-associated CEA. "Tumor-associated CEA" includes CEA family members whose presence and / or overexpression correlates with the presence of cancer and / or tumor, e.g., CEA known or suspected to be overexpressed by cancer and / or tumor cells. CEA family members associated with tumors and / or cancers are known to those skilled in the art, e.g., CEACAM1, CEACAM6, CEACAM7, and / or CEACAM5.
[0185] In one embodiment, the CEA is a carcinoembryonic antigen-related cell adhesion molecule (CEACAM).
[0186] In one embodiment, the CEACAM is selected from the group consisting of CEACAM1 (such as GenBank: NG_029051.2), CEACAM3 (such as GenBank: D90278.1), CEACAM4 (such as GenBank: D90276.1), CEACAM5 (such as GenBank: M17303.1), CEACAM6 (such as GenBank: M29541.1), CEACAM7 (such as GenBank: L31792.1), CEACAM8 (such as GenBank: L31792.1), CEACAM9 (such as GenBank: L31792.1), CEACAM10 (such as GenBank: L31792.1), CEACAM11 (such as GenBank: L31792.1), CEACAM12 (such as GenBank: L31792.1), CEACAM13 (such as GenBank: L31792.1), CEACAM14 (such as GenBank: L31792.1), CEACAM15 (such as GenBank: L31792.1), CEACAM16 (such as GenBank: L31792.1), CEACAM17 (such as GenBank: L31792.1), CEACAM18 (such as GenBank: L31792.1), CEACAM19 (such as GenBank: L31792.1), CEACAM11 (such as GenBank: L31792.1), CEACAM12 (such as GenBank: L31792.1), CEACAM13 (such as GenBank: L31792.1), CEACAM14 (such as GenBank: L31792.1), CEACAM15 (such as GenBank: L31792.1), CEACAM16 (such as GenBank: L31792.1), CEACAM17 (such as GenBank: L31792.1), C enBank:X52378.1), CEACAM16 (GenBank:EU021223.1), CEACAM18 (GenBank:AC020914.9), CEACAM19 (GenBank:BC083499.1), CEACAM20 (GenBank:AY358129.1), and CEACAM21 (GenBank:BC106727.1). Reference to the foregoing CEACAM molecules will be understood to include splice variants.
[0187] Preferably, the CEACAM is one or more selected from the list consisting of CEACAM1, CEACAM5, and CEACAM6. Preferably, the CEACAM is CEACAM1. Most preferably, the CEACAM is CEACAM5.
[0188] In a preferred embodiment, B2 is capable of specifically binding to CEACAM5 but not to other CEACAMs, in particular CEACAM1.
[0189] In one embodiment, B2 is capable of specifically binding to CEA in a target cell. Preferably, the target cell is a cancer cell and / or a tumor cell.
[0190] Preferably, the CEA in the target cells is an intermediate level of CEA or a high level of CEA.
[0191] In one embodiment, an intermediate level of CEA expression is greater than or equal to about 10,000 CEA receptors per target cell, e.g., greater than or equal to about 11,000, greater than or equal to about 12,000, greater than or equal to about 13,000, greater than or equal to about 14,000, greater than or equal to about 15,000, greater than or equal to about 16,000, greater than or equal to about 17,000, greater than or equal to about 18,000, greater than or equal to about 19,000, greater than or equal to about 20,000, greater than or equal to about 21,000, or greater than or equal to about 22,000. The target cells are characterized as expressing 5,000 or more, about 30,000 or more, about 35,000 or more, about 40,000 or more, about 50,000 or more, about 60,000 or more, about 70,000 or more, about 80,000 or more, about 90,000 or more, about 100,000 or more, about 125,000 or more, about 150,000 or more, or about 175,000 or more CEA receptors. In another embodiment, the intermediate level of CEA expression is characterized by target cells expressing about 10,000 to about 200,000 CEA receptors per target cell, for example, about 20,000 to about 175,000 CEA receptors per target cell, or about 20,000 to about 200,000 CEA receptors per target cell, or about 50,000 to about 175,000 CEA receptors per target cell, or about 50,000 to about 200,000 CEA receptors per target cell. Preferably, the CEA receptor is a CEACAM5 receptor.
[0192] In one embodiment, a high level of CEA expression is greater than or equal to about 200,000 CEA receptors per target cell, e.g., greater than or equal to about 225,000, greater than or equal to about 250,000, greater than or equal to about 275,000, greater than or equal to about 300,000, greater than or equal to about 325,000, greater than or equal to about 350,000, greater than or equal to about 375,000, greater than or equal to about 400,000, greater than or equal to about 425,000, or greater than or equal to about 460,000. In another embodiment, the high level of CEA expression is characterized by target cells expressing about 200,000 to about 1,000,000 CEA receptors per target cell, such as about 200,000 to about 500,000 CEA receptors per target cell, or about 300,000 to about 500,000 CEA receptors per target cell. Preferably, the CEA receptor is a CEACAM5 receptor.
[0193] In one embodiment, B2 is unable to specifically bind to cells with no or low levels of CEA expression. In one embodiment, low levels of CEA expression are characterized by cells expressing less than about 10,000 CEA receptors per cell, e.g., less than about 9,000, less than about 8,000, less than about 7,000, less than about 6,000, less than about 5,000, less than about 4,000, less than about 3,000, less than about 2,000, or less than about 1,000 CEA receptors per cell.
[0194] Advantageously, the binding domain B2 binds human CEA at a concentration of 2×10 -6 Less than M or 1.5 x 10 -8 Less than M or 2.5 x 10 -9 Less than M or 2 x 10 -9 Less than M or 1.5 x 10 -12 Less than M or 1×10 -12 Less than M, preferably 1.5 x 10 -8 Less than M or 2.5 x 10 -9Less than M or 1.5 x 10 -12 K under M D Preferably, K D is measured in Octet and is described, for example, in the Examples.
[0195] For example, binding domain B2 preferably does not bind to non-target molecules such as CTLA-4-Fc and / or human ubiquitin. In certain embodiments relating to a particular CEACAM, the non-target molecule may be a different CEACAM, e.g., for CEACAM5, the non-target molecule may be CEACAM, or vice versa. Thus, typically, the K in the binding domain for human CEA D K for CTLA-4-Fc and / or other non-target molecules such as human ubiquitin or any other unrelated or associated material in the environment. D More preferably, it will be less than 2 times, preferably less than 5 times, more preferably less than 10 times. D will be less than 50-fold, even more preferably less than 100-fold, and even more preferably less than 200-fold.
[0196] Binding domain B2 is preferably capable of binding to its target with an affinity that is at least 2-fold, 10-fold, 50-fold, 100-fold or more than its affinity to bind to another non-target molecule.
[0197] In summary, the binding domain B2 preferably exhibits the following functional characteristics: a) Human CEA, 2 × 10 -6 M or less, more preferably 2.5×10 -9 Less than M or 1.5 x 10 -12 M or less, more preferably 1.5×10 -12 K is less than M D Join by value, b) does not bind to non-target molecules such as CTLA-4-Fc and / or human ubiquitin.
[0198] In one embodiment, binding domain B2 preferentially binds to CEA on cells over soluble CEA. "Preferentially binds to CEA on cells over soluble CEA" includes that in the presence of CEA on cells (e.g., on the surface of a cell) and soluble CEA, B2 is more likely to bind to CEA on cells than to soluble CEA.
[0199] In one embodiment, binding domain B2 comprises one or more light chain CDR sequences selected from those in Table D(2) and / or one or more heavy chain CDR sequences selected from Table D(1a) and / or Table D(1b). Thus, binding domain B2 comprises: (a) CEA heavy chain CDRs, SEQ ID NOs: 216-310, 335, and / or (b) CEA light chain CDR, which may comprise one or more CDR sequences selected from the group consisting of SEQ ID NOs: 90, 91, 94, 311-334.
[0200] In one embodiment, binding domain B2 comprises one, two or three light chain CDR sequences from a particular row for an individual antibody reference in Table D(2) and / or one, two or three heavy chain CDR sequences from the corresponding rows for an antibody with the same reference in Table D(1a) and / or Table D(1b). For example, binding domain B2 comprises one or more of the light chain CDR sequences of AC_05059 (SEQ ID NOs: 90, 91, and 311) and one or more of the heavy chain CDR sequences of AC_05059 (SEQ ID NOs: 216, 217, and 218, or 280, 281, and 218), or one or more of the light chain CDR sequences of AC_05060 (SEQ ID NOs: 312, 91, and 313) and one or more of the heavy chain CDR sequences of AC_05060 (SEQ ID NOs: 219, 220, and 221, or 282, 283 and 221). or one or more of the light chain CDR sequences of AC_05061 (SEQ ID NOs: 90, 91 and 314) and one or more of the heavy chain CDR sequences of AC_05061 (SEQ ID NOs: 222, 223, and 224, or 284, 285, and 224), or one or more of the light chain CDR sequences of AC_05062 (SEQ ID NOs: 315, 316, and 94) and one or more of the heavy chain CDR sequences of AC_05062 (SEQ ID NOs: 222, 223, and 225, or 284, 285, and 225), or one or more of the light chain CDR sequences of AC_05064 (SEQ ID NOs: 90, 91, and 317) and one or more of the heavy chain CDR sequences of AC_05064 (SEQ ID NOs: 222, 223, and 226, or 284, 285, and 226), or one or more of the light chain CDR sequences of AC_05079 (SEQ ID NOs: 90, 91, and 311) and one of the heavy chain CDR sequences of AC_05079 (SEQ ID NOs: 216, 217, and 227, or 280, 281, and 227). or one or more of the light chain CDR sequences of AC_05081 (SEQ ID NOs: 90, 91, and 311) and one or more of the heavy chain CDR sequences of AC_05081 (SEQ ID NOs: 216, 217, and 229, or 280, 281, and 229), or one or more of the light chain CDR sequences of AC_05088 (SEQ ID NOs: 90, 91, and 311) and one or more of the heavy chain CDR sequences of AC_05088 (SEQ ID NOs: 216, 217, and 237, or 280, 281, and 237),or one or more of the light chain CDR sequences of AC_05089 (SEQ ID NOs: 90, 91, and 311) and one or more of the heavy chain CDR sequences of AC_05089 (SEQ ID NOs: 216, 217, and 238, or 280, 281, and 238), or one or more of the light chain CDR sequences of AC_05090 (SEQ ID NOs: 90, 91, and 311) and one or more of the heavy chain CDR sequences of antibody AC_05090 or ffAC_05337 (SEQ ID NOs: 216, 217, and 239, or 280, 281, and 239), or AC_05091 or one or more of the light chain CDR sequences of AC_05093 (SEQ ID NOs: 90, 91, and 311) and one or more of the heavy chain CDR sequences of AC_05091 (SEQ ID NOs: 216, 217, and 240, or 280, 281, and 240), or one or more of the light chain CDR sequences of AC_05093 (SEQ ID NOs: 90, 91, and 311) and one or more of the heavy chain CDR sequences of AC_05093 (SEQ ID NOs: 216, 217, and 241, or 280, 281, and 241), or one or more of the light chain CDR sequences of AC_05094 (SEQ ID NOs: 90, 91, and 311). and one or more of the heavy chain CDR sequences of AC_05094 (SEQ ID NOs: 216, 217, and 242, or 280, 281, and 242), or one or more of the light chain CDR sequences of AC_05096 (SEQ ID NOs: 90, 91, and 311) and one or more of the heavy chain CDR sequences of AC_05096 (SEQ ID NOs: 216, 217, and 244, or 280, 281, and 244), one or more of the light chain CDR sequences of AC_05097 (SEQ ID NOs: 90, 91, and 311) and one or more of the heavy chain CDR sequences of AC_05097 (SEQ ID NOs: 21 6, 217, and 245, or 280, 281, and 245), or one or more of the light chain CDR sequences of Fab1 (SEQ ID NO: 90, 91, and 322) and one or more of the heavy chain CDR sequences of Fab1 (SEQ ID NO: 248, 249, and 250, or 289, 290, and 250), or one or more of the light chain CDR sequences of Fab3 (SEQ ID NO: 324, 325, and 326) and one or more of the heavy chain CDR sequences of Fab3 (SEQ ID NO: 254, 255, and 256, or 293, 294, and 256). Most preferably, B2 comprises AC_05088, AC_05090 / ffAC_05337, AC_05093,AC_05097, Fab1, and / or Fab3 CDRs, and / or VL and VH.
[0201] As further explained in the Examples, references to exemplary B2 polypeptides (such as "Fab1") are a nomenclature based on the library in which a particular binder was identified, and are not a specific reference to a particular type or fragment of antibody. In other words, "Fab1" is not necessarily a Fab fragment. Thus, the CDR, VL, and VH amino acid sequences defined for each of the exemplary B2 polypeptides can be used for any compatible antibody format or fragment thereof.
[0202] Preferred CEA binding domains may comprise at least a heavy chain CDR3 as defined in any individual row of Table D(1a), and / or a light chain CDR3 as defined in any individual row of Table D(2).
[0203] Thus, in one embodiment, binding domain B2 comprises all six CDR sequences in a given antibody (VH / VL) reference, for example binding domain B2 comprises AC_05059, AC_05060, AC_05061, AC_05062, AC_05064, AC_05079, AC_05080, AC_05081, AC_05082, AC_05083, AC_05084, AC_05085, AC_05086, AC_05087, AC_05088, AC_05089, AC_05090, AC_05091, AC_05092, AC_05093, AC_05094, AC_05095, AC_05096, AC_05097, AC_05098, AC_05099, AC_05000, 084, AC_05085, AC_05086, AC_05087, AC_05088, AC_05089, AC_05090, AC_05091, AC_05092, AC_050 93, AC_05094, AC_05095, AC_05096, AC_05097, AC_05098, AC_05099, AC_05100, Fab1, Fab2, Fab3, Fa b4, Fab5, Fab6, Fab7, Fab8, Fab9, Fab10, Fab11, ffAC_05337 and mAb2, preferably AC_05059, AC_05060, AC_05061, AC_05062, AC_05064, AC_05079, AC_05081, AC_05088, AC_05089, AC_05090, AC_05091, AC_05093, AC_05094, AC_05096, AC_05097, Fab1, ffAC_05337 and Fab3, most preferably the CEA-binding domain of AC_05088, AC_05090, ffAC_05337, AC_05093, AC_05097, Fab1, and Fab3.
[0204] In one embodiment, binding domain B2 comprises the VH and / or VL amino acid sequence shown in Table B. In one embodiment, binding domain B2 comprises the VH and VL amino acid sequence shown in Table B for a particular antibody reference. For example, binding domain B2 may comprise the VH sequence of AC_05059 (SEQ ID NO: 33) and / or the VL sequence of AC_05059 (SEQ ID NO: 31), or binding domain B2 may comprise the VH sequence of AC_05060 (SEQ ID NO: 37) and / or the VL sequence of AC_05060 (SEQ ID NO: 35), or binding domain B2 may comprise the VH sequence of AC_05062 (SEQ ID NO: 45) and / or the VL sequence of AC_05062 (SEQ ID NO: 43), or binding domain B2 may comprise the VH sequence of AC_05062 (SEQ ID NO: 45) and / or the VL sequence of AC_05062 (SEQ ID NO: 43). or binding domain B2 may comprise the VH sequence of AC_05046 (SEQ ID NO: 49) and / or the VL sequence of AC_05064 (SEQ ID NO: 47), or binding domain B2 may comprise the VH sequence of AC_05079 (SEQ ID NO: 53) and / or the VL sequence of AC_05079 (SEQ ID NO: 51), or binding domain B2 may comprise the VH sequence of AC_05081 (SEQ ID NO: 61) and / or the VL sequence of AC_05081 (SEQ ID NO: 59), or binding domain B2 may comprise the VH sequence of AC_05088 (SEQ ID NO: 122) and / or the VL sequence of AC_05089 (SEQ ID NO: 130). or binding domain B2 may comprise the VL sequence of AC_05088 (SEQ ID NO: 120), or binding domain B2 may comprise the VH sequence of AC_05089 (SEQ ID NO: 126) and / or the VL sequence of AC_05089 (SEQ ID NO: 124), or binding domain B2 may comprise the VH sequence of AC_05090 (SEQ ID NO: 130) and / or the VL sequence of AC_05090 (SEQ ID NO: 128), or binding domain B2 may comprise the VH sequence of AC_05091 (SEQ ID NO: 134) and / or the VL sequence of AC_05091 ( or binding domain B2 may comprise the VH sequence of AC_05093 (SEQ ID NO: 142) and / or the VL sequence of AC_05093 (SEQ ID NO: 140), or binding domain B2 may comprise the VH sequence of AC_05094 (SEQ ID NO: 146) and / or the VL sequence of AC_05094 (SEQ ID NO: 144), or binding domain B2 may comprise the VH sequence of AC_05096 (SEQ ID NO: 154) and / or the VL sequence of AC_05096 (SEQ ID NO: 152),Or the binding domain B2 may comprise the VH sequence of AC_05097 (SEQ ID NO: 158) and / or the VL sequence of AC_05097 (SEQ ID NO: 156), or the binding domain B2 may comprise the VH sequence of Fab1 (SEQ ID NO: 174) and / or the VL sequence of Fab1 (SEQ ID NO: 172), or the binding domain B2 may comprise the VH sequence of Fab3 (SEQ ID NO: 182) and / or the VL sequence of Fab3 (SEQ ID NO: 180), or the binding domain B2 may comprise the VH sequence of ffAC_05337 (SEQ ID NO: 433) and / or the VL sequence of ffAC_05337 (SEQ ID NO: 432).
[0205] In one embodiment, the CEA binding domain of B2 is selected from the group consisting of AC_05059, AC_05060, AC_05061, AC_05062, AC_05064, AC_05079, AC_05080, AC_05081, AC_05082, AC_05083, AC_05084, AC_05085, AC_05086, AC_05087, AC_05088, AC_05089, AC_05090, AC_05091, AC_05092, AC_05093, AC_05094, AC_05095, AC_05096, AC_05097, AC_05098, 5088, AC_05089, AC_05090, AC_05091, AC_05092, AC_05093, AC_05094, AC_05095, AC_05096 , AC_05097, AC_05098, AC_05099, AC_05100, Fab1, Fab2, Fab3, Fab4, Fab5, Fab6, Fab7, Fab8 , Fab9, Fab10, Fab11, ffAC_05337 and the CEA binding domain of mAb2, preferably AC_05059, AC_05060, AC_05061, AC_05062, AC_05064, AC_05079, AC_05081, AC_05088, AC_05089, AC_05090, AC_05091, AC_05093, AC_05094, AC_05096, AC_05097, Fab1, the CEA binding domain of ffAC_05337, and Fab3, and most preferably the CEA binding domain of AC_05088, AC_05090, ffAC_05337, AC_05093, AC_05097, Fab1, and Fab3.
[0206] Thus, the CDR or VH and VL sequences of binding domain B2 are (a) AC_05059 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 218, or 280, 281, and 218, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 31, VH: SEQ ID NO: 33) (b) AC_05060 (heavy chain CDRs SEQ ID NOs: 219, 220, and 221, or 282, 283, and 221, light chain CDRs: SEQ ID NOs: 312, 91, and 313, VL: SEQ ID NO: 35, VH: SEQ ID NO: 37) (c) AC_05061 (heavy chain CDRs: SEQ ID NOs: 222, 223, and 224, or 284, 285, and 224, light chain CDRs: SEQ ID NOs: 90, 91, and 314, VL: SEQ ID NO: 39, VH: SEQ ID NO: 41) (d) AC_05062 (heavy chain CDRs: SEQ ID NOs: 222, 223, and 225, or 284, 285, and 225, light chain CDRs: SEQ ID NOs: 315, 316, and 94, VL: SEQ ID NO: 43, VH: SEQ ID NO: 45) (e) AC_05064 (heavy chain CDRs: SEQ ID NOs: 222, 223, and 226, or 284, 285, and 226, light chain CDRs: SEQ ID NOs: 90, 91, and 317, VL: SEQ ID NO: 47, VH: SEQ ID NO: 49) (f) AC_05079 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 227, or 280, 281, and 227, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 51, VH: SEQ ID NO: 53) (g) AC_05080 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 228, or 280, 281, and 228, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 55, VH: SEQ ID NO: 57) (h) AC_05081 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 229, or 280, 281, and 229, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 59, VH: SEQ ID NO: 61) (i) AC_05082 (heavy chain CDRs: SEQ ID NOs: 222, 223, and 230, or 284, 285, and 230, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 63, VH: SEQ ID NO: 65) (j) AC_05083 (heavy chain CDRs: SEQ ID NOs: 222, 223, and 231, or 284, 285, and 231, light chain CDRs: SEQ ID NOs: 318, 91, and 319, VL: SEQ ID NO: 67, VH: SEQ ID NO: 69) (k) AC_05084 (heavy chain CDRs: SEQ ID NOs: 222, 223, and 232, or 284, 285, and 232, light chain CDRs: SEQ ID NOs: 90, 91, and 320, VL: SEQ ID NO: 71, VH: SEQ ID NO: 106) (l) AC_05085 (heavy chain CDRs: SEQ ID NOs: 219, 233, and 234, or 286, 287, and 234, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 108, VH: SEQ ID NO: 110) (m) AC_05086 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 235, or 280, 281, and 235, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 112, VH: SEQ ID NO: 114) (n) AC_05087 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 236, or 280, 281, and 236, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 116, VH: SEQ ID NO: 118) (o) AC_05088 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 237, or 280, 281, and 237, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 120, VH: SEQ ID NO: 122) (p)AC_05089 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 238, or 280, 281, and 238, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 124, VH: SEQ ID NO: 126) (q) AC_05090 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 239, or 280, 281, and 239, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 128, VH: SEQ ID NO: 130) (r) AC_05091 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 240, or 280, 281, and 240, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 132, VH: SEQ ID NO: 134) (s) AC_05092 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 218, or 280, 281, and 218, light chain CDRs: SEQ ID NOs: 321, 91, and 311, VL: SEQ ID NO: 136, VH: SEQ ID NO: 138) (t)AC_05093 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 241, or 280, 281, and 241, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 140, VH: SEQ ID NO: 142) (u) AC_05094 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 242, or 280, 281, and 242, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 144, VH: SEQ ID NO: 146) (v) AC_05095 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 243, or 280, 281, and 243, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 148, VH: SEQ ID NO: 150) (w)AC_05096 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 244, or 280, 281, and 244, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 152, VH: SEQ ID NO: 154) (x) AC_05097 (heavy chain CDRs: SEQ ID NOs: 217, 216, and 245, or 280, 281, and 245, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 156, VH: SEQ ID NO: 158) (y) AC_05098 (heavy chain CDRs: SEQ ID NOs: 219, 220, and 246, or 282, 283, and 246, light chain CDRs: SEQ ID NOs: 312, 91, and 313, VL: SEQ ID NO: 160, VH: SEQ ID NO: 162) (z) AC_05099 (heavy chain CDRs: SEQ ID NOs: 222, 223, and 224, or 288, 285, and 224, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 164, VH: SEQ ID NO: 166) (aa) AC_05100 (heavy chain CDRs: SEQ ID NOs: 222, 223, and 247, or 288, 285, and 247, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 168, VH: SEQ ID NO: 170) (ab) Fab1 (heavy chain CDRs: SEQ ID NOs: 248, 249, and 250, or 289, 290, and 250, light chain CDRs: SEQ ID NOs: 90, 91, and 322, VL: SEQ ID NO: 172, VH: SEQ ID NO: 174) (ac) Fab2 (heavy chain CDRs: SEQ ID NOs: 251, 252, and 253, or 291, 292, and 253, light chain CDRs: SEQ ID NOs: 90, 91, and 323, VL: SEQ ID NO: 176, VH: SEQ ID NO: 178) (ad) Fab3 (heavy chain CDRs: SEQ ID NOs: 254, 255, and 256, or 293, 294, and 256, light chain CDRs: SEQ ID NOs: 324, 325, and 326, VL: SEQ ID NO: 180, VH: SEQ ID NO: 182) (ae) Fab4 (heavy chain CDRs: SEQ ID NOs: 257, 258, and 259, or 295, 296, and 259, light chain CDRs: SEQ ID NOs: 90, 91, and 327, VL: SEQ ID NO: 184, VH: SEQ ID NO: 186) (af) Fab5 (heavy chain CDRs: SEQ ID NOs: 260, 261, and 262, or 297, 298, and 262, light chain CDRs: SEQ ID NOs: 324, 325, and 328, VL: SEQ ID NO: 188, VH: SEQ ID NO: 190) (ag) Fab6 (heavy chain CDRs: SEQ ID NOs: 263, 264, and 265, or 299, 300, and 265, light chain CDRs: SEQ ID NOs: 324, 325, and 329, VL: SEQ ID NO: 192, VH: SEQ ID NO: 194) (ah) Fab7 (heavy chain CDRs: SEQ ID NOs: 266, 267, and 268, or 301, 302, and 268, light chain CDRs: SEQ ID NOs: 90, 91, and 330, VL: SEQ ID NO: 196, VH: SEQ ID NO: 198) (ai) Fab8 (heavy chain CDRs: SEQ ID NOs: 269, 270, and 271, or 303, 304, and 271, light chain CDRs: SEQ ID NOs: 90, 91, and 331, VL: SEQ ID NO: 200, VH: SEQ ID NO: 202) (aj) Fab9 (heavy chain CDRs: SEQ ID NOs: 272, 335, and 273, or 305, 306, and 273, light chain CDRs: SEQ ID NOs: 90, 91, and 332, VL: SEQ ID NO: 204, VH: SEQ ID NO: 206) (ak) Fab10 (heavy chain CDRs: SEQ ID NOs: 274, 275, and 276, or 307, 308, and 276, light chain CDRs: SEQ ID NOs: 90, 91, and 333, VL: SEQ ID NO: 208, VH: SEQ ID NO: 210) (al) Fab11 (heavy chain CDRs: SEQ ID NOs: 277, 278, and 279, or 309, 310, and 279, light chain CDRs: SEQ ID NOs: 324, 325, and 334, VL: SEQ ID NO: 212, VH: SEQ ID NO: 214), and / or (am)ffAC_05337 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 239, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 432, VH: SEQ ID NO: 433), preferably (am)ffAC_05337 (heavy chain CDRs: SEQ ID NOs: 216, 217, and 239, light chain CDRs: SEQ ID NOs: 90, 91, and 311, VL: SEQ ID NO: 432, VH: SEQ ID NO: 433).
[0207] The numbering of an antibody (e.g., antibody X / Y) defines the heavy chain variable region (X) and the light chain variable region (Y), respectively (or if a single number is given, only the heavy chain variable region [X] is defined). As mentioned above, the sequence may be one or more CDR sequences, or a VH sequence and / or a VL sequence. As mentioned above, the sequence of the bispecific polypeptide may include certain mutations.
[0208] A variant of any one of the heavy or light chain amino acid sequences or CDR sequences listed herein may be a substitution, deletion, or addition variant of the sequence. A variant may include 1, 2, 3, 4, 5, up to 10, up to 20, up to 30 or more amino acid substitutions and / or deletions from the sequence. "Deletion" variants may include deletion of individual amino acids, deletion of small groups of amino acids, such as 2, 3, 4, or 5 amino acids, or deletion of larger amino acid regions, such as deletion of a particular amino acid domain or other feature. "Substitution" variants preferably involve replacing one or more amino acids with the same number of amino acids, making conservative amino acid substitutions. For example, an amino acid may be replaced with an alternative amino acid with similar properties, such as another basic amino acid, another acidic amino acid, another neutral amino acid, another charged amino acid, another hydrophilic amino acid, another hydrophobic amino acid, another polar amino acid, another aromatic amino acid, or another aliphatic amino acid. Some properties of the 20 main amino acids that can be used to select suitable replacements are as follows: [Table 5]
[0209] Amino acids herein may be referred to by their full name, their three letter code, or their one letter code.
[0210] Preferred "derivatives" or "variants" include those in which an amino acid that appears in the sequence instead of a naturally occurring amino acid is a structural analog thereof. The amino acids used in the sequence may also be derivatized or modified, e.g., labeled, so long as the function of the polypeptide is not significantly adversely affected.
[0211] The above-mentioned derivatives and variants may be prepared during the synthesis of the antibody or by post-production modification, or if the polypeptide is in recombinant form, using known techniques of site-directed mutagenesis, random mutagenesis, or enzymatic cleavage and / or ligation of nucleic acids.
[0212] Preferably, the variants have an amino acid sequence that has more than 60%, or more than 70%, such as 75 or 80%, preferably more than 85%, such as more than 90 or 95% amino acid identity to the sequences shown in the sequences disclosed herein. This level of amino acid identity can be found over the entire length of the sequence of the relevant SEQ ID NO, or over a portion of the sequence, such as over 20, 30, 50, 75, 100, 150, 200 or more amino acids, depending on the size of the full length polypeptide.
[0213] In one embodiment, binding domain B2 is specific for CEA, typically human CEA, and is: (a) a heavy chain CDR1 sequence consisting of the sequence: "G, F, T, F, S, S, S, Y" or comprising the consensus sequence of "G, F, T, F, G / S, S, Y, Y / A"; (b) a heavy chain CDR2 sequence consisting of the sequence: "I, G, S, G, S, Y, S, T" or including the consensus sequence of "I, S, G, Y / S, G, Y / G, S, T"; (c) a heavy chain CDR3 sequence comprising the consensus sequence of "A, R, Y, P, S, V, P / L, F, P, Q, S, P / H / L, H / P / L, L / F / V / W, D, Y" or comprising the consensus sequence of "A, R, H / Y, G, Y, G / S / T, V / H, L / F, D, Y"; (d) a light chain CDR1 sequence consisting of "Q, S, I, S, S, Y" or comprising the consensus sequence "Q, S, I, R / S, S, Y"; (e) a light chain CDR2 sequence consisting of the sequence: "A, A, S"; (f) sequence: a light chain CDR3 sequence consisting of "Q, Q, A, G, N, P, H, T" or comprising the consensus sequence of "Q, Q, G / Y, T / P / A, W / -, Y / -, F / V, P, F / Y, T".
[0214] In an alternative embodiment, binding domain B2 is specific for CEA, typically human CEA, and is: (a) a heavy chain CDR1 sequence consisting of the sequence: "G, F, T, F, S, S, S, Y"; (b) a heavy chain CDR2 sequence consisting of the sequence: "I, G, S, G, S, Y, S, T"; (c) a heavy chain CDR3 sequence, comprising the consensus sequence of "A, R, Y, P, S, V, P / L, F, P, Q, S, P / H / L, H / P / L, L / F / V / W, D, Y"; (d) a light chain CDR1 sequence consisting of the sequence: "Q, S, I, S, S, Y"; (e) a light chain CDR2 sequence consisting of the sequence: "A, A, S"; (f) light chain CDR3 sequences consisting of the sequences: "Q, Q, A, G, N, P, H, T". Binding domain B2 may comprise at least the heavy chain CDR3 defined in (c) of this embodiment and / or the light chain CDR3 defined in (f). Binding domain B2 may comprise all three heavy chain CDR sequences of (a), (b), and (c), and / or all three light chain CDR sequences of (d), (e), and (f).
[0215] In a further alternative embodiment, binding domain B2 is specific for CEA, typically human CEA, and is (a) a heavy chain CDR1 sequence, comprising the consensus sequence "G, F, T, F, G / S, S, Y, Y / A"; (b) a heavy chain CDR2 sequence, comprising the consensus sequence "I, S, G, Y / S, G, Y / G, S, T"; (c) a heavy chain CDR3 sequence, comprising the consensus sequence "A, R, H / Y, G, Y, G / S / T, V / H, L / F, D, Y"; (d) a light chain CDR1 sequence, comprising the consensus sequence "Q, S, I, R / S, S, Y"; (e) a light chain CDR2 sequence consisting of the sequence: "A, A, S"; (f) a light chain CDR3 sequence comprising the consensus sequence "Q, Q, G / Y, T / P / A, W / -, Y / -, F / V, P, F / Y, T."
[0216] Binding domain B2 may comprise at least the heavy chain CDR3 defined in (c) and / or the light chain CDR3 defined in (f) of this embodiment. Binding domain B2 may comprise all three heavy chain CDR sequences of (a), (b) and (c) and / or all three light chain CDR sequences of (d), (e) and (f).
[0217] Exemplary complete heavy and light chain variable region amino acid sequences for binding domain B2 are shown in Table B. Exemplary nucleic acid sequences encoding each amino acid sequence are also shown. The numbering of the VH and VL regions in Table B corresponds to the numbering system used in Tables D(1a), D(1b), and / or D(2). Thus, for example, the amino acid sequence of "AC_05088, light chain VL" is an example of a complete VL region sequence that includes all three CDRs of VL number AC_05088 shown in Table D(2), and the amino acid sequence of "AC_05088, heavy chain VH" is an example of a complete VH region sequence that includes all three CDRs of VH number AC_05088 shown in Tables D(1a) and / or D(1b).
[0218] In an exemplary embodiment, binding domain B2 comprises: (a) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05059 (SEQ ID NOs: 216, 217, and 218, or 280, 281, and 218, and / or SEQ ID NOs: 90, 91, and 311); (b) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05060 (SEQ ID NOs: 219, 220, and 221, or 282, 283, and 221, and / or SEQ ID NOs: 312, 91, and 313). (c) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05061 (SEQ ID NOs: 222, 223, and 224, or 284, 285, and 224, and / or SEQ ID NOs: 90, 91, and 314). (d) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05062 (SEQ ID NOs: 222, 223, and 225, or 284, 285, and 225, and / or SEQ ID NOs: 315, 316, and 94). (e) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05064 (SEQ ID NOs: 222, 223, and 226, or 284, 285, and 226, and / or SEQ ID NOs: 90, 91, and 317); (f) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05079 (SEQ ID NOs: 216, 217, and 227, or 280, 281, and 227, and / or SEQ ID NOs: 90, 91, and 311). (g) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05080 (SEQ ID NOs: 216, 217, and 228, or 280, 281, and 228, and / or SEQ ID NOs: 90, 91, and 311); (h) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05081 (SEQ ID NOs: 216, 217, and 229, or 280, 281, and 229, and / or SEQ ID NOs: 90, 91, and 311); (i) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05082 (SEQ ID NOs: 222, 223, and 230, or 284, 285, and 230, and / or SEQ ID NOs: 90, 91, and 311); (j) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05083 (SEQ ID NOs: 222, 223, and 231, or 284, 285, and 231, and / or SEQ ID NOs: 318, 91, and 319); (k) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05084 (SEQ ID NOs: 222, 223, and 232, or 284, 285, and 232, and / or SEQ ID NOs: 90, 91, and 320); (l) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05085 (SEQ ID NOs: 219, 233, and 234, or 286, 287, and 234, and / or SEQ ID NOs: 90, 91, and 311); (m) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05086 (SEQ ID NOs: 216, 217, and 235, or 280, 281, and 235, and / or SEQ ID NOs: 90, 91, and 311). (n) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05087 (SEQ ID NOs: 216, 217, and 236, or 280, 281, and 236, and / or SEQ ID NOs: 90, 91, and 311); (o) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05088 (SEQ ID NOs: 216, 217, and 237, or 280, 281, and 237, and / or SEQ ID NOs: 90, 91, and 311); (p) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05089 (SEQ ID NOs: 216, 217, and 238, or 280, 281, and 238, and / or SEQ ID NOs: 90, 91, and 311); (q) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05090 / ffAC_05337 (SEQ ID NOs: 216, 217, and 239, or 280, 281, and 239, and / or SEQ ID NOs: 90, 91, and 311); (r) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05091 (SEQ ID NOs: 216, 217, and 240, or 280, 281, and 240, and / or SEQ ID NOs: 90, 91, and 311); (s) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05092 (SEQ ID NOs: 216, 217, and 218, or 280, 281, and 218, and / or SEQ ID NOs: 321, 91, and 311); (t) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05093 (SEQ ID NOs: 216, 217, and 241, or 280, 281, and 241, and / or SEQ ID NOs: 90, 91, and 311); (u) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05094 (SEQ ID NOs: 216, 217, and 242, or 280, 281, and 242, and / or SEQ ID NOs: 90, 91, and 311); (v) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05095 (SEQ ID NOs: 216, 217, and 243, or 280, 281, and 243, and / or SEQ ID NOs: 90, 91, and 311). (w) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05096 (SEQ ID NOs: 216, 217, and 244, or 280, 281, and 244, and / or SEQ ID NOs: 90, 91, and 311); (x) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05097 (SEQ ID NOs: 217, 216, and 245, or 280, 281, and 245, and / or SEQ ID NOs: 90, 91, and 311); (y) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05098 (SEQ ID NOs: 219, 220, and 246, or 282, 283, and 246, and / or SEQ ID NOs: 312, 91, and 313); (z) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05099 (SEQ ID NOs: 222, 223, and 224, or 288, 285, and 224, and / or SEQ ID NOs: 90, 91, and 311); (aa) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05100 (SEQ ID NOs: 222, 223, and 247, or 288, 285, and 247, and / or SEQ ID NOs: 90, 91, and 311) (ab) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab1 (SEQ ID NOs: 248, 249, and 250, or 289, 290, and 250, and / or SEQ ID NOs: 90, 91, and 322). (ac) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab2 (SEQ ID NOs: 251, 252, and 253, or 291, 292, and 253, and / or SEQ ID NOs: 90, 91, and 323); (ad) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab3 (SEQ ID NOs: 254, 255, and 256, or 293, 294, and 256, and / or SEQ ID NOs: 324, 325, and 326); (ae) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab4 (SEQ ID NOs: 257, 258, and 259, or 295, 296, and 259, and / or SEQ ID NOs: 90, 91, and 327); (af) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab5 (SEQ ID NOs: 260, 261, and 262, or 297, 298, and 262, and / or SEQ ID NOs: 324, 325, and 328); (ag) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab6 (SEQ ID NOs: 263, 264, and 265, or 299, 300, and 265, and / or SEQ ID NOs: 324, 325, and 329); (ah) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab7 (SEQ ID NOs: 266, 267, and 268, or 301, 302, and 268, and / or SEQ ID NOs: 90, 91, and 330); (ai) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab8 (SEQ ID NOs: 269, 270, and 271, or 303, 304, and 271, and / or SEQ ID NOs: 90, 91, and 331); (aj) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab9 (SEQ ID NOs: 272, 335, and 273, or 305, 306, and 273, and / or SEQ ID NOs: 90, 91, and 332) (ak) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab10 (SEQ ID NOs: 274, 275, and 276, or 307, 308, and 276, and / or SEQ ID NOs: 90, 91, and 333); and / or (a1) comprises the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab11 (sequence numbers 277, 278, and 279, or 309, 310, and 279, and / or sequence numbers 324, 325, and 334).
[0219] Thus, binding domain B2 is (a) Heavy chain variable region and / or light chain variable region of antibody AC_05059 (SEQ ID NO: 33 and / or SEQ ID NO: 31) (b) the heavy chain variable region and / or the light chain variable region of antibody AC_05060 (SEQ ID NO: 37 and / or SEQ ID NO: 35) (c) the heavy chain variable region and / or the light chain variable region of antibody AC_05061 (SEQ ID NO: 41 and / or SEQ ID NO: 39) (d) the heavy chain variable region and / or the light chain variable region of antibody AC_05062 (SEQ ID NO: 45 and / or SEQ ID NO: 43) (e) heavy chain variable region and / or light chain variable region of antibody AC_05064 (SEQ ID NO: 49 and / or SEQ ID NO: 47) (f) heavy chain variable region and / or light chain variable region of antibody AC_05079 (SEQ ID NO: 53 and / or SEQ ID NO: 51) (g) heavy chain variable region and / or light chain variable region of antibody AC_05080 (SEQ ID NO: 57 and / or SEQ ID NO: 55) (h) heavy chain variable region and / or light chain variable region of antibody AC_05081 (SEQ ID NO: 61 and / or SEQ ID NO: 59) (i) the heavy chain variable region and / or the light chain variable region of antibody AC_05082 (SEQ ID NO: 65 and / or SEQ ID NO: 63) (j) heavy chain variable region and / or light chain variable region of antibody AC_05083 (SEQ ID NO: 69 and / or SEQ ID NO: 67) (k) the heavy chain variable region and / or the light chain variable region of antibody AC_05084 (SEQ ID NO: 106 and / or SEQ ID NO: 71) (l) the heavy chain variable region and / or the light chain variable region of antibody AC_05085 (SEQ ID NO: 110 and / or SEQ ID NO: 108) (m) the heavy chain variable region and / or the light chain variable region of antibody AC_05086 (SEQ ID NO: 114 and / or SEQ ID NO: 112) (n) the heavy chain variable region and / or the light chain variable region of antibody AC_05087 (SEQ ID NO: 118 and / or SEQ ID NO: 116) (o) heavy chain variable region and / or light chain variable region of antibody AC_05088 (SEQ ID NO: 122 and / or SEQ ID NO: 120) (p) the heavy chain variable region and / or the light chain variable region of antibody AC_05089 (SEQ ID NO: 126 and / or SEQ ID NO: 124) (q) the heavy chain variable region and / or the light chain variable region of antibody AC_05090 (SEQ ID NO: 130 and / or SEQ ID NO: 128) (r) the heavy chain variable region and / or the light chain variable region of antibody AC_05091 (SEQ ID NO: 134 and / or SEQ ID NO: 132) (s) heavy chain variable region and / or light chain variable region of antibody AC_05092 (SEQ ID NO: 138 and / or SEQ ID NO: 136) (t) heavy chain variable region and / or light chain variable region of antibody AC_05093 (SEQ ID NO: 142 and / or SEQ ID NO: 140) (u) heavy chain variable region and / or light chain variable region of antibody AC_05094 (SEQ ID NO: 146 and / or SEQ ID NO: 144) (v) the heavy chain variable region and / or the light chain variable region of antibody AC_05095 (SEQ ID NO: 150 and / or SEQ ID NO: 148) (w) the heavy chain variable region and / or the light chain variable region of antibody AC_05096 (SEQ ID NO: 154 and / or SEQ ID NO: 152) (x) the heavy chain variable region and / or the light chain variable region of antibody AC_05097 (SEQ ID NO: 158 and / or SEQ ID NO: 156) (y) heavy chain variable region and / or light chain variable region of antibody AC_05098 (SEQ ID NO: 162 and / or SEQ ID NO: 160) (z) the heavy chain variable region and / or the light chain variable region of antibody AC_05099 (SEQ ID NO: 166 and / or SEQ ID NO: 164) (aa) heavy chain variable region and / or light chain variable region of antibody AC_05100 (SEQ ID NO: 170 and / or SEQ ID NO: 168) (ab) the heavy chain variable region and / or the light chain variable region of antibody Fab1 (SEQ ID NO: 174 and / or SEQ ID NO: 172) (ac) heavy chain variable region and / or light chain variable region of antibody Fab2 (SEQ ID NO: 178 and / or SEQ ID NO: 176) (ad) the heavy chain variable region and / or the light chain variable region of antibody Fab3 (SEQ ID NO: 182 and / or SEQ ID NO: 180) (ae) heavy chain variable region and / or light chain variable region of antibody Fab4 (SEQ ID NO: 186 and / or SEQ ID NO: 184) (af) heavy chain variable region and / or light chain variable region of antibody Fab5 (SEQ ID NO: 190 and / or SEQ ID NO: 188) (ag) heavy chain variable region and / or light chain variable region of antibody Fab6 (SEQ ID NO: 194 and / or SEQ ID NO: 192) (ah) heavy chain variable region and / or light chain variable region of antibody Fab7 (SEQ ID NO: 198 and / or SEQ ID NO: 196) (ai) the heavy chain variable region and / or the light chain variable region of antibody Fab8 (SEQ ID NO: 202 and / or SEQ ID NO: 200) (aj) heavy chain variable region and / or light chain variable region of antibody Fab9 (SEQ ID NO: 206 and / or SEQ ID NO: 204) (ak) heavy chain variable region and / or light chain variable region of antibody Fab10 (SEQ ID NO: 210 and / or SEQ ID NO: 208) (a1) the heavy chain variable region and / or the light chain variable region of antibody Fab11 (SEQ ID NO: 214 and / or SEQ ID NO: 212) (am) the heavy chain variable region and / or the light chain variable region of the antibody mAb2 (SEQ ID NO: 387 and / or SEQ ID NO: 385), and / or (an) may comprise the heavy chain variable region and / or the light chain variable region of antibody ffAC_05337 (sequence number 433 and / or sequence number 432).
[0220] In one embodiment, binding domain B2 comprises: (a) the light chain and / or the heavy chain of antibody AC_05059 (SEQ ID NO: 388 and / or SEQ ID NO: 389) (b) the light chain and / or the heavy chain of antibody AC_05060 (SEQ ID NO: 390 and / or SEQ ID NO: 391) (c) the light chain and / or the heavy chain of antibody AC_05061 (SEQ ID NO: 392 and / or (SEQ ID NO: 393) (d) the light chain and / or the heavy chain of antibody AC_05062 (SEQ ID NO: 394 and / or SEQ ID NO: 395) (e) the light chain and / or the heavy chain of antibody AC_05064 (SEQ ID NO: 396 and / or SEQ ID NO: 397) (f) light chain and / or heavy chain of antibody AC_05079 (SEQ ID NO: 398 and / or SEQ ID NO: 399) (g) light chain and / or heavy chain of antibody AC_05081 (SEQ ID NO: 400 and / or SEQ ID NO: 401) (h) light chain and / or heavy chain of antibody AC_05088 (SEQ ID NO: 402 and / or SEQ ID NO: 403) (i) the light chain and / or the heavy chain of antibody AC_05089 (SEQ ID NO: 404 and / or SEQ ID NO: 405) (j) light chain and / or heavy chain of antibody AC_05090 (SEQ ID NO: 406 and / or SEQ ID NO: 407) (k) the light chain and / or the heavy chain of antibody AC_05091 (SEQ ID NO: 408 and / or SEQ ID NO: 409) (l) light chain and / or heavy chain of antibody AC_05093 (SEQ ID NO: 410 and / or SEQ ID NO: 411) (m) light chain and / or heavy chain of antibody AC_05094 (SEQ ID NO: 412 and / or SEQ ID NO: 413) (n) light chain and / or heavy chain of antibody AC_05096 (SEQ ID NO: 414 and / or SEQ ID NO: 415) (o) light chain and / or heavy chain of antibody AC_05097 (SEQ ID NO: 416 and / or SEQ ID NO: 417) (p) the light chain and / or the heavy chain of the antibody Fab1 (SEQ ID NO: 418 and / or SEQ ID NO: 419); and / or (q) the light chain and / or the heavy chain of antibody Fab3 (SEQ ID NO: 420 and / or (SEQ ID NO: 421).
[0221] It will be understood by those skilled in the art that the mutations described herein for the RUBY™ format and / or optimized RUBY™ format can be applied to the above light and / or heavy chain sequences of binding domain B2 and are included herein.
[0222] In one embodiment, binding domain B2 may comprise one or more variants of the light chain variable region and / or said heavy chain variable region (and / or light chain and / or heavy chain) as defined above having at least 90% sequence identity thereto, or 95% sequence identity thereto, or 99% sequence identity thereto. Binding domain B2 may also comprise variants of the CDR sequences specified herein, e.g. variants in which up to 1, 2, 3, 4 or 5 amino acid residues have been substituted, deleted or added compared to the specified reference sequences.
[0223] In a second aspect, the present invention provides a polypeptide comprising a binding domain, designated B2, as defined herein, capable of specifically binding to CEA. Preferably, the polypeptide of the second aspect of the invention is monospecific. In an alternative preferred embodiment, the polypeptide of the second aspect of the invention is bispecific, preferably a bispecific antibody.
[0224] All of the features of B2 discussed for the first aspect of the invention are relevant to and included in the second aspect of the invention. Thus, in one embodiment, the CEA binding domain of B2 is selected from the group consisting of AC_05059, AC_05060, AC_05061, AC_05062, AC_05064, AC_05079, AC_05080, AC_05081, AC_05082, AC_05083, AC_05084, AC_05085, AC_05086, AC_05087, AC_05089, AC_05090, AC_05091, AC_05092, AC_05093, AC_05094, AC_05095, AC_05096, AC_05097, AC_05098, AC_05099, AC_05000, AC_05001, AC_05002, AC_05003, AC_05004, AC_05005, AC_05006, AC_05007, AC_05008, AC_05009 ... 087, AC_05088, AC_05089, AC_05090, AC_05091, AC_05092, AC_05093, AC_05094, AC_05095 , AC_05096, AC_05097, AC_05098, AC_05099, ffAC_05337 and AC_05100 CEA binding domain, Fab1, Fa b2, Fab3, Fab4, Fab5, Fab6, Fab7, Fab8, Fab9, Fab10, Fab11, and mAb2, preferably AC_05059, AC_05060, AC_05061, AC_05062, AC_05064, AC_05079, AC_05081, AC_05088, AC_05089, AC_05090, AC_05091, AC_05093, AC_05094, AC_05096, and AC_05097, Fab1, and Fab3, most preferably AC_05088, AC_05090, AC_05093, and AC_05097, Fab1, ffAC_05337 and Fab3. The CDRs, VL, VH, light chain and / or heavy chain of the above antibodies described in the first aspect of the invention relate to and are included in the second aspect of the invention.
[0225] Advantageously, the binding domain B2 of the second aspect of the invention binds human CEA at a concentration of 2×10 -6 Less than M or 1.5 x 10 -7 Less than M or 1.5 x 10 -8 Less than M or 2.5 x 10 -8 Less than M or 4.5 x 10 -8 Less than M or 5.5 x 10 -8 Less than M or 6.5 x 10 -9 Less than M or 2.5 x 10 -9 Less than M or 2 x 10 -9Less than M or 9.5 x 10 -10 Less than M or 4.5 x 10 -10 Less than M or 7.5 x 10 -11 Less than M or 8.5 x 10 -12 Less than M or 1.5 x 10 -12 Less than M or 1×10 -12 M, preferably 1.5 x 10 -8 Less than M or 2.5 x 10 -9 Less than M or 1.5 x 10 -12 K under M D Preferably, K D is measured by Octet and is described, for example, in the Examples. D is measured in Octet and is described, for example, in the Examples.
[0226] In a third aspect, the present invention provides a bispecific polypeptide comprising a first binding domain, designated B3, capable of specifically binding to a target antigen which is not CD40, and a second binding domain, designated B2, as defined herein, capable of specifically binding to CEA.
[0227] All of the features of B2 discussed for the first and second aspects of the invention are relevant to and encompassed in the third aspect of the invention. Thus, in one embodiment, the CEA binding domain of B2 is selected from the group consisting of AC_05059, AC_05060, AC_05061, AC_05062, AC_05064, AC_05079, AC_05080, AC_05081, AC_05082, AC_05083, AC_05084, AC_05085, AC_05086, AC_05087, AC_05089, AC_05090, AC_05091, AC_05092, AC_05093, AC_05094, AC_05095, AC_05096, AC_05097, AC_05098, AC_05099, AC_05000, AC_05001, AC_05002, AC_05003, AC_05004, AC_05005, AC_05006, AC_05007, AC_05008, AC_05009 ... 087, AC_05088, AC_05089, AC_05090, AC_05091, AC_05092, AC_05093, AC_05094, AC_05095 , AC_05096, AC_05097, AC_05098, AC_05099, and AC_05100, Fab1, Fab2, Fab3, Fab4, Fab5, F The CEA binding domain is selected from ab6, Fab7, Fab8, Fab9, Fab10, Fab11, ffAC_05337 and the CEA binding domain of mAb2, preferably AC_05059, AC_05060, AC_05061, AC_05062, AC_05064, AC_05079, AC_05081, AC_05088, AC_05089, AC_05090, AC_05091, AC_05093, AC_05094, AC_05096 and AC_05097, Fab1 and Fab3, most preferably AC_05088, AC_05090, AC_05093 and AC_05097, Fab1, ffAC_05337 and Fab3. The CDRs, VL, VH, light chain and / or heavy chain of the above antibodies described in the first aspect of the invention relate to and are included in the second aspect of the invention.
[0228] Preferably, the target antigen is a protein and / or a peptide.
[0229] In one embodiment, B3 is capable of targeting an immune cell, such that the target antigen is an immune cell target antigen. The immune cell can be any immune cell described herein, including a T cell, a NK cell, a myeloid cell, and / or an antigen-presenting cell (such as a dendritic cell).
[0230] In one embodiment, B3 can target dendritic cells (DCs), and thus the target antigen is a DC-targeted antigen.
[0231] Binding domain B3 specifically binds to the DC target antigen, i.e., binds to the DC target antigen, but does not bind or binds with lower affinity to other molecules. Binding domain B3 may have some binding affinity to the same DC target antigen from other mammals, such as non-human primates (e.g., Macaca fascicularis (cynomolgus monkey), Macaca mulatta). Binding domain B3 preferably does not bind to non-target molecules.
[0232] Binding domain B3 is preferably capable of binding to its target with an affinity that is at least 2-fold, 10-fold, 50-fold, 100-fold or more than its affinity to bind to another non-target molecule.
[0233] In one embodiment, the DC target antigen is capable of mediating internalization.
[0234] In one embodiment, the DC target antigen is capable of mediating cross-presentation.
[0235] In one embodiment, the DC target antigen is specifically expressed on mature DCs.
[0236] In one embodiment, the DC target antigen is specifically expressed on immature DCs.
[0237] In a preferred embodiment of the third aspect of the invention, the bispecific polypeptide is a bispecific antibody, such as a bispecific antibody in RUBY™ format or optimized RUBY™ format (both as described herein).
[0238] Exemplary CD40-CEA Bispecific Antibodies In one embodiment of the bispecific polypeptide of the invention, binding domain B1 is an IgG and binding domain B2 is an scFv. Conversely, binding domain B1 can be an scFv and binding domain B2 can be an IgG.
[0239] In one embodiment, binding domain B1 is an immunoglobulin and binding domain B2 is a Fab. Conversely, binding domain B1 can be a Fab and binding domain B2 can be an immunoglobulin. The bispecific polypeptide can optionally be in RUBY™ format or optimized RUBY™ format, both of which are described herein. The format of the bispecific polypeptide is as described above and shown in Figure 23, and the bispecific polypeptide can include certain mutations as described above.
[0240] The bispecific polypeptides of the invention may comprise the CDRs of any of the light chains of the B1 domains described above (as shown in Table C(2) below) and / or the CDRs of any of the heavy chains of the B1 domains described above (as shown in Table C(1) below) in combination with the CDRs of any of the light chains of the B2 domains described above (as shown in Table D(2)) and / or the CDRs of any of the heavy chains of the B2 domains described above (as shown in Table D(1a) and / or Table D(1b)).
[0241] The bispecific polypeptides of the invention may comprise the CDRs of any of the light chain variable regions of the B1 domains described above (as shown in Table A below), and / or any of the heavy chain variable regions of the B1 domains described above (as shown in Table A below), in combination with any of the light chain variable regions of the B2 domains described above (as shown in Table B), and / or any of the heavy chain variable regions of the B2 domains described above (as shown in Table B).
[0242] Thus, in certain embodiments, B1 and B2 comprise respective variable regions comprising the CDRs identified above. For example, B1 may comprise the heavy and / or light chain variable region of antibody G12 (SEQ ID NO: 19 and / or SEQ ID NO: 17) or the heavy and / or light chain variable region of G12_mut (SEQ ID NO: 29 and / or SEQ ID NO: 17), and B2 may comprise the heavy and / or light chain variable region of any of the reference CEA antibodies: (a) Heavy chain variable region and / or light chain variable region of antibody AC_05059 (SEQ ID NO: 33 and / or SEQ ID NO: 31) (b) the heavy chain variable region and / or the light chain variable region of antibody AC_05060 (SEQ ID NO: 37 and / or SEQ ID NO: 35) (c) the heavy chain variable region and / or the light chain variable region of antibody AC_05061 (SEQ ID NO: 41 and / or SEQ ID NO: 39) (d) the heavy chain variable region and / or the light chain variable region of antibody AC_05062 (SEQ ID NO: 45 and / or SEQ ID NO: 43) (e) heavy chain variable region and / or light chain variable region of antibody AC_05064 (SEQ ID NO: 49 and / or SEQ ID NO: 47) (f) heavy chain variable region and / or light chain variable region of antibody AC_05079 (SEQ ID NO: 53 and / or SEQ ID NO: 51) (g) heavy chain variable region and / or light chain variable region of antibody AC_05080 (SEQ ID NO: 57 and / or SEQ ID NO: 55) (h) heavy chain variable region and / or light chain variable region of antibody AC_05081 (SEQ ID NO: 61 and / or SEQ ID NO: 59) (i) the heavy chain variable region and / or the light chain variable region of antibody AC_05082 (SEQ ID NO: 65 and / or SEQ ID NO: 63) (j) heavy chain variable region and / or light chain variable region of antibody AC_05083 (SEQ ID NO: 69 and / or SEQ ID NO: 67) (k) the heavy chain variable region and / or the light chain variable region of antibody AC_05084 (SEQ ID NO: 106 and / or SEQ ID NO: 71) (l) the heavy chain variable region and / or the light chain variable region of antibody AC_05085 (SEQ ID NO: 110 and / or SEQ ID NO: 108) (m) the heavy chain variable region and / or the light chain variable region of antibody AC_05086 (SEQ ID NO: 114 and / or SEQ ID NO: 112) (n) the heavy chain variable region and / or the light chain variable region of antibody AC_05087 (SEQ ID NO: 118 and / or SEQ ID NO: 116) (o) heavy chain variable region and / or light chain variable region of antibody AC_05088 (SEQ ID NO: 122 and / or SEQ ID NO: 120) (p) the heavy chain variable region and / or the light chain variable region of antibody AC_05089 (SEQ ID NO: 126 and / or SEQ ID NO: 124) (q) the heavy chain variable region and / or the light chain variable region of antibody AC_05090 (SEQ ID NO: 130 and / or SEQ ID NO: 128) (r) the heavy chain variable region and / or the light chain variable region of antibody AC_05091 (SEQ ID NO: 134 and / or SEQ ID NO: 132) (s) heavy chain variable region and / or light chain variable region of antibody AC_05092 (SEQ ID NO: 138 and / or SEQ ID NO: 136) (t) Antibody AC_05093 heavy chain variable region and / or light chain variable region (SEQ ID NO: 142 and / or SEQ ID NO: 140) (u) heavy chain variable region and / or light chain variable region of antibody AC_05094 (SEQ ID NO: 146 and / or SEQ ID NO: 144) (v) the heavy chain variable region and / or the light chain variable region of antibody AC_05095 (SEQ ID NO: 150 and / or SEQ ID NO: 148) (w) the heavy chain variable region and / or the light chain variable region of antibody AC_05096 (SEQ ID NO: 154 and / or SEQ ID NO: 152) (x) the heavy chain variable region and / or the light chain variable region of antibody AC_05097 (SEQ ID NO: 158 and / or SEQ ID NO: 156) (y) heavy chain variable region and / or light chain variable region of antibody AC_05098 (SEQ ID NO: 162 and / or SEQ ID NO: 160) (z) the heavy chain variable region and / or the light chain variable region of antibody AC_05099 (SEQ ID NO: 166 and / or SEQ ID NO: 164) (aa) heavy chain variable region and / or light chain variable region of antibody AC_05100 (SEQ ID NO: 170 and / or SEQ ID NO: 168) (ab) the heavy chain variable region and / or the light chain variable region of antibody Fab1 (SEQ ID NO: 174 and / or SEQ ID NO: 172) (ac) heavy chain variable region and / or light chain variable region of antibody Fab2 (SEQ ID NO: 178 and / or SEQ ID NO: 176) (ad) the heavy chain variable region and / or the light chain variable region of antibody Fab3 (SEQ ID NO: 182 and / or SEQ ID NO: 180) (ae) heavy chain variable region and / or light chain variable region of antibody Fab4 (SEQ ID NO: 186 and / or SEQ ID NO: 184) (af) heavy chain variable region and / or light chain variable region of antibody Fab5 (SEQ ID NO: 190 and / or SEQ ID NO: 188) (ag) heavy chain variable region and / or light chain variable region of antibody Fab6 (SEQ ID NO: 194 and / or SEQ ID NO: 192) (ah) heavy chain variable region and / or light chain variable region of antibody Fab7 (SEQ ID NO: 198 and / or SEQ ID NO: 196) (ai) the heavy chain variable region and / or the light chain variable region of antibody Fab8 (SEQ ID NO: 202 and / or SEQ ID NO: 200) (aj) heavy chain variable region and / or light chain variable region of antibody Fab9 (SEQ ID NO: 206 and / or SEQ ID NO: 204) (ak) heavy chain variable region and / or light chain variable region of antibody Fab10 (SEQ ID NO: 210 and / or SEQ ID NO: 208) (a1) the heavy chain variable region and / or the light chain variable region of antibody Fab11 (SEQ ID NO: 214 and / or SEQ ID NO: 212); and / or (am) may comprise the heavy chain variable region and / or the light chain variable region of antibody mAb2 (SEQ ID NO: 387 and / or SEQ ID NO: 385).
[0243] In a preferred embodiment, B1 may comprise the heavy chain variable region and / or light chain variable region of antibody ffAC_05337 (sequence number 430 and / or sequence number 431), and B2 may comprise the heavy chain variable region and / or light chain variable region of antibody ffAC_05337 (sequence number 433 and / or sequence number 432).
[0244] The B1 domain may comprise the light chain variable region and / or the heavy chain variable region of any of the B1 domains described above, and the B2 domain may comprise the light chain variable region and / or the heavy chain variable region of any of the B2 domains described above, or a variant of said light chain variable region and / or said heavy chain variable region having at least 90% sequence identity thereto.
[0245] Typically, the bispecific polypeptides of the invention comprise a constant region sequence in addition to the variable region sequences defined above. The bispecific polypeptides of the invention may be in any suitable format. For example, the bispecific polypeptides may be in RUBY™ format or optimized RUBY™ format (described above and shown in Figure 23), or in Morrison format.
[0246] An exemplary heavy chain constant region amino acid sequence that may be combined with any of the VH region sequences disclosed herein (to form a complete heavy chain) is the following IgG1 heavy chain constant region sequence: ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:349)
[0247] Similarly, an exemplary light chain constant region amino acid sequence that may be combined with any VL region sequence disclosed herein (to form a complete light chain) is the kappa chain constant region sequence reproduced below. RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:350)
[0248] Other light chain constant region sequences are known in the art and can also be combined with any of the VL regions disclosed herein.
[0249] In one embodiment, the polypeptide may comprise the following constant region amino acid sequence: (a) Reference sequence CH1 (SEQ ID NO: 354): [ka] (The bold and underlined part is part of the hinge region, but is present in the Fab fragment.) and / or (b) Reference sequence C kappa (SEQ ID NO:355): RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC and / or Reference sequence C lambda (SEQ ID NO: 356) GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS and / or Reference sequence C lambda (SEQ ID NO: 357) GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS and / or Reference sequence C lambda (SEQ ID NO: 358) GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS
[0250] As mentioned above, these reference sequences may contain one or more mutations to prevent the formation of aggregates and / or Fab by-products. Such mutation positions (specified herein above) may be provided for any of the constant region sequences listed above.
[0251] In one embodiment, the bispecific polypeptide is in RUBY™ format or optimized RUBY™ format and comprises an immunoglobulin and a Fab fragment, wherein the Fab fragment is fused to the C-terminus of the heavy chain of the immunoglobulin via the light chain of the Fab fragment.
[0252] Thus, in one embodiment, binding domain B1 is an immunoglobulin and binding domain B2 is a Fab fragment, which is fused via the light chain of the Fab fragment to the C-terminus of the heavy chain of the immunoglobulin. In an alternative embodiment, binding domain B2 is an immunoglobulin and binding domain B1 is a Fab fragment, which is fused via the light chain of the Fab fragment to the C-terminus of the heavy chain of the immunoglobulin. In addition, the bispecific polypeptide comprises one or more mutations selected from those described above for the RUBY™ format and / or optimized RUBY™ format.
[0253] In one embodiment the bispecific polypeptide is Multi1, Multi2, Multi3, Multi4, Multi5, Multi6, Multi7, Multi8, Multi9, Multi10, Multi11, Multi12, Multi13, Multi14, Multi17, Multi18, Multi19, Multi20, Multi23, Multi24, Multi25, Multi26, Multi27, Multi28, Multi29, Multi30, Multi31, Multi32, Multi33, Multi34, Multi35, Multi37, Multi38, Multi3 9, Multi40, Multi41, Multi42, Multi44, Multi46, Multi47, Multi48, Multi49, AC_05333, AC_05334, AC_05336, AC_05337, AC_05338, AC_05339, AC_05341, ffAC_05337, ffAC_05339, and / or AC_05355, preferably Multi34, Multi42, Multi46, and / or ffAC_05337.
[0254] In one embodiment the bispecific polypeptide is Multi1, Multi2, Multi3, Multi4, Multi5, Multi6, Multi7, Multi8, Multi9, Multi10, Multi11, Multi12, Multi13, Multi14, Multi17, Multi18, Multi19, Multi20, Multi23, Multi24, Multi25, Multi26, Multi27, Multi28, Multi29, Multi30, Multi31, Multi32, Multi33, Multi34, Multi35, Multi37, Multi38, Multi39 , Multi40, Multi41, Multi42, Multi44, Multi46, Multi47, Multi48, Multi49, AC_05333, AC_05334, AC_05336, AC_05337, AC_05338, AC_05339, AC_05341, ffAC_05337, ffAC_05339 and / or AC_05355, preferably Multi34, Multi42, Multi46 and / or ffAC_05337, and / or binding domain B1 and / or binding domain 2 comprising the light chain variable region and / or the heavy chain variable region of an antibody selected from the list consisting of: Multi34, Multi42, Multi46 and / or ffAC_05337.
[0255] In one embodiment the bispecific polypeptide is selected from the group consisting of Multi1, Multi2, Multi3, Multi4, Multi5, Multi6, Multi7, Multi8, Multi9, Multi10, Multi11, Multi12, Multi13, Multi14, Multi17, Multi18, Multi19, Multi20, Multi23, Multi24, Multi25, Multi26, Multi27, Multi28, Multi29, Multi30, Multi31, Multi32, Multi33, Multi34, Multi35, Multi37, Multi38, Multi39, Multi40, Multi41, Multi42, Multi43, Multi44, Multi45, Multi46, Multi47, Multi48, Multi49, Multi50, Multi51, Multi52, Multi53, Multi54, Multi55, Multi56, Multi57, Multi58, Multi59, Multi60, Multi61, Multi62, Multi63, Multi64, Multi65, Multi66, Multi67, Multi68, Multi69, Multi70, Multi71, Multi72, Multi73, Multi74, Multi75, Multi76, Multi77, Multi78, Multi79, Multi80, Multi81, Multi82, Multi83, Multi84, Multi85, Multi86, Multi87, Multi88, Multi89, Multi90, Multi91, Multi92, Multi93, Multi94, Multi95, Multi96, Multi97, Multi98, Multi99, Multi100, Multi101, Multi102, Multi103, Multi104, Multi105, Multi106, Multi107, Multi108, Multi109, Multi110, Multi111, Multi12, Multi13, Multi14, Multi17, Multi18, Multi19, Multi20, Multi23, Multi24, Multi25, Multi26, Multi27, Multi28, Multi29, Multi30, Multi31, Multi32, Multi3 and / or AC_05337, ffAC_05339, and / or AC_05355, preferably Multi34, Multi42, Multi46, and / or ffAC_05337; and / or binding domain B1 and / or binding domain 2 comprising the light chain and / or the heavy chain of an antibody selected from the list consisting of: ti39, Multi40, Multi41, Multi42, Multi44, Multi46, Multi47, Multi48, Multi49, AC_05333, AC_05334, AC_05336, AC_05337, AC_05338, AC_05339, AC_05341, ffAC_05337, ffAC_05339, and / or AC_05355, preferably Multi34, Multi42, Multi46, and / or ffAC_05337.
[0256] In one embodiment, the bispecific polypeptide comprises chain H1 comprising a sequence selected from the list consisting of SEQ ID NO:359, SEQ ID NO:362, SEQ ID NO:365, and / or SEQ ID NO:367.
[0257] In one embodiment, the bispecific polypeptide comprises chain L1 comprising a sequence selected from the list consisting of SEQ ID NO:360, SEQ ID NO:363, SEQ ID NO:372, and / or SEQ ID NO:368.
[0258] In one embodiment, the bispecific polypeptide comprises chain H2 comprising a sequence selected from the list consisting of SEQ ID NO:361, SEQ ID NO:364, SEQ ID NO:366, and / or SEQ ID NO:369.
[0259] In one embodiment, the bispecific polypeptide comprises: - comprising a chain H1 comprising a sequence selected from the list consisting of SEQ ID NO: 359, SEQ ID NO: 362, SEQ ID NO: 365, and / or SEQ ID NO: 367; and / or - comprising a chain L1 comprising a sequence selected from the list consisting of SEQ ID NO: 360, SEQ ID NO: 363, SEQ ID NO: 372, and / or SEQ ID NO: 368; and / or - comprising chain H2 comprising a sequence selected from the list consisting of SEQ ID NO: 361, SEQ ID NO: 364, SEQ ID NO: 366, and / or SEQ ID NO: 369.
[0260] In one embodiment, the bispecific polypeptide comprises: - comprising two chains H1 each comprising a sequence selected from the list consisting of SEQ ID NO: 359, SEQ ID NO: 362, SEQ ID NO: 365, and / or SEQ ID NO: 367; and / or - comprising two chains L1 each comprising a sequence selected from the list consisting of SEQ ID NO: 360, SEQ ID NO: 363, SEQ ID NO: 372, and / or SEQ ID NO: 368; and / or - comprises two chains H2 each comprising a sequence selected from the list consisting of SEQ ID NO:361, SEQ ID NO:364, SEQ ID NO:366, and / or SEQ ID NO:369.
[0261] In one embodiment, the bispecific polypeptide may comprise one or more variants of chain H1, chain L1 and / or chain H2 as defined above, having at least 90% sequence identity thereto, or 95% sequence identity thereto, or 99% sequence identity thereto.
[0262] In one embodiment, the bispecific polypeptide comprises: and / or comprising chain H1 comprising SEQ ID NO: 359 comprises a chain L1 comprising SEQ ID NO: 360, and / or - Contains chain H2 comprising SEQ ID NO:361.
[0263] In one embodiment, the bispecific polypeptide comprises: and / or comprising chain H1 comprising SEQ ID NO: 362 and / or comprising a chain L1 comprising SEQ ID NO: 363 - Contains chain H2 comprising SEQ ID NO:364.
[0264] In one embodiment, the bispecific polypeptide comprises: and / or comprising chain H1 comprising SEQ ID NO: 365 and / or comprising chain L1 comprising SEQ ID NO: 372 - Contains chain H2 comprising SEQ ID NO:366.
[0265] In one embodiment, the bispecific polypeptide comprises: and / or comprising chain H1 comprising SEQ ID NO: 367 and / or comprising a chain L1 comprising SEQ ID NO: 368 - Contains chain H2 comprising SEQ ID NO:369.
[0266] In one embodiment, the bispecific polypeptide comprises: - comprising two chains H1 comprising SEQ ID NO: 359, and / or - comprising two chains L1 comprising SEQ ID NO: 360, and / or - Contains two chains H2 containing SEQ ID NO:361.
[0267] In one embodiment, the bispecific polypeptide comprises: - comprising two chains H1 comprising SEQ ID NO: 362, and / or - comprising two chains L1 comprising SEQ ID NO: 363, and / or - Contains two chains H2 containing SEQ ID NO:364.
[0268] In one embodiment, the bispecific polypeptide comprises: - comprising two chains H1 comprising SEQ ID NO: 365, and / or - comprising two chains L1 comprising SEQ ID NO: 372, and / or - Contains two chains H2 containing SEQ ID NO:366.
[0269] In one embodiment, the bispecific polypeptide comprises: - comprising two chains H1 comprising SEQ ID NO: 367, and / or - comprising two chains L1 comprising SEQ ID NO: 368, and / or - Contains two chains H2 containing SEQ ID NO:369.
[0270] In one embodiment the bispecific polypeptide is selected from the group consisting of Multi1, Multi2, Multi3, Multi4, Multi5, Multi6, Multi7, Multi8, Multi9, Multi10, Multi11, Multi12, Multi13, Multi14, Multi17, Multi18, Multi19, Multi20, Multi23, Multi24, Multi25, Multi26, Multi27, Multi28, Multi29, Multi30, Multi31, Multi32, Multi33, Multi34, Multi ti35, Multi37, Multi38, Multi39, Multi40, Multi41, Multi42, Multi44, Multi46, Multi47, Multi48, Multi49, AC_05333, AC_05334, AC_05336, AC_05337, AC_05338, AC_05339, AC_05341, ffAC_05337, ffAC_05339 and / or AC_05355, preferably an antibody selected from the list consisting of Multi34, Multi42, Multi46 and / or ffAC_05337.
[0271] In one embodiment the bispecific polypeptide is selected from the group consisting of Multi1, Multi2, Multi3, Multi4, Multi5, Multi6, Multi7, Multi8, Multi9, Multi10, Multi11, Multi12, Multi13, Multi14, Multi17, Multi18, Multi19, Multi20, Multi23, Multi24, Multi25, Multi26, Multi27, Multi28, Multi29, Multi30, Multi31, Multi32, Multi33, Mu as defined above. and / or AC_05355, which may include one or more variants thereof, having at least 90% sequence identity or 95% sequence identity thereto.
[0272] Exemplary full heavy and light chain sequences Binding domain B1: 1132 / 1133 heavy chain (VH: Q44R, CH1: H168A, F170G, CH2: L234A, L235A) containing the RUBY mutation (SEQ ID NO: 371): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRRAPGKGLEWVSIGSYGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYVNFGMDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVATGPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPPAPEAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1132 / 1133 light chain containing the RUBY mutation (VL:Q44E, CkappaL135Y, S176W) (SEQ ID NO:372): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQEKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGRNPPTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 1132 / 1133 heavy chain (SEQ ID NO:378): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSIGSYGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYVNFGMDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1132 / 1133 light chain (SEQ ID NO: 379): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGRNPPTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC G12 heavy chain (SEQ ID NO:380): EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK G12 light chain (SEQ ID NO:381): QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKL TVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS G12_mut heavy chain (SEQ ID NO: 382): EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK G12_mut light chain (SEQ ID NO: 383): QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKL TVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
[0273] Binding domain B2: AC_05059, light chain (SEQ ID NO:388): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05059, Heavy Chain (SEQ ID NO:389): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPHLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05060, light chain (SEQ ID NO:390): DIQMTQSPSSLSASVGDRVTITCRASQSIRDYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGTFPFTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05060, Heavy Chain (SEQ ID NO:391): EVQLLESGGGLVQPGGSLRLSCAASGFTFGSYYMSWVRQAPGKGLEWVSGISGYGYYTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHGYGVIDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05061, Light Chain (SEQ ID NO:392): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGAYVPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05061, Heavy Chain (SEQ ID NO:393): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYGYTHFDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05062, Light Chain (SEQ ID NO:394): DIQMTQSPSSLSASVGDRVTITCRASQAISGYLNWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05062, Heavy Chain (SEQ ID NO:395): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYRWHGSVFDYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05064, Light Chain (SEQ ID NO:396): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYPWYFPYTFGQGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05064, Heavy Chain (SEQ ID NO:397): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYGYSVLDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05079, light chain (SEQ ID NO:398): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05079, Heavy Chain (SEQ ID NO:399): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPPLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05081, Light Chain (SEQ ID NO: 400): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05081, Heavy Chain (SEQ ID NO: 401): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFQPHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05088, light chain (SEQ ID NO: 402): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05088, Heavy Chain (SEQ ID NO: 403): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVLFPPHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05089, light chain (SEQ ID NO: 404): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05089, Heavy Chain (SEQ ID NO: 405): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPHHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05090, light chain (SEQ ID NO: 406): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05090, Heavy Chain (SEQ ID NO:407): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPLHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05091, Light Chain (SEQ ID NO: 408): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05091, Heavy Chain (SEQ ID NO:409): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPHFDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05093, Light Chain (SEQ ID NO: 410): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05093, Heavy Chain (SEQ ID NO:411): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPHVDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05094, Light Chain (SEQ ID NO: 412): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05094, Heavy Chain (SEQ ID NO:413): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPHWDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05096, Light Chain (SEQ ID NO:414): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05096, Heavy Chain (SEQ ID NO:415): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFRPHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05097, Light Chain (SEQ ID NO:416): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05097, Heavy Chain (SEQ ID NO:417): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFSPHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Fab1, light chain (SEQ ID NO:418): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSHGPLLTFGQGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Fab1, Heavy Chain (SEQ ID NO:419): QVQLVQSGAEVKKPGSSVKVSCKASGGTFGYYAIHWVRQAPGQGLEWMGGIGSIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAWSSDHMDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Fab3, light chain (SEQ ID NO:420): EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYWYPLTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Fab3, Heavy Chain (SEQ ID NO:421): QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSSSIHWVRQAPGQGLEWMGHIYPSFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARHSGSRFFSPMDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0274] As discussed above, methods for the production of the polypeptides of the present invention are well known in the art.
[0275] Advantageously, the polypeptide is or comprises a recombinant polypeptide. Suitable methods for the production of such recombinant polypeptides are well known in the art, such as expression in prokaryotic or eukaryotic host cells (see, for example, Green & Sambrook, 2012, Molecular Cloning, A Laboratory Manual, Fourth Edition, Cold Spring Harbor, New York, the relevant disclosures of which are incorporated herein by reference).
[0276] The polypeptides of the present invention can also be produced using commercially available in vitro translation systems such as rabbit reticulocyte lysate or wheat germ lysate (available from Promega). Preferably, the translation system is rabbit reticulocyte lysate. Conveniently, the translation system can be coupled to a transcription system such as the TNT transcription translation system (Promega). This system has the advantage of producing suitable mRNA transcripts from the encoding DNA polynucleotide in the same reaction as translation.
[0277] Those skilled in the art will appreciate that the polypeptides of the present invention can alternatively be artificially synthesized, for example, using well-known liquid or solid phase synthesis techniques (such as t-Boc or Fmoc solid phase peptide synthesis).
[0278] Polynucleotides, Vectors, and Cells A fourth aspect of the invention provides an isolated nucleic acid molecule encoding a bispecific polypeptide according to any one of the preceding claims, or its constituent polypeptide chains. For example, the nucleic acid molecule may comprise any of the nucleotide sequences provided in Tables A and B.
[0279] Thus, the polynucleotide of the present invention may encode any of the polypeptides described herein, or all or a portion of B1, or all or a portion of B2. The terms "nucleic acid molecule" and "polynucleotide" are used interchangeably herein and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Non-limiting examples of polynucleotides include genes, gene fragments, messenger RNA (mRNA), cDNA, recombinant polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. The polynucleotides of the present invention may be provided in isolated or substantially isolated form. Substantially isolated means that there may be substantial, but not complete, isolation of the polypeptide from any surrounding medium. Polynucleotides may be mixed with carriers or diluents that do not interfere with their intended use and still be considered substantially isolated.
[0280] A nucleic acid sequence "encoding" a selected polypeptide is a nucleic acid molecule that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. As used herein, such nucleic acid sequences can include, but are not limited to, cDNA from viral, prokaryotic or eukaryotic mRNA, genomic sequences from viral or prokaryotic DNA or RNA, and even synthetic DNA sequences. A transcription termination sequence may usually be located 3' to the coding sequence.
[0281] Representative polynucleotides encoding exemplary antibody heavy or light chain amino acid sequences may comprise or consist of any one of the nucleotide sequences disclosed herein, such as those shown in Tables A and B.
[0282] A suitable polynucleotide sequence may alternatively be a variant of one of these specific polynucleotide sequences.For example, the variant may be any of the substitution, deletion, or addition variants of the above nucleic acid sequences.Variant polynucleotides may include 1, 2, 3, 4, 5, up to 10, up to 20, up to 30, up to 40, up to 50, up to 75 or more nucleic acid substitutions and / or deletions from the sequences shown in the sequence listing.
[0283] Suitable variants may be at least 70% homologous to any one of the polynucleotides of the nucleic acid sequences disclosed herein, preferably at least 80% or 90%, more preferably at least 95%, 97%, or 99% homologous thereto. Preferably, homology and identity at these levels exists at least for the coding region of the polynucleotide. Methods for measuring homology are well known in the art, and it will be understood by the skilled artisan that in the present context, homology is calculated based on nucleic acid identity. Such homology may exist over a region of at least 15, preferably at least 30, for example at least 40, 60, 100, 200 or more consecutive nucleotides. Such homology may exist over the entire length of the unmodified polynucleotide sequence.
[0284] Methods for measuring polynucleotide homology or identity are known in the art. For example, the UWGCG package provides the BESTFIT program (e.g., using its default settings) that can be used to calculate homology (Devereux et al., 1984, the disclosure of which is incorporated herein by reference).
[0285] The PILEUP and BLAST algorithms can also be used to calculate homology or align sequences (typically on their default settings), e.g., as described in Altschul, 1993; Altschul et al., 1990, the disclosures of which are incorporated herein by reference.
[0286] Software for performing BLAST analysis is publicly available from the National Center for Biotechnology Information (http: / / www.ncbi.nlm.nih.gov / ). The algorithm involves identifying high-scoring sequence pairs (HSPs) by identifying the first short words of length W in the query sequence that either match or meet a positive threshold score T when aligned with words of the same length in the database sequences. T is referred to as the neighborhood word score threshold (Altschul et al, supra). These initial neighborhood word hits act as seeds to initiate searches to find HSPs that contain them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. The extension of the word hits in each direction is stopped when the cumulative alignment score falls below zero due to the accumulation of one or more negative scoring residue alignments or when the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff & Henikoff, 1992, the disclosure of which is incorporated herein by reference), alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.
[0287] The BLAST algorithm performs a statistical analysis of the similarity between two sequences, see, e.g., Karlin & Altschul, 1993, the disclosure of which is incorporated herein by reference. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in a comparison of a first sequence to a second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
[0288] A homologue may differ from a sequence in the related polynucleotide by 3, 5, 10, 15, 20 or more mutations (each of which may be a substitution, deletion or insertion). These mutations may be measured over a region of at least 30, such as at least 40, 60, or 100 or more contiguous nucleotides of the homologue.
[0289] In one embodiment, variant sequences may vary from the specific sequences shown in the sequence listing due to the redundancy of the genetic code. The DNA code has four primary nucleic acid residues (A, T, C, and G) that are used to "spell" three letter codons that represent amino acids in proteins encoded by the genes of an organism. The linear sequence of codons along the DNA molecule is translated into a linear sequence of amino acids in the protein(s) encoded by those genes. The code is highly degenerate, with 61 codons that code for the 20 natural amino acids, and three codons that represent "stop" signals. Thus, most amino acids are coded for by more than one codon, and in fact, some are coded for by four or more different codons. Thus, a variant polynucleotide of the invention may code for the same polypeptide sequence as another polynucleotide of the invention, but may have a different nucleic acid sequence due to the use of different codons to code for the same amino acids.
[0290] Thus, a polypeptide of the present invention may be produced from or delivered in the form of a polynucleotide which encodes and is capable of expressing it.
[0291] The polynucleotides of the present invention can be synthesized according to methods well known in the art, as described for example in Green & Sambrook (2012, Molecular Cloning-a laboratory manual, 4th edition; Cold Spring Harbor Press, the disclosure of which is incorporated herein by reference).
[0292] The nucleic acid molecules of the invention can be provided in the form of expression cassettes that contain control sequences operably linked to an insert sequence, thus allowing the expression of the polypeptides of the invention in vivo. These expression cassettes are then typically provided within vectors (e.g., plasmids or recombinant viral vectors). Such expression cassettes can be directly administered to the host subject. Alternatively, a vector containing the polynucleotides of the invention can be administered to the host subject. Preferably, the polynucleotides are prepared and / or administered using a genetic vector. A suitable vector can be any vector that is capable of carrying a sufficient amount of genetic information and allowing the expression of the polypeptides of the invention.
[0293] Thus, the present invention includes expression vectors comprising such polynucleotide sequences. Such expression vectors are routinely constructed in the field of molecular biology and may, for example, include the use of plasmid DNA and appropriate initiators, promoters, enhancers, and other elements such as polyadenylation signals that may be required, which are positioned in the correct orientation to allow expression of the peptides of the present invention. Other suitable vectors will be apparent to those skilled in the art (see Green & Sambrook, supra).
[0294] The present invention also includes cells that have been modified to express the polypeptides of the present invention. Such cells include transient, or preferably stable, higher eukaryotic cell lines, such as mammalian cells or insect cells, lower eukaryotic cells, such as yeast or prokaryotic cells, such as bacterial cells. Particular examples of cells that can be modified by insertion of vectors or expression cassettes encoding the polypeptides of the present invention include mammalian human embryonic kidney (HEK) (e.g., HEK293T), CHO, HeLa, NS0, and COS cells. Preferably, the cell line selected is not only stable, but also allows mature glycosylation and cell surface expression of the polypeptide.
[0295] Such cell lines of the invention may be cultured using routine methods to produce a polypeptide of the invention, or may be used therapeutically or prophylactically to deliver an antibody of the invention to a subject. Alternatively, the polynucleotide, expression cassette or vector of the invention may be administered ex vivo to cells derived from a subject and the cells then returned to the subject's body.
[0296] In one embodiment, the nucleic acid molecule encodes an antibody heavy chain or a variable region thereof.
[0297] In one embodiment, the nucleic acid molecule encodes an antibody light chain or a variable region thereof.
[0298] "Nucleic acid molecule" includes DNA, which may be single-stranded or double-stranded (e.g., genomic or complementary DNA), and mRNA molecules. "Isolated" means that the nucleic acid molecule is not located or otherwise provided within a cell.
[0299] In one embodiment, the nucleic acid molecule is a cDNA molecule.
[0300] It will be understood by those of skill in the art that nucleic acid molecules can be codon optimized for expression of an antibody polypeptide in a particular host cell, e.g., for expression in a human cell (see, e.g., Angov, 2011, the disclosure of which is incorporated herein by reference).
[0301] Also within the scope of the present invention are: (a) a fifth aspect of the invention provides a vector (such as an expression vector) comprising a nucleic acid molecule according to the fourth aspect of the invention; (b) a sixth aspect of the invention provides a host cell (such as a mammalian cell, e.g. a human cell, or a Chinese hamster ovary cell, e.g. a CHOK1SV cell) comprising a nucleic acid molecule according to the fourth aspect of the invention, or a vector according to the fifth aspect of the invention, and (c) A seventh aspect of the invention provides a method of making a polypeptide according to the first, second or third aspect of the invention, the method comprising culturing a population of host cells according to the sixth aspect of the invention under conditions in which the polypeptide is expressed, and isolating the polypeptide therefrom.
[0302] Production method In an eighth aspect, the invention provides compositions comprising molecules of the invention, such as antibodies, bispecific polypeptides, polypeptides, polynucleotides, vectors, and cells described herein. For example, the invention provides compositions comprising one or more molecules of the invention, such as one or more antibodies and / or bispecific polypeptides of the invention, and at least one pharma- ceutically acceptable carrier.
[0303] It will be appreciated by those skilled in the art that the pharmaceutical compositions may also include additional compounds, including chelating agents such as EDTA, citrate, EGTA, or glutathione.
[0304] The pharmaceutical compositions can be prepared in a manner known in the art that is sufficiently storage stable and suitable for administration to humans and animals. For example, the pharmaceutical compositions can be lyophilized by freeze drying, spray drying, spray cooling, or by using particle formation from supercritical particle formation.
[0305] By "pharmacologically acceptable" is meant a non-toxic material that does not reduce the effectiveness of the CD40 and CEA binding activity of the bispecific polypeptide of the invention. Such pharma- ceutically acceptable buffers, carriers, or excipients are well known in the art (see Remington's Pharmaceutical Sciences, 18th edition, A. R. Gennaro, Ed., Mack Publishing Company (1990), and handbook of Pharmaceutical Excipients, 3rd edition, A. Kibbe, Ed., Pharmaceutical Press (2000), the disclosures of which are incorporated herein by reference).
[0306] The term "buffer" is intended to mean an aqueous solution containing an acid-base mixture for the purpose of stabilizing the pH. Examples of buffers are Trizma, Bicine, Tricine, MOPS, MOPSO, MOBS, Tris, Hepes, HEPBS, MES, phosphate, carbonate, acetate, citrate, glycolate, lactate, borate, ACES, ADA, tartrate, AMP, AMPD, AMPSO, BES, CABS, cacodylate, CHES, DIPSO, EPPS, ethanolamine, glycine, HEPPSO, imidazole, imidazole lactate, PIPES, SSC, SSPE, POPSO, TAPS, TABS, TAPSO and TES.
[0307] The term "diluent" is intended to mean an aqueous or non-aqueous solution intended for diluting a polypeptide in a pharmaceutical preparation. The diluent may be one or more of saline, water, polyethylene glycol, propylene glycol, ethanol, oils (such as safflower oil, corn oil, peanut oil, cottonseed oil, or sesame oil).
[0308] The term "adjuvant" is intended to mean any compound added to a formulation to increase the biological effect of the polypeptide of the present invention. The adjuvant may be, for example, but is not limited to, one or more of zinc, copper, or silver salts with different anions, such as fluoride, chloride, bromide, iodide, thiocyanate, sulfite, hydroxide, phosphate, carbonate, lactate, glycolate, citrate, borate, tartrate, and acetate with different acyl composition. The adjuvant may also be cationic cellulose ethers, cationic cellulose esters, cationic polymers such as deacetylated hyaluronic acid, chitosan, cationic dendrimers, cationic synthetic polymers such as poly(vinylimidazole), and cationic polypeptides such as polyhistidine, polylysine, polyarginine, and peptides containing these amino acids.
[0309] The excipient may be one or more of carbohydrates, polymers, lipids and minerals. Examples of carbohydrates include lactose, glucose, sucrose, mannitol and cyclodextrin, which are added to the composition, for example, to facilitate lyophilization. Examples of polymers are starch, cellulose ethers, cellulose carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, alginate, carrageenan, hyaluronic acid and its derivatives, polyacrylic acid, polysulfonates, polyethylene glycol / polyethylene oxide, polyethylene oxide / polypropylene oxide copolymers, polyvinyl alcohol / polyvinyl acetate with different hydrolysis degrees, and polyvinylpyrrolidone, all of which are of different molecular weights, which are added to the formulation, for example, for viscosity control, to achieve bioadhesion, or to protect lipids from chemical and proteolytic degradation. Examples of lipids are fatty acids, phospholipids, mono-, di-, and triglycerides, ceramides, sphingolipids and glycolipids, all of different acyl chain length and saturation, egg lecithin, soy lecithin, hydrogenated egg, and soy lecithin, which are added to the composition for similar reasons as for the polymers. Examples of minerals are talc, magnesium oxide, zinc oxide, and titanium oxide, which are added to the composition to obtain benefits such as reduced liquid accumulation or favorable pigment properties.
[0310] The polypeptides of the present invention may be formulated into any type of pharmaceutical composition known in the art to be suitable for their delivery.
[0311] In one embodiment, the pharmaceutical composition of the present invention may be in the form of liposomes, in which the polypeptide is combined with amphiphilic agents such as lipids that exist in aggregated form as micelles, insoluble monolayers, and liquid crystals, in addition to other pharma- ceutically acceptable carriers. Suitable lipids for liposomal formulations include, but are not limited to, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponins, bile acids, and the like. Suitable lipids also include the above lipids modified with poly(ethylene glycol) at the polar head group to extend bloodstream circulation time. Preparation of such liposomal formulations can be found, for example, in US 4,235,871, the disclosure of which is incorporated herein by reference.
[0312] The pharmaceutical composition of the present invention can also be in the form of biodegradable microparticles.Aliphatic polyesters such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), copolymers of PLA and PGA (PLGA) or poly(caprolactone) (PCL) and polyanhydrides are widely used as biodegradable polymers in the production of microparticles.The preparation of such microparticles can be found in US5,851,451 and EP0213303, the disclosures of which are incorporated herein by reference.
[0313] In a further embodiment, the pharmaceutical composition of the present invention is provided in the form of a polymer gel, in which polymers such as starch, cellulose ethers, cellulose carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, alginates, carrageenans, hyaluronic acid and their derivatives, polyacrylic acid, polyvinylimidazole, polysulfonates, polyethylene glycol / polyethylene oxide, polyethylene oxide / polypropylene oxide copolymers, polyvinyl alcohol / polyvinyl acetate with different degrees of hydrolysis, and polyvinylpyrrolidone are used to thicken the solution containing the drug. The polymer may also include gelatin or collagen.
[0314] Alternatively, the polypeptide may simply be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol or oils (e.g., safflower oil, corn oil, peanut oil, cottonseed oil, or sesame oil), tragacanth gum, and / or various buffers.
[0315] It should be understood that the pharmaceutical composition of the present invention may contain ions and a defined pH to enhance the action of the active polypeptide. In addition, the composition may be subjected to conventional pharmaceutical operations such as sterilization, and / or may contain conventional adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, fillers, etc.
[0316] The pharmaceutical compositions according to the invention can be administered by any suitable route known to those skilled in the art. Thus, routes of administration include parenteral (intravenous, subcutaneous, intramuscular), topical, ocular, nasal, pulmonary, buccal, oral, parenteral, vaginal, and rectal. Administration via implants is also possible.
[0317] In a preferred embodiment, the pharmaceutical compositions are administered parenterally, for example, intravenously, intraventricularly, intraarticularly, intraarterially, intraperitoneally, intrathecally, intraventricularly, intrathoracically, intracranially, intramuscularly, or subcutaneously, or they may be administered by infusion techniques. They are conveniently used in the form of a sterile aqueous solution which may contain sufficient salts or other substances, such as glucose, to make them isotonic with blood. The aqueous solution should be suitably buffered (preferably to a pH of 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
[0318] Preparations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain antioxidants, buffers, bacteriostatic agents, and solutes that render the solution isotonic with the blood of the intended recipient, as well as aqueous and non-aqueous sterile suspensions that may contain suspending agents and thickening agents.The preparations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a lyophilized (lyophilized) state requiring only the addition of a sterile liquid carrier, for example water for injection, immediately prior to use.Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the kind previously described.
[0319] Thus, the pharmaceutical compositions of the present invention are particularly suitable for parenteral administration, for example intravenous administration.
[0320] Alternatively, the pharmaceutical composition can be administered intranasally or by inhalation (e.g., in the form of an aerosol spray) from a pressurized container, pump, spray, or nebulizer using a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 1,1,1,2-tetrafluoroethane (hydrofluoroalkanes such as HFA134A3 or 1,1,1,2,3,3,3-heptafluoropropane (HFA227EA3), carbon dioxide, or other suitable gas). In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. The pressurized container, pump, spray, or nebulizer can contain a solution or suspension of the active polypeptide, for example, using a mixture of ethanol and a propellant as a solvent, and can additionally contain a lubricant, for example, sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
[0321] The pharmaceutical composition will be administered to the patient in a pharma- ceutical effective dose. As used herein, "therapeutically effective amount" or "effective amount" or "therapeutically effective" refers to an amount that provides a therapeutic effect for a given condition and administration regimen. It is a predetermined amount of active material calculated to produce a desired therapeutic effect in association with necessary additives and diluents, i.e., carriers or administration vehicles. It is further intended to mean an amount sufficient to reduce, and most preferably prevent, clinically significant deficits in the activity, function, and response of the host. Alternatively, a therapeutically effective amount is an amount sufficient to produce an improvement in a clinically significant condition in the host. As will be appreciated by those skilled in the art, the amount of a compound may vary depending on its specific activity. A suitable dosage may contain a predetermined amount of active composition calculated to produce a desired therapeutic effect in association with necessary diluents. In the methods of making and using the compositions of the present invention, a therapeutically effective amount of the active ingredient is provided. The therapeutically effective amount can be determined by an ordinarily skilled medical or veterinary practitioner based on patient characteristics such as age, weight, sex, condition, comorbidities, other diseases, etc., as is well known in the art. The administration of a pharma- ceutically effective dose can be carried out both by single administration in the form of individual dose units or several smaller dose units, and by multiple administration of subdivided doses at specific intervals. Alternatively, the dose can be provided as a continuous infusion over a long period of time.
[0322] Particularly preferred compositions are formulated for systemic administration.
[0323] The composition may be preferably formulated for sustained release over a period of time. Thus, the composition may be provided in or as part of a matrix that facilitates sustained release. A preferred sustained release matrix may include montanide or gamma-polyglutamic acid (PGA) nanoparticles.
[0324] The bispecific polypeptides can be formulated in various concentrations depending on the potency / toxicity of the polypeptides used. For example, the formulation may contain the active polypeptide at a concentration of 0.1 μM to 1 mM, more preferably 1 μM to 500 μM, 500 μM to 1 mM, 300 μM to 700 μM, 1 μM to 100 μM, 100 μM to 200 μM, 200 μM to 300 μM, 300 μM to 400 μM, 400 μM to 500 μM, 500 μM to 600 μM, 600 μM to 700 μM, 800 μM to 900 μM, or 900 μM to 1 mM. Typically, the formulation contains the active polypeptide at a concentration of 300 μM to 700 μM.
[0325] Typically, therapeutic doses of bispecific polypeptides (with or without therapeutic moieties) in human patients are in the range of 100 μg to 700 mg per administration (based on a body weight of 70 kg). For example, a maximum therapeutic dose may be in the range of 0.1 to 20 mg / kg per administration, such as 0.1 to 5 mg / kg or 1 to 5 mg / kg or 0.1 to 2 mg / kg. It will be appreciated that such doses may be administered at different intervals as determined by the oncologist / physician, for example doses may be administered daily, twice weekly, weekly, biweekly, or monthly.
[0326] It will be appreciated by those skilled in the art that the pharmaceutical compositions of the present invention may be administered alone or in combination with other therapeutic agents used in the treatment of cancers and / or tumors, such as antimetabolites, alkylating agents, anthracyclines and other cytotoxic antibiotics, vinca alkaloids, etoposide, platinum compounds, taxanes, topoisomerase I inhibitors, other cytostatic drugs, antiproliferative immunosuppressants, antiangiogenic drugs, cancer vaccines, adoptive cell transfer (T cells / DC, NK cells), corticosteroids, sex hormones and hormone antagonists, and other therapeutic antibodies (such as antibodies against CEA or immune checkpoint modulators).
[0327] For example, the pharmaceutical compositions of the invention may be administered in combination with an immunotherapeutic agent that binds to a target selected from the group consisting of PD-1 / PD-L1, VGFR, EGFR, HER2, CTLA-4, CD137, OX40, GITR, LAG3, TIM3, CD27, VISTA, and KIR.
[0328] Thus, the present invention encompasses combination therapies comprising a bispecific polypeptide of the invention together with a further immunotherapeutic agent that specifically binds to an immune checkpoint molecule and is effective in the treatment of cancer and / or tumors. It will be appreciated that the therapeutic benefit of the further immunotherapeutic agent may be mediated by attenuating the function of an inhibitory immune checkpoint molecule and / or by activating the function of a stimulatory immune checkpoint or costimulatory molecule.
[0329] In one embodiment, the additional immunotherapeutic agent is (a) immunotherapeutic agents that inhibit the function of PD-1 and / or PD-L1; (b) immunotherapeutic agents that inhibit the function of CTLA-4; (c) immunotherapeutic agents that activate the function of CD137; (d) immunotherapeutic agents that bind to and activate the function of OX40; (e) immunotherapeutic agents that inhibit the function of LAG3; (f) immunotherapeutic agents that inhibit the function of TIM3; (g) immunotherapeutic agents that inhibit the function of VISTA; (h) immunotherapeutic agents that inhibit the function of VGFR; (i) immunotherapeutic agents that inhibit the function of EGFR, and (j) an immunotherapeutic agent that inhibits the function of HER2.
[0330] Thus, the further immunotherapeutic agent may be a PD-1 inhibitor, such as an anti-PD-1 antibody, or an antigen-binding fragment thereof capable of inhibiting PD-1 function (e.g., nivolumab, pembrolizumab, lambrolizumab, PDR-001, MEDI-0680, and AMP-224). Alternatively, the PD-1 inhibitor may comprise or consist of an anti-PD-L1 antibody, or an antigen-binding fragment thereof capable of inhibiting PD-1 function (e.g., durvalumab, atezolizumab, avelumab, and MDX-1105).
[0331] In another embodiment, the additional immunotherapeutic agent is a CTLA-4 inhibitor, such as an anti-CTLA-4 antibody, or antigen-binding portion thereof.
[0332] In a further embodiment, the additional immunotherapeutic agent activates CD137, such as an agonist anti-CD137 antibody, or antigen-binding portion thereof.
[0333] In a further embodiment, the additional immunotherapeutic agent activates OX40, such as an agonist anti-OX40 antibody, or antigen-binding portion thereof.
[0334] In a further embodiment, the further immunotherapeutic agent inhibits the function of LAG3, TIM3, or VISTA (Lines et al. 2014).
[0335] In another embodiment, the additional immunotherapeutic agent is a VGFR inhibitor, such as an anti-VGFR antibody, or antigen-binding portion thereof.
[0336] In a further embodiment, the additional immunotherapeutic agent activates EGFR, such as an agonist anti-EGFR antibody, or antigen-binding portion thereof.
[0337] In a further embodiment, the additional immunotherapeutic agent activates HER2, such as an agonist anti-HER2 antibody, or antigen-binding portion thereof.
[0338] Those skilled in the art will appreciate that the presence of two active agents (as detailed above) may provide a synergistic benefit in the treatment of tumors in a subject. "Synergistic" includes that the therapeutic effect of the combination of the two agents (e.g., as determined by reference to the growth rate or size of the tumor) is greater than the additive therapeutic effect of the two agents administered by themselves. Such synergy may be identified by testing the active agents alone and in combination in relevant cell line models of solid tumors.
[0339] Also within the scope of the invention are kits comprising a polypeptide or other composition of the invention and instructions for use. The kits may further comprise one or more additional reagents, such as additional therapeutic or prophylactic agents as discussed above.
[0340] Medical Uses and Methods The polypeptides according to the invention may be used for treatment or prevention. In treatment applications, the polypeptides or compositions are administered to a subject already suffering from a disorder or condition in an amount sufficient to cure, alleviate, or partially arrest the condition or one or more of its symptoms. Such therapeutic treatment may result in a decrease in the severity of disease symptoms, or an increase in the frequency or duration of symptom-free periods. An amount sufficient to achieve this is defined as a "therapeutically effective amount". In prophylactic applications, the polypeptides or compositions are administered to a subject not yet exhibiting symptoms of the disorder or condition in an amount sufficient to prevent or delay the onset of symptoms. Such an amount is defined as a "prophylactically effective amount". Subjects may be identified as being at risk for developing a disease or condition by any suitable means.
[0341] Thus, a ninth aspect of the invention provides a bispecific polypeptide according to the first or third aspect of the invention, or a polypeptide according to the second aspect of the invention for use in medicine.
[0342] A tenth aspect of the invention provides a bispecific polypeptide according to the first or third aspect of the invention or a polypeptide according to the second aspect of the invention for use in treating cancer and / or tumours and / or non-cancerous conditions in a subject. Cancer and / or tumours may be referred to as neoplastic disorders.
[0343] An eleventh aspect of the invention provides the use of a bispecific polypeptide according to the first or third aspect of the invention or a polypeptide according to the second aspect of the invention in the preparation of a medicament for treating cancer and / or a tumour and / or a non-cancerous condition in a subject.
[0344] In one embodiment the bispecific polypeptide or polypeptide for use of the tenth aspect of the invention or the use of the eleventh aspect of the invention is for use in combination with one or more additional therapeutic agents.
[0345] In one embodiment, the one or more additional therapeutic agents are immunotherapeutic agents that bind to a target selected from the group consisting of PD-1 / PD-L1, VGFR, EGFR, HER2, CTLA-4, CD137, OX40, GITR, LAG3, TIM3, CD27, and KIR.
[0346] In one embodiment the bispecific polypeptide or polypeptide for the use of the tenth aspect of the invention or the use of the eleventh aspect of the invention is for systemic administration.
[0347] A twelfth aspect of the invention provides a method for the treatment and / or diagnosis of cancer and / or a tumour and / or a non-cancerous condition in a subject, the method comprising administering to the subject an effective amount of a bispecific polypeptide according to the first or third aspect of the invention or a polypeptide according to the second aspect of the invention.
[0348] An alternative twelfth aspect of the invention provides an in vitro method for the diagnosis of cancer and / or tumours comprising a use according to the first or third aspect of the invention or a polypeptide according to the second aspect of the invention.
[0349] In one embodiment, the method comprises administering the bispecific polypeptide systemically.
[0350] In one embodiment, the method further comprises administering to the subject one or more additional therapeutic agents.
[0351] "Treatment" includes both therapeutic and prophylactic treatment of a patient. The term "prophylactic" is used to encompass the use of an agent or formulation thereof described herein that either prevents or reduces the likelihood of a neoplastic disorder in a patient or subject, or the spread, dissemination, or metastasis of cancer cells. The term "prophylactic" also encompasses the use of an agent or formulation thereof described herein to prevent the recurrence of a neoplastic disorder in a patient who has previously been treated for cancer and / or tumors.
[0352] Preferably, the cancer and / or tumor is CEA, e.g., a cancer and / or tumor associated with CEA expression. "Associated with CEA" includes that CEA is the cancer and / or the tumor is caused by CEA and / or CEA is a marker for the cancer and / or tumor.
[0353] In one embodiment, the cancer and / or tumor comprises target cells which comprise expression of CEA.
[0354] Preferably, the expression of CEA is an intermediate level of CEA expression or a high level of CEA expression.
[0355] In one embodiment, an intermediate level of CEA expression is greater than or equal to about 10,000 CEA receptors per target cell, e.g., greater than or equal to about 11,000, greater than or equal to about 12,000, greater than or equal to about 13,000, greater than or equal to about 14,000, greater than or equal to about 15,000, greater than or equal to about 16,000, greater than or equal to about 17,000, greater than or equal to about 18,000, greater than or equal to about 19,000, greater than or equal to about 20,000, greater than or equal to about 21,000, or greater than or equal to about 22,000. The target cells are characterized as expressing 5,000 or more, about 30,000 or more, about 35,000 or more, about 40,000 or more, about 50,000 or more, about 60,000 or more, about 70,000 or more, about 80,000 or more, about 90,000 or more, about 100,000 or more, about 125,000 or more, about 150,000 or more, or about 175,000 or more CEA receptors. In another embodiment, the intermediate level of CEA expression is characterized by target cells expressing about 10,000 to about 200,000 CEA receptors per target cell, for example, about 20,000 to about 175,000 CEA receptors per target cell, or about 20,000 to about 200,000 CEA receptors per target cell, or about 50,000 to about 175,000 CEA receptors per target cell, or about 50,000 to about 200,000 CEA receptors per target cell. Preferably, the CEA receptor is a CEACAM5 receptor.
[0356] In one embodiment, a high level of CEA expression is greater than or equal to about 200,000 CEA receptors per target cell, e.g., greater than or equal to about 225,000, greater than or equal to about 250,000, greater than or equal to about 275,000, greater than or equal to about 300,000, greater than or equal to about 325,000, greater than or equal to about 350,000, greater than or equal to about 375,000, greater than or equal to about 400,000, greater than or equal to about 425,000, or greater than or equal to about 460,000. In another embodiment, the high level of CEA expression is characterized by target cells expressing about 200,000 to about 1,000,000 CEA receptors per target cell, such as about 200,000 to about 500,000 CEA receptors per target cell, or about 300,000 to about 500,000 CEA receptors per target cell. Preferably, the CEA receptor is a CEACAM5 receptor.
[0357] In one embodiment, the cancer and / or tumor does not include cells with no or low levels of CEA expression. In one embodiment, low levels of CEA expression are characterized by cells expressing about 10,000 or less CEA receptors per target cell, such as about 9,000 or less, about 8,000 or less, about 7,000 or less, about 6,000 or less, about 5,000 or less, about 4,000 or less, about 3,000 or less, about 2,000 or less, or about 1,000 or less CEA receptors per cell.
[0358] In one embodiment, the CEA is tumor-associated CEA.
[0359] Preferably, the CEA is CEACAM.
[0360] In one embodiment, the CEACAM is one or more selected from the list consisting of CEACAM1, CEACAM3, CEACAM4, CEACAM5, CEACAM6, CEACAM7, CEACAM8, CEACAM16, CEACAM18, CEACAM19, CEACAM20, and CEACAM21. It will be understood that reference to the foregoing CEACAM molecules includes splice variants.
[0361] Preferably, the CEACAM is one or more selected from the list consisting of CEACAM1, CEACAM5, and CEACAM6. Preferably, the CEACAM is CEACAM1. Most preferably, the CEACAM is CEACAM5.
[0362] In a preferred embodiment, B2 is capable of specifically binding to CEACAM5 but is incapable of binding to other CEACAMs, in particular CEACAM1.
[0363] In one embodiment, the cancer and / or tumor is one or more cancers and / or tumors selected from the list consisting of prostate cancer and / or prostate tumors, breast cancer and / or breast tumors, lung cancer and / or lung tumors, colorectal cancer and / or colorectal tumors, melanoma, bladder cancer and / or bladder tumors, brain / CNS cancer and / or brain / CNS tumors, cervical cancer and / or cervical tumors, esophageal cancer and / or esophageal tumors, gastric cancer and / or gastric tumors, head and neck cancer and / or head and neck tumors, kidney cancer and / or kidney tumors, liver cancer and / or liver tumors, carcinoma, leukemia, lymphoma, ovarian cancer and / or ovarian tumors, pancreatic cancer and / or pancreatic tumors, tonsil cancer and / or tonsil tumors, and sarcoma. Preferably, carcinoma.
[0364] Preferably, the one or more cancers and / or tumors are selected from the list consisting of breast cancer and / or breast tumors, lung cancer and / or lung tumors, colorectal cancer and / or colorectal tumors, gastric cancer and / or gastric tumors, and / or pancreatic cancer and / or pancreatic tumors.
[0365] In a preferred embodiment, the cancer and / or tumor is colorectal cancer and / or colorectal tumor.
[0366] In a preferred embodiment, the cancer and / or tumor is tonsil cancer and / or tonsil tumor.
[0367] Preferably, the carcinoma is one or more carcinomas selected from the list consisting of gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, cervical cancer, bile duct cancer, and medullary thyroid cancer.
[0368] In a preferred embodiment, the carcinoma is colorectal cancer.
[0369] Preferably, the tumor is a solid tumor.
[0370] In one embodiment, the non-cancerous condition is a non-cancerous condition associated with CEA, e.g., CEA expression. "Associated with CEA" includes that CEA is a non-cancerous condition caused by CEA and / or that CEA is a marker for the non-cancerous condition.
[0371] In one embodiment, the non-cancerous condition comprises a target cell comprising expression of CEA.
[0372] Preferably, the expression of CEA is an intermediate level of CEA expression or a high level of CEA expression, as discussed herein.
[0373] Preferably, the one or more non-cancerous conditions are selected from the list consisting of ulcerative colitis, pancreatitis, cirrhosis of the liver, COPD, Crohn's disease, and / or hypothyroidism.
[0374] In one embodiment, the subject is a human.
[0375] Optimized RUBY™ format A thirteenth aspect of the invention provides a bispecific polypeptide comprising an optimized RUBY™ format, preferably wherein the bispecific polypeptide has specificity for a first antigen and a second antigen.
[0376] In certain embodiments, the bispecific polypeptide comprises: (a) an immunoglobulin molecule having specificity for a first antigen, the immunoglobulin molecule comprising a first heavy chain polypeptide and a first light chain polypeptide; and (b) at least one Fab fragment having specificity for a second antigen, the Fab fragment comprising a second heavy chain polypeptide and a second light chain polypeptide; the second light chain polypeptide is fused to the C-terminus of the first heavy chain polypeptide; The bispecific antibodies contain one or more of the mutations discussed in connection with the optimized RUBY™ format to enhance association of the polypeptides, particularly the first heavy chain polypeptide with the first light chain polypeptide and / or enhance association of the second heavy chain polypeptide with the second light chain polypeptide.
[0377] All of the features of the optimized RUBY™ format, and related embodiments of the required RUBY™ format, as discussed for the first aspect of the invention, are relevant to and encompassed by the thirteenth aspect of the invention, in particular the features discussed below.
[0378] The optimized RUBY™ format has the structure shown in Figure 23 with further optimized mutations when compared to the RUBY™ format. As will be appreciated by those skilled in the art, the technology related to antibody formats has broad applicability to a wide range of different target antigens.
[0379] While bispecific polypeptides in the "RUBY™ format" can be reproducibly produced with excellent levels of purity, bispecific polypeptides in the "Optimized RUBY™ format" can be reproducibly produced with even higher levels of purity. Furthermore, bispecific polypeptides in the "Optimized RUBY™ format" have been engineered to have a reduced risk of eliciting an immunogenic response directed against the bispecific polypeptide itself.
[0380] In one embodiment of the thirteenth aspect of the invention the bispecific polypeptide is a bispecific antibody.
[0381] In one embodiment, the bispecific polypeptide comprises an immunoglobulin arranged as an antibody with two arms, and thus two binding sites for a first antigen, and two of the Fab fragments, each providing a binding site for a second antigen. Thus, there are two binding sites for the first antigen and two binding sites for the second antigen. In a preferred embodiment of the thirteenth aspect of the invention, the first antigen and / or the second antigen are not CD40 and / or CEA. In a further preferred embodiment of the thirteenth aspect of the invention, the first antigen and / or the second antigen are proteins and / or peptides that are not CD40 and / or CEA.
[0382] In one embodiment, one or more Fab fragments are linked to the C-terminus of the immunoglobulin via a linker.
[0383] In one embodiment of the first aspect of the invention, the bispecific polypeptide is tetravalent and capable of bivalent binding to each of two antigens.
[0384] The optimized mutations are described below as "Optimized Mutations Set 1" and "Optimized Mutations Set 2" - including "Set 2a" and / or "Set 2b". One of skill in the art will appreciate that various combinations of these optimized mutations can be used in the bispecific polypeptides of the invention, as well as in combination with any of the "RUBY™ format" mutations described above. It will also be understood that variations of these mutations described herein also function as part of the present invention. All mutations in the variable domains (VH or VL) are numbered according to the IMGT numbering system, and all mutations in the constant domains are numbered according to the EU numbering system.
[0385] Mutation Set 1 - Mutations in the variable domain heavy (VH): T65E, T65A, T65I.
[0386] Mutation Set 2 - Any individual and / or any combination of the mutations listed in Set 2a and Set 2b. Mutations in Set 2a-CH1: Y180A, Y180G, Y180I, Y180N, Y180S, Y180T, Y180V, or Y180W, and / or S183N or S183T, and / or V188G, preferably Y180T. Set 2b-C Mutations in the kappa domain: A111R, A111T, A111W or A111V, and / or T109P, preferably T109P and / or A111V, and / or mutations in the variable domain light (VL): I126A, I126G, I126H, I126N, I126P, I126Q, I126S, or I126T.
[0387] In one embodiment of the invention, the mutation is (a) position T65 in VH (according to the IMGT numbering system), and / or (b) one or more of the following positions in CH1: Y180, S183, and V188, preferably Y180 (according to the EU numbering system); and / or (c) one or more of the following positions in the C kappa domain: A111 and T109 (according to the EU or Kabat numbering system); and / or (d) position I126 in the VL (according to the IMGT numbering system).
[0388] In a particular embodiment, the mutation is at position T65 in the variable domain heavy (VH) (according to the IMGT numbering system).
[0389] In certain embodiments, the mutation is at one or more of the following positions in CH1: Y180, S183, and V188, preferably Y180 (according to the EU numbering system).
[0390] In certain embodiments, the mutations are at one or more of the following positions in the C kappa domain: A111 and T109 (according to the EU or Kabat numbering system), and / or at position I126 in the VL (according to the IMGT numbering system).
[0391] In one embodiment of the invention, the mutation is (a) X65E / A / I (according to the IMGT numbering system) in VH, and / or (b) one or more of the following mutations in CH1: X180A / G / I / N / S / T / V / W, X183N / T, and X188G, preferably X180T (according to the EU numbering system); and / or (c) one or more of the following mutations in the C kappa domain: X111R / T / W / V, and X109P, preferably X111V and X109P (according to the EU or Kabat numbering system); and / or (d) X126A / G / H / N / P / Q / S / T in VL (according to the IMGT numbering system). *X stands for any amino acid
[0392] In a particular embodiment, the mutation is X65E / A / I (according to the IMGT numbering system) in the VH chain. *X stands for any amino acid
[0393] In certain embodiments, the mutations are one or more of the following mutations in CH1: X180A / G / I / N / S / T / V / W, X183N / T, and X188G, preferably X180T (according to the EU numbering system). *X stands for any amino acid
[0394] In certain embodiments, the mutations are one or more of the following mutations in the C kappa domain: X111R / T / W / V, and X109P, preferably X111V and X109P (according to the IMGT numbering system), and / or the mutations are X126A / G / H / N / P / Q / S / T (according to the IMGT numbering system) in the VL. *X stands for any amino acid
[0395] For example, the mutation (a) one or more of the following mutations in VH: T65E, T65A, and T65I (according to the IMGT numbering system); and / or (b) one or more of the following mutations in CH1: Y180A, Y180G, Y180I, Y180N, Y180S, Y180T, Y180V, Y180W, S183N, S183T, V188G, preferably Y180T (according to the EU numbering system); and / or (c) one or more of the following mutations in the C kappa domain: A111R, A111T, A111W, A111V, and T109P, preferably T109P and A111V (according to the EU numbering system); and / or (d) one or more of the following mutations in the VL: I126A, I126G, I126H, I126N, I126P, I126Q, I126S, and I126T (according to the IMGT numbering system).
[0396] In particular examples, the mutations are one or more of the following mutations in VH: T65E, T65A, and T65I (according to the IMGT numbering system).
[0397] In particular examples, the mutation is one or more of the following mutations in CH1: Y180A, Y180G, Y180I, Y180N, Y180S, Y180T, Y180V, Y180W, S183N, S183T, V188G, preferably Y180T (according to the EU numbering system).
[0398] In particular examples, the mutations are one or more of the following mutations in the C-kappa domain: A111R, A111T, A111W, A111V, and T109P, preferably T109P and A111V (according to the EU or Kabat numbering system), and / or one or more of the following mutations in the VL: I126A, I126G, I126H, I126N, I126P, I126Q, I126S, and I126T (according to the IMGT numbering system).
[0399] As discussed above, any combination of "RUBY™ format" mutations and "optimized RUBY™ format" mutations can be used in the same bispecific antibody, such as any one or more of the following "RUBY™ format" mutations, or variations described herein, in (a)-(d), combined with any one or more of the following "optimized RUBY™ format" mutations, or variations described herein, in (e)-(g): (a) one or more of the following mutations in the CH1 domain: H168A, F170G, and / or T187E (according to the EU numbering system); (b) one or more of the following mutations in the C kappa domain: L135Y, S176W, S114A, and / or N137K (according to the EU or Kabat numbering system), and / or the following mutations in the C lambda domain: L135Y, S176W, T114A, and / or S137K (according to the Kabat numbering system); (c) Mutation in VL: Q44R or Q44E (according to the IMGT numbering system), a.d. (d) mutation in VH: Q44E or Q44R (according to the IMGT numbering system); (e) a mutation in VH: T65E, T65A, or T65I (according to the IMGT numbering system); (f) a mutation in CH1: Y180T (according to the EU numbering system); and / or (g) Mutations in C kappa: T109P and / or A111V (according to the EU numbering system).
[0400] Thus, in certain embodiments, a bispecific antibody with combined "RUBY™ format" and "optimized RUBY™ format" mutations comprises the following mutations: one or more of the following mutations in the CH1 domain: H168A, F170G, Y180T, and / or T187E (according to the EU numbering system); one or more of the following mutations in the C kappa domain: T109P, A111V, L135Y, S176W, S114A, and / or N137K (according to the EU or Kabat numbering system), and / or one or more of the following mutations in the C lambda domain: L135Y, S176W, T114A, and / or S137K (according to the Kabat numbering system); Mutations in the VL: Q44R or Q44E (according to the IMGT numbering system), and / or It may include one or more of the following mutations in VH: Q44E or Q44R, and / or T65E, T65A, or T65I (according to the IMGT numbering system).
[0401] The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.
[0402] The use of the word "a" or "an," when used in conjunction with the term "comprising" in the claims and / or specification, may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."
[0403] These and other embodiments of the invention will be better appreciated and understood when considered in conjunction with the above description and the accompanying drawings. It should be understood, however, that the above description, while indicating various embodiments of the invention and numerous specific details thereof, is given by way of illustration and not limitation. Many substitutions, modifications, additions, and / or rearrangements may be made within the scope of the invention without departing from the spirit thereof, and the invention includes all such substitutions, modifications, additions, and / or rearrangements.
[0404] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0405] Preferred, non-limiting examples embodying certain aspects of the present invention will now be described with reference to the following drawings. [Brief description of the drawings]
[0406] [Figure 1] ELISA analysis of 22 CEA antibodies isolated using phage displayed in combination with next generation sequencing. Binders in IgG1 format were analyzed for binding to human CEACAM5 (abbreviated CAM5) (hatched bars) or human CEACAM1 (abbreviated CAM1) (back bars). [Diagram 2]Ability of CD40 and CEACAM5 targeted RUBY™ bsAb to bind both antigens simultaneously as measured by dual target ELISA. Panel A shows the binding curves for Multi34, Multi35, Multi37 and Multi38. Panel B shows the binding curves for Multi39, Multi40, Multi41, Multi42 and Panel C shows the binding curves for Multi44, Multi45, Multi46 and Multi47. Finally, Panel D shows the binding curves for Multi48, Multi4 and AC_05339. [Diagram 3] Cross-reactivity of RUBY™ bsAbs (Mult34, Multi35, Multi37-Multi42, Multi44-Multi49) with CEA protein family members CEACAM1, 5, 6, and 8 as assessed by ELISA. [Figure 4] Kinetic measurements in Octet of the interaction between captured CD40 CEACAM5-targeting bispecific antibodies (Multi34, Multi42, Multi46, and AC_5339) to soluble monomeric human CEACAM5 (various concentrations ranging from 100 to 1.6 nM). Association was measured for 100 seconds, followed by dissociation in 1x kinetics buffer for 100 seconds. [Diagram 5] Kinetic measurements in Octet of bispecific antibodies in solution (various concentrations ranging from 50 to 0.8 nM) interacting with captured human CEACAM5-biotin. Association was measured for 100 s, followed by dissociation in kinetics buffer for 100 s. [Figure 6]Binding of CD40-CEACAM5 bispecific antibodies to CEACAM5 transfected CHO cells. Binding of CD40-CEA bispecific antibodies was detected by flow cytometry using fluorochrome-conjugated anti-human IgG. Panel A shows the binding curves for Multi34 and Multi35. Panel B shows the binding curves for Multi41, Multi42, Multi44, and ffAC_5339. Panel C shows the binding curves for Multi46, Multi47, Multi48, and Multi49. Panel D shows the binding curves for ffAC_5337 and AC_5339. Panel E shows the binding curves for AC_05355 and AC_05339. [Figure 7] Binding of CD40-CEACAM5 bispecific antibody to CEACAM1-transfected CHO cells (A-D) and CHOwt cells (F). Binding of CD40-CEACAM5 bispecific antibody was detected by flow cytometry using fluorochrome-conjugated anti-human IgG. [Figure 8] Binding of CD40-CEACAM5 bispecific antibody to CEACAM5-expressing tumor cells. The tumor cell lines MKN45 (A-C), which expresses high levels of CEACAM5, LS174T (D-E), which expresses intermediate levels of CEACAM5, and Lovo (G-J), which expresses low levels of CEACAM5. Binding of CD40-CEACAM5 bispecific antibody was detected by flow cytometry using fluorochrome-conjugated anti-human IgG. [Figure 9] Effect of CD40-CEACAM5 bispecific antibodies on cultured CD40 reporter cells with titrated antibodies in the presence or absence of CEACAM5 expressed on CHO cells. Responses were calculated as fold induction over background. [Figure 10]Effect of CD40-CEACAM5 bispecific antibodies on CD40 reporter cells when co-cultured with tumor cells with different CEACAM5 receptor densities. CD40 clone G12 containing CD40-CEACAM5 (A-D), CD40 clone G12 containing CEACAM5-CD40 (E-H), and CD40 clone 1132 containing CD40-CEACAM5 (I-J). Responses were calculated as fold induction over background. [Figure 11] Effect of CD40-CEACAM5 bispecific antibodies on CEACAM5-expressing CHO cells and CD40 reporter cells co-cultured with titrated antibodies in the presence or absence of soluble CEACAM5. Responses were calculated as fold induction over background. [Figure 12] Effect of CD40-CEACAM5 bispecific antibodies on B cell activation. Primary human B cells were cultured with titrated antibodies in the presence or absence of CEACAM5 expressed on CHO cells. After 2 days, CD86 expression on B cells was analyzed by FACS. [Figure 13] Effect of CD40-cCEACAM5 bispecific antibody AC_05355 on B cell activation in the presence of human or cynomolgus CEACAM5 transfected cells. Primary human B cells were cultured with titrated antibodies in the presence of human or cynomolgus CEACAM5 expressed on CHO cells. After 2 days, CD86 expression on B cells was analyzed by FACS. Graph shows pooled results from 6 donors. [Figure 14] BsAb AC_05339 (0.02 nM) without crosslinking CHO-CEACAM5 or CHO-wt cells activates HEK Blue CD40L™ reporter cells in the presence of Raji cells after 20 h incubation in the Transwell system. Activation monitored as SEAP release into the culture medium measured using QuantiBlue™. Mean + SD of triplicate determinations. [Figure 15]BsAb Multi34 (3-0.004 nM, single sample) crosslinked to CHO-CEACAM5 cells activating HEK Blue CD40L™ reporter cells without the presence of Raji sink cells in a Transwell system. Activation monitored as release of SEAP into the medium after 20 hours of culture, measured using QuantiBlue™. [Figure 16] BsAb Multi42 (3-0.004 nM, single sample) crosslinked to CHO-CEACAM5 cells to activate HEK Blue CD40L™ reporter cells without the presence of Raji sink cells in a Transwell system. Activation monitored as release of SEAP into the medium after 20 hours of culture, measured using QuantiBlue™. [Figure 17] BsAb Multi46 (100-0.1 nM, single sample) crosslinked to CHO-CEACAM5 cells to activate HEK Blue CD40L™ reporter cells without the presence of Raji sink cells in a Transwell system. Activation monitored as release of SEAP into the medium after 20 hours of culture, measured using QuantiBlue™. [Figure 18] Co-localization of tumor debris and Raji cells. Raji cells were incubated with MKN45 tumor debris expressing CEACAM5 and AC_05339 or control antibody 1132 with silenced Fc, more specifically with IgG1 isotype and with L234A and L235A mutations (antibody is referred to herein as 1132.m2). Images were captured with a Cytation5 live imaging system, and the number of tumor debris co-localized with Raji cells after 4 hours was analyzed using Gen5 software. [Figure 19]MC38-CEACAM5 tumor growth and MC38-wt rechallenge. hCD40tg mice inoculated with MC38-CEACAM5 tumors were administered the indicated treatments on days 7, 10, and 13 post-inoculation. Tumors were measured frequently until the first mouse in any of the treatment groups reached a tumor volume exceeding the ethical limit. Statistical analysis of tumor volumes on day 38 was performed using the Mann-Whitney test (n=10, *p<0.05). Naive control hCD40tg mice or mice cured of MC38-CEACAM5 tumors by treatment with CD40-CEACAM5 bsAb (complete responders) were inoculated (rechallenged) with MC38-wt tumors. Tumors were measured frequently until the first mouse in any of the treatment groups reached a tumor volume exceeding the ethical limit. [Figure 20] Effect of CD40-CEACAM5 bispecific antibody AC_05355 on B cell activation in the presence of cynomolgus CEACAM5 (cCEACAM5) transfected CHO cells. Primary cynomolgus B cells were cultured with titrated antibodies in the presence of cCEACAM5 expressed on CHO cells. After 2 days, CD86 expression on B cells was analyzed by FACS. Graph shows pooled data from 2 donors. [Figure 21] MC38-CEACAM5 tumor growth. hCD40tg mice inoculated with MC38-CEACAM5 tumors were administered the indicated treatments on days 10, 13, and 16 after inoculation. Tumors were measured frequently until the first mouse in any of the treatment groups reached a tumor volume exceeding the ethical limit. Statistical analysis of tumor volumes on day 17 was performed using the Mann-Whitney test (n=10, *p<0.05). [Figure 22]This shows a schematic diagram of the structure of exemplary formats of bispecific antibodies of the invention. In each format, the constant region is shown in light grey fill, the variable heavy chain region VH1 is shown as a black and white grid, the variable light chain region VL1 is shown as an open box, the variable heavy chain region VH2 is shown as a black fill, and the variable light chain region VL2 is shown as a white box with diagonal lines. The CD40 binding domain (binding domain 1) is typically represented as a pair of black and white grid and open box domains (VH1 / VL1), and the CEA binding domain (binding domain 2) is typically represented as a pair of black fill and open box domains (VH2 / VL2). However, it will be understood that in all of the formats shown, binding domain 1 and binding domain 2 can be swapped. That is, the CD40 binding domain can occur in the position shown in this figure for the CEA binding domain, and vice versa. [Figure 23] This shows an exemplary configuration of a bispecific antibody construct in the RUBY™ format. The bispecific antibody in Figure 21 is assembled from three types of polypeptide chains: (1) an IgG heavy chain (white) fused to a Fab light chain (lattice) via a polypeptide linker, (2) an IgG light chain (brick), and (3) a Fab heavy chain (black). Mutations are introduced at the interface between the heavy and light chains. [Figure 24] CD40xTAA bsAb mediates tumor debris localization to antigen-presenting cells. The number of CEA+ tumor debris clustering with CD40+ cells was quantified using live cell imaging software after 8 hours of culture. Graph shows the mean (+SD) of duplicate wells in one representative experiment out of four (CEA). [Diagram 25]Isolated cells from human colorectal cancer tumors were analyzed for (left) their CEA expression (gated on total live cells), (center) their ability to provide cross-linking to CD40xCEA Neo-X-Prime bsAb in a CD40 reporter assay, and (right) CD83 upregulation following stimulation of tumor-infiltrating immune cells (gated on CD45+CD3-CD56- live cells) with CD40xCEA Neo-X-Prime bsAb or isotypexCD40 bsAb (data from one representative experiment of three). [Figure 26] Simultaneous binding of CD40 and CEA by CD40xCEA bsAb mediates activation of tonsillar cancer APCs in vitro. Human CD45+HLA-DR+CD3- cells from tonsillar cancer biopsies were co-cultured with UV-irradiated CHO cells transfected with human CEA in the presence of CD40xCEA bsAb, CD40 mAb, or isotype control. After 13 hours of culture, cells were harvested and the frequency of CD86+CD40+ cells was examined using flow cytometry for CD19+CD20+ B cells, CD14+ macrophages, CD1c+cDC2, and XCR1+cDC1. [Figure 27] Accumulation of CD40xCEA bsAb in CEA-expressing tumors, but not of the corresponding CD40mAb. Human CD40 transgenic mice were inoculated sc with MC38-hCEA tumor cells (MC-38-CEA-2, Kerafast) and administered ip on days 10 and 13 with 100 μg of anti-CD40 antibody or a molar equivalent dose (167 μg) of CD40xCEA bsAb or isotype bsAb. On day 14, tumors were dissected. Frozen tumor sections were stained for human IgG to assess accumulation of the administered antibodies and for CEA to assess CEA expression patterns in tumors. Representative images of (A) IgG staining and (B) CEA staining are shown. The staining pattern obtained after treatment with CD40xCEA was significantly stronger than the control, and the staining pattern is consistent with the CEA staining of tumors. [Figure 28]Cryopreserved tumors from human CD40 transgenic mice (B16.F10-hCD40+#6, 7, and 9 used as controls, hereafter referred to as B16 and MB49#2, 4, and 5) were analyzed. 8 μm frozen sections were prepared and stained. Spleens of the mice were used as positive controls. Sections were analyzed with a Leica DMRX-e microscope and representative pictures were taken. A) Representative images from MB49 tumors. B) Immunohistochemical staining was scored as follows: negative (0), few positive cells (1+), moderate number of positive cells (2+), many positive cells (3+), or very many positive cells (4+). The analysis shows that a significantly higher degree of infiltrating T cells is observed in MB49 tumors compared to B16 tumors used as controls. Antibodies used for staining: CD4: Rat IgG, Affymetrix, 14-0042 1:200, CD8 Rat IgG, Affymetrix, 14-0081 1:200, CD3 Rabbit, Dako, A0452 1:100, CD45 Rat IgG, Biodesign 1:100. C) Frequency of immune cell populations in MB49-EpCAM tumors with similar in vivo growth and immune infiltration as MB49 tumors. Human CD40 transgenic mice were injected sc in the right flank with MB49-hEpCAM cells (0.25x106) in 100μl PBS. 12 days after tumor inoculation, tumors were dissected, isolated, and stained for flow cytometric analysis of immune cell content. The frequencies of NK cells (CD45+, CD11b-, CD19-MHCII-, TCR beta-, NK1.1+), T cells (CD45+, CD11b-, CD19-MHCII-, TCR beta+, NK1.1-), B cells (CD45+, Ly6G-, CD3-, NK1.1-, CD19+), monocytes / macrophages (CD45+, Ly6G-, CD3-, NK1.1-, CD64+), and DCs (CD45+, Ly6G-, CD3-, NK1.1-, CD64-, CD11c+, MHCII+) within the total viable CD45+ population were assessed. [Figure 29]Data from NHP studies. A) B cell activation of cynoCEA×CD40RUBY™ on cynomolgus and human B cells in the presence of CEA transfected cells (Macaque CEA, NP_001040590.1). Primary cynomolgus B cells were cultured with titrated antibody in the presence of CEA expressed on CHO cells. After 2 days, CD86 expression on B cells was analyzed by FACS. The graph shows pooled data from two cynomolgus and four human donors. The data show that the CEA×CD40 bsAb in RUBY™ format induces upregulation of CD86 to a similar extent on cynomolgus and human B cells. CEA conditional activation of CD40 on cynomolgus and human B cells is similar to that observed with the human CEA×CD40 bsAb in RUBY™ used in the in vitro assay. The cynoCEAxCD40 bsAb binds with similar affinity to human and cynomolgus CEA (hCEA vs. cCEA, right panel). In B) and C) the main data from the toxicological evaluation in cynomolgus monkeys are presented. Cynomolgus CEAxCD40 bispecific antibody was administered to cynomolgus monkeys via intravenous infusion once a week for 2 weeks at two different dose levels (10 mg / kg and 37.5 mg / kg). One female and one male were evaluated at each dose level. B) Data on L-aspartate aminotransferase (ASAT) and L-alanine aminotransferase (ALAT) and C) levels of IL-6 and TNF-alpha over time. In addition, plasma levels of the following cytokines were measured by bead-based multiplex immunoassays: IL-2, IL-6, IL-8, IL-10, MCP-1, IFN-γ, and TNF-α. The conclusion from the study was that there were no findings associated with the cyoCEAxCD40 bsAb at the dose levels evaluated. [Diagram 30]Structure of RUBY™ bsAbs and binding of RUBY™ bsAbs to their various antigen targets as measured by ELISA. (A) Chain 1 consists of an IgG heavy chain, a short polypeptide linker, and an additional light chain of a Fab fragment, chain 2 is a light chain that binds to the VH and CH1 domains of the IgG portion, and chain 3 is a short heavy chain that binds to the light chain added to the IgG. (B) Dual ELISA showing simultaneous binding of CD40 x EpCAM RUBY™ bsAbs to their respective antigen targets. ELISA plates were coated with human CD40 and bsAbs were added followed by detection using biotinylated EpCAM. (C) Dual ELISA showing simultaneous binding of CD40 x CEA RUBY™ bsAbs to their respective antigen targets. ELISA plates were coated with human CEACAM5 and bsAbs were added followed by detection using biotinylated CD40. (D) Mono ELISA showing binding of GFP x EpCAM control RUBY™ bsAb to human EpCAM. ELISA plates were coated with human EpCAM, bsAb was added, and then detected using goat anti-human kappa light chain-HRP. (E) Mono ELISA showing binding of cynoCEA×CD40RUBY™ bsAb to human CD40. ELISA plates were coated with human CD40, followed by addition of cynoCEA×CD40 RUBY™ bsAb, and detected using goat anti-human kappa light chain-HRP. (F) Mono ELISA showing binding of cynoCEA×CD40 RUBY™ bsAb to human CEACAM5. ELISA plates were coated with human CEA, followed by addition of cynoCEA×CD40 RUBY™ bsAb, and detected using goat anti-human kappa light chain-HRP. In summary, bispecific antibodies were successfully generated in the RUBY™ format, and the generated bsAbs showed good binding to their respective antigen targets, as illustrated by the ELISA binding assessment. [Diagram 31]MC38-CEACAM5 2 tumor growth and survival. hCD40tg mice inoculated with MC38-CEACAM5 2 tumors were administered the indicated treatments on days 7, 10, and 13 after inoculation. Tumors were measured frequently, and graphs show the mean tumor volume (+SD) for each group until the first mouse in any treatment group reached a tumor volume exceeding ethical limits, and the % surviving mice in each treatment group. [Diagram 32] Isolated cells from human gastric cancer tumors were analyzed for (left) their CEA expression (gated on total live cells), (center) their ability to provide cross-linking to CD40xCEA Neo-X-Prime bsAb (ffAC_05337) in a CD40 reporter assay, and (right, 1 nM CD40xCEA) CD83 upregulation following stimulation of tumor-infiltrating immune cells (gated on CD45+CD3-CD56- live cells) with CD40xCEA Neo-X-Prime bsAb or isotypexCD40 bsAb (data from one representative experiment of four). [Diagram 33] Effect of bispecific antibody ffAC_05337 on CD40 reporter cells when co-cultured with tumor cells with different CEA receptor densities in the presence and absence of soluble CEA: MKN45, high CEA expressing cells (A), LS174T, moderate CEA expressing cells (B), HT29, and LOVO, low CEA expressing cells (C-D). Responses were calculated as fold induction over background. [Diagram 34] Effect of bispecific antibody ffAC_05337 on CD40 reporter cells co-cultured with CEA-expressing CHO cells and titrated antibody in the presence or absence of soluble CEA. Responses were calculated as fold induction over background.
[0407] Sequence Listing [Table 6-1] [Table 6-2] [Table 6-3]
Table 6-4
Table 6-5
Table 7-1
Table 7-2
Table 7-3
Table 7-4
Table 7-5
Table 7-6
Table 7-7
Table 7-8
Table 7-9
Table 7-10
Table 7-11
Table 7-12
Table 7-13
Table 7-14
Table 7-15
Table 7-16
Table 7-17
Table 7-18
Table 7-19
Table 7-20
Table 7-21
Table 7-22
Table 7-23
Table 8
Table 9
Table 10
Table 11-1
Table 11-2
Table 12-1
Table 12-2
[0408] Contrast antibody array 3174 VH aa (array number 422) EVQLLEQSGAELVRPGTSVKISCKASGYAFTNYWLGWVKQRPGHGLEWIGDIFPGSGNIHYNEKFKGKATLTADKSSSTAYMQLSSLTFEDSAVYFCARLRNWDEPMDYWGQGTTVTVSS 3174 VH nt (Accession No. 423) GAGGTGCAGCTGCTGGAACAGTCTGGCGCCGAACTCGTTAGACCTGGCACAAGCGTGAAGATCAGCTGCAAGGCCAGCGGCTACGCCTTCACAAATTATTGGCTCGGCTGGGTCAAACAGAGGCCAGGACACGGACTGGAATGGATCGGCGATATCTTCCCCGGCAGCGGCAACATCCACTACAACGAGAAGTTCAAGGGCAAAGCCACACTGACCGCCGACAAGAGCAGCAGCACAGCCTATATGCAGCTGAGCAGCCTGACCTTCGAGGACAGCGCCGTGTACTTCTGCGCCAGGCTGAGAAACTGGGACGAGCCTATGGATTACTGGGGCCAGGGCACCACAGTGACAGTGTCTAGC 3174 VL aa (Accession No. 424) ELVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLEIK 3174 VL nt (Accession No. 425) GAACTGGTTATGACACAGAGCCCTAGCAGCCTGACAGTGACAGCCGGCGAGAAAGTGACAATGAGCTGCAAGAGCAGCCAGAGCCTGCTGAACAGCGGCAACCAGAAGAACTACCTGACCTGGTATCAGCAGAAGCCCGGACAGCCTCCTAAGCTGCTGATCTATTGGGCCAGCACCAGAGAAAGCGGCGTGCCCGATAGATTCACAGGCAGCGGCAGCGGAACCGACTTTACCCTGACAATTAGCAGCGTGCAGGCCGAGGACCTGGCCGTGTATTATTGTCAGAACGACTACAGCTACCCTCTGACCTTCGGAGCCGGCACCAAGCTGGAAATCAAG 1210 VH aa (SEQ ID NO: 426) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYYGGYYSAWMDYWGQGTLVTVSS 1210 VH nt (SEQ ID NO: 427) GAGGTGCAGCTGCTCGAGAGCGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGCCTCTCCTGTGCAGCCAGCGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTATGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACGGCTGTATATTATTGTGCGCGCTACTACGGTGGTTACTACTCTGCTTGGATGGACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA 1210 VL aa (SEQ ID NO: 428) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYGYLHTFGQGTKLEIK 1210 VL nt (SEQ ID NO: 429) GACATCCAGATGACCCAGTCTCCATCCTCCCTGAGCGCATCTGTAGGAGACCGCGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGAAGCGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTATTACTGTCAACAGACTTACGGTTACCTGCACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA
[0409] Mutant IgG1 antibody sequence IgG1 LALA sequence: ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 336)
[0410] Linker sequence SGGGGSGGGGS (SEQ ID NO:337) SGGGGSGGGGSAP (SEQ ID NO: 338) NFSQP (SEQ ID NO: 339) KRTVA (SEQ ID NO: 340) GGGSGGGG (SEQ ID NO:341) GGGGSGGGGS (SEQ ID NO:342) GGGGSGGGGSGGGGS (SEQ ID NO: 343) GSTSGSGKPGSGEGSTKG (SEQ ID NO: 344) THTCPPCPEPKSSDK (SEQ ID NO: 345) GGGS (SEQ ID NO:346) EAAKEAAKGGGGS (SEQ ID NO: 347) EAAKEAAK (SEQ ID NO: 348) (SG)m, where m=1~7.
[0411] IgG constant region sequence IgG1 heavy chain constant region sequence: ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK [SEQ ID NO:349] IgG1 light chain constant region sequence: RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC [SEQ ID NO:350] Modified IgG4 heavy chain constant region sequence: ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVE VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNRYTQKSLSLSLGK [SEQ ID NO:351] Modified IgG4 heavy chain constant region sequence: ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVE VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK [SEQ ID NO:352] Wild type IgG4 heavy chain constant region sequence: ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVE VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK [SEQ ID NO:353] Reference sequence CH1 (SEQ ID NO:354): [ka] (The bold and underlined section is part of the hinge region, which is present in the additional Fab fragment in the RUBY bsAb.) Reference sequence C kappa (SEQ ID NO:355): RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Reference sequence Clamda, immunoglobulin constant lambda 1 (SEQ ID NO: 356) GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS Reference sequence Clamda, immunoglobulin constant lambda 2 (SEQ ID NO: 357) GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS Reference sequence C lambda, immunoglobulin constant lambda 3 (SEQ ID NO: 358) GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS
[0412] Exemplary Sequence of CD40xCEACAM5 RUBY™ bsAb Multi34 Chain H1 (SEQ ID NO: 359) EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRRAPGKGLEWLSYISGGSSYIFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV ATGPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQRKPGKAPK LLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSHGPLLTFGQGTKLEIKRPVAAPAVFIFPPSDEQLKSGTASVVCLLKNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Chain L1 (SEQ ID NO: 360) QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQELPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKL TVLGQPKAAPSVTLFPPSSEELQANKATLVCYISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAWSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS Chain H2 (SEQ ID NO: 361) QVQLVQSGAEVKKPGSSVKVSCKASGGTFGYYAIHWVREAPGQGLEWMGGIGSIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAWSSDHMDYWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLTSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
[0413] Multi42 Chain H1 (SEQ ID NO: 362) QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSSSIHWVRRAPGQGLEWMGHIYPSFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARHSGSRFFSPMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VATGPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSQSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQRLPGTAP KLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVLGQPKAAPAVTLFPPSSEELQANKATLVCLIKDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAWSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS Chain L1 (SEQ ID NO: 363) EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQEKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYWYPLTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Chain H2 (SEQ ID NO:364) EVQLLESSGGGLVQPGGSLRLSCAASGFTFSTYGMHWVREAPGKGLEWLSYISGGSSYIFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYCARILRGGSGMDLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLTSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
[0414] Multi46 H1 EVQLLESSGGLVQPGGSLRLSCAASGFTFSSYAMSWVRRAPGKGLEWVSGIGSYGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYVNFGMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVAT GPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGKGGGGSGGGGSGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQRKPGKAPK LLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSHGPLLTFGQGTKLEIKRPVAAPAVFIFPPSDEQLKSGTASVVCLLKNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAYEKHKVYACEVTHQGLSSPVTKSFNRGEC Chain L1 (SEQ ID NO: 372) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQEKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGRNPPTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Chain H2 (SEQ ID NO: 366) QVQLVQSGAEVKKPGSSVKVSCKASGGTFGYYAIHWVREAPGQGLEWMGGIGSIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAWSSDHMDYWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLTSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
[0415] ffAC_05337 alias ffAC_5337, ffP_A_05337 or ffP_A_5337 Chain H1 (SEQ ID NO: 367) EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRRAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPLHLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VATGPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSQSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQRLPGTAP KLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVLGQPKAAPAVTLFPPSSEELQANKATLVCLIKDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAWSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS Chain L1 (SEQ ID NO: 368) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQEKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Chain H2 (SEQ ID NO: 369) EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVREAPGKGLEWLSYISGGSSYIFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLTSVVEVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
[0416] Exemplary full heavy and light chain sequences Binding domain B1: 1132 / 1133 heavy chain (VH: Q44R, CH1: H168A, F170G, CH2: L234A, L235A) containing the RUBY mutation (SEQ ID NO: 371): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRRAPGKGLEWVSIGSYGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYVNFGMDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVATGPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPPAPEAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1132 / 1133 light chain containing the RUBY mutation (VL:Q44E, CkappaL135Y, S176W) (SEQ ID NO:372): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQEKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGRNPPTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCYLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLWSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 1132 / 1133 heavy chain (SEQ ID NO:378): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSIGSYGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYVNFGMDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1132 / 1133 light chain (SEQ ID NO: 379): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGRNPPTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC G12 heavy chain (SEQ ID NO:380): EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK G12 light chain (SEQ ID NO:381): QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKL TVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS G12_mut heavy chain (SEQ ID NO: 382): EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK G12_mut light chain (SEQ ID NO: 383): QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKL TVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
[0417] Binding domain B2: AC_05059, light chain (SEQ ID NO:388): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05059, Heavy Chain (SEQ ID NO:389): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05060, light chain (SEQ ID NO:390): DIQMTQSPSSLSASVGDRVTITCRASQSIRDYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGTFPFTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05060, Heavy Chain (SEQ ID NO:391): EVQLLESGGGLVQPGGSLRLSCAASGFTFGSYYMSWVRQAPGKGLEWVSGISGYGYYTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHGYGVIDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05061, Light Chain (SEQ ID NO:392): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGAYVPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05061, Heavy Chain (SEQ ID NO:393): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYGYTHFDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05062, Light Chain (SEQ ID NO:394): DIQMTQSPSSLSASVGDRVTITCRASQAISGYLNWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05062, Heavy Chain (SEQ ID NO:395): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYRWHGSVFDYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05064, Light Chain (SEQ ID NO:396): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYPWYFPYTFGQGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05064, Heavy Chain (SEQ ID NO:397): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYGYSVLDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05079, light chain (SEQ ID NO:398): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05079, Heavy Chain (SEQ ID NO:399): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPPLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05081, Light Chain (SEQ ID NO: 400): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05081, Heavy Chain (SEQ ID NO: 401): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFQPHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05088, light chain (SEQ ID NO: 402): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05088, Heavy Chain (SEQ ID NO: 403): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVLFPPHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05089, light chain (SEQ ID NO: 404): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05089, Heavy Chain (SEQ ID NO: 405): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPHHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05090, Light Chain (SEQ ID NO: 406): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05090, Heavy Chain (SEQ ID NO:407): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPLHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05091, Light Chain (SEQ ID NO: 408): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05091, Heavy Chain (SEQ ID NO:409): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPHFDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05093, Light Chain (SEQ ID NO: 410): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05093, Heavy Chain (SEQ ID NO:411): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPHVDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05094, Light Chain (SEQ ID NO: 412): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05094, Heavy Chain (SEQ ID NO:413): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFPPHWDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05096, Light Chain (SEQ ID NO:414): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05096, Heavy Chain (SEQ ID NO:415): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFRPHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK AC_05097, Light Chain (SEQ ID NO:416): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQAGNPHTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AC_05097, Heavy Chain (SEQ ID NO:417): EVQLLESGGGLVQPGGSLRLSCAASGTFSSSYMGWVRQAPGKGLEWVSSIGSGSYSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYPSVPFSPHLDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Fab1, light chain (SEQ ID NO:418): DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSHGPLLTFGQGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Fab1, Heavy Chain (SEQ ID NO:419): QVQLVQSGAEVKKPGSSVKVSCKASGGTFGYYAIHWVRQAPGQGLEWMGGIGSIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAWSSDHMDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Fab3, light chain (SEQ ID NO:420): EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYWYPLTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Fab3, Heavy Chain (SEQ ID NO:421): QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSSSIHWVRQAPGQGLEWMGHIYPSFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARHSGSRFFSPMDYWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0418] Example 1 - Isolation of CEACAM5-binding agents Objectives and Background The purpose of the study was to isolate anti-human CEACAM5 binding domains.
[0419] Materials and Methods Testing involved the use of two different phage display antibody libraries, AlligatorGOLD® and AlligatorFAB. Isolation of binders was performed using phage display, either using cells presenting antigen or with biotinylated antigen bound on magnetic beads. Screening of binders was performed using high throughput (HT) ELISA, FACS, or next generation sequencing (NGS).
[0420] Phage selection: Phage display selections were performed using either AlligatorGold® or AlligatorFab library according to the selection strategy shown in Table 1. An overview of the different parameters used in the selection rounds during the phage selection process can be found in Table 2 (Alligator GOLD, soluble antigen), Table 3 and Table 4 (Alligator GOLD, cell selection), or Table 5 (AlligatorFab library, soluble antigen). Overall, the starting library was heat challenged at 45°C for 1 hour to ensure that the starting library contained only temperature-stable antibody variants. A negative selection step was added to remove potentially sticky binders as well as binders that were reactive to the presence of the Fc moiety (using ubiquitin-His and CTLA-4-Fc). In addition, a pre-selection against other CEACAM family members was performed to ensure the specificity of the developed clones. The selection strategy was also designed to facilitate the isolation of clones with high affinity by gradually decreasing the antigen concentration and increasing the number of washing steps. CEACAM5 from a commercial source was used as the soluble antigen (R&D Systems, #4128-CM-050). [Table 13] [Table 14] TIFF2024543043000046.tif37162 [Table 15] [Table 16] [Table 17]
[0421] Screening of clones by ELISA Screening was performed with phage-displayed binders (test screen) or using soluble scFv / Fab in bacterial supernatants. Briefly, phage ELISA was performed using CEACAM5 (#4128-CM-050, R&D Systems) or CTLA-4 Fc coated on microtiter plates to capture scFv / FAb-displaying phages. Bound phages were detected using HRP-conjugated monoclonal anti-M13 antibody (#27-9421-001, GE Healthcare). Positive phage clones were sequenced (Sanger sequencing at GATC). Unique phage clones were cloned into soluble scFv / Fab format. ELISA with soluble scFv / FAb was performed using the same antigen. Soluble scFv / Fab fragments were produced from bacterial TOP10 cultures. Crude supernatants were tested for binding to antigen. Detection was performed using an HRP-conjugated monoclonal anti-Flag antibody (#A8592, Sigma).
[0422] Screening of clones by FACS Genes encoding human CEACAM 5, human CEACAM 1, or a chimera of CEACAM5 and CEACAM1 (CEACAM1 / 5) were cloned into pcDNA3.1 and stably transfected into CHO cells. FACS screening was performed using either CHO cells transiently transfected for CEACAM5 expression or control wild-type CHO cells diluted in FACS buffer (DPBS / 0.5% BSA). Cells were seeded (150000 cells / well) in 96-well microtiter PP plates (#351190, Falcon). Soluble Fab domain supernatants, free of bacteria by centrifugation, were diluted 1:1 in FACS buffer and added (50 μl) to the seeded CHO cells. After 90 min incubation at 4° C., cells were washed repeatedly with FACS buffer and resuspended in a solution containing secondary antibody (α-hIgGF(ab')-PE, #19-116-097, Jackson ImmunoResearch) diluted at a ratio of 1:1000. After 1 h incubation at 4° C., cells were washed with FACS buffer, resuspended in Cellfix solution (#340181, BD), and signals were measured on a flow cytometer (BD).
[0423] Screening clones using next generation sequencing (NGS) DNA purified from phage pools in rounds #4, #5, and #6 from AlligatorGOLD® selection with soluble antigen was used to amplify scFV-encoding DNA by PCR using primers (listed in Table 6). PCR was performed using Pfu Ultra II Hotstart PCR Master Mix (#600850, Agilent Technologies). After denaturing 1 ng of DNA template at 98°C for 30 seconds, DNA was amplified in 15 or 18 cycles of PCR reaction (98°C for 30 seconds, 58°C for 30 seconds, and 72°C for 30 seconds) with an extension step of 2 minutes at 72°C. The material was purified from agarose gel and further tagged with DNA barcode primers (listed in Table 6). After denaturing 1 ng of DNA template at 98°C for 30 seconds, the DNA was amplified in 15 or 18 cycles of PCR reactions (98°C for 10 seconds, 68°C for 30 seconds, and 72°C for 31 seconds) with an extension step of 2 minutes at 72°C. The DNA was purified (DNA was purified using the GeneRead size selection kit, #180514 Qiagen) and then sent for Illumina sequencing at the SciLife facility NGI in Stockholm. Data analysis included quality control of the resulting sequences and gene trimming. Top candidates were aligned to sequences from clones isolated in conventional ELISA screening. [Table 18]
[0424] Results and Conclusions Phage selection and screening led to the isolation of 38 binding domains for human CEACAM5: 29 clones were derived from the Alligator GOLD® library and 11 clones were derived from the Alligator FAB library.
[0425] Example 2 - Characterization of CEACAM5-binding scFv Objectives and Background The aim of the studies recited in this experiment was to further characterize the CEACAM5-binding single chain fragments (scFv) isolated in Example 1.
[0426] Materials and Methods The scFv were cloned into an IgG1 format and produced in mammalian culture. The antibodies were analyzed in a series of different assays to test their quality and binding ability to CEACAM5 and the related CEA family protein CEACAM1.
[0427] Expression and QC analysis The IgG1 antibodies listed in Tables 7 and 8, as well as the expression control monoclonal antibody 1188, were transiently expressed using Expi293HEK (Life Technologies) cells in volumes ranging from 600 μl to 30 mL according to the manufacturer's protocol. Purification of antibodies from the supernatants was performed with Protein A using an NGC system (BioRad) or Predictor MabSelectSure 50 μl 96-well plates (GE Healthcare). Aggregation was measured using SE-HPLC on a 1260InfinityII system (Agilent Technologies) using a TSK gel Super SW mAB HTP 4 μm, 4.6×150 mm column (TOSOH Bioscience) and 100 mM sodium phosphate, pH 6.8, 300 mM NaCl as the mobile phase at ambient temperature and a flow rate of 0.35 ml / min.
[0428] CEACAM5 cell binding CHO cells stably transfected with pcDNA3.1 carrying the genes for either human CEACAM5, human CEACAM1, or the CEACAM5 / CEACAM1 chimera, and CHO wild-type (wt) cells were incubated with 0.5 and 5 μg / ml IgG1 antibody or selected samples titrated at antibody concentrations ranging from 67 nM to 0.4 pM. Antibody binding was detected using a fluorescent dye-conjugated anti-human IgG and analyzed using flow cytometry.
[0429] ELISA, CEA binding, and cross-reactivity 96-well plates were coated with 0.5 μg / mL of antigen, hCEACAM-5 (4128-CM-050, R&D Systems), hCEACAM-1 (2244-CM-050, R&D Systems), hCEACAM-6 (3934-CM-050, R&D Systems), or CEACAM-8 (9639-CM-050, R&D Systems) in PBS overnight at 4 °C. After washing with PBS / 0.05% Tween 20 (PBST), plates were blocked with PBST, 2% BSA for at least 30 min at room temperature, followed by a second round of washing. Antibody samples diluted to either 0.4 μg / ml or 10 μg / ml for selected samples titrated in NGS for isolated binders or from 67 nM to 0.4 pM in PBST, 0.5% BSA were then added and allowed to bind for at least 1 h at room temperature. After washing, the plates were incubated with 50 μl of detection antibody (0.5 μg / ml HRP-conjugated goat anti-human kappa light chain, #STAR127P, AbD Serotec). Finally, a final round of washing was performed and bound complexes were detected using SuperSignal Pico Luminescent as substrate and luminescent signal was measured using a Fluostar Optima.
[0430] Octet binding test Kinetic measurements were performed on an Octet RED96 platform using several different settings. Monoclonal antibodies (listed in Table 9) starting at 100 nM and serially diluted in half were captured on an anti-human IgG Fc Capture (AHC) biosensor chip (Sartorius #18-5060). Human CEACAM5-His (R&D Systems #4128-CM-050) diluted to 100 nM in 1× kinetics buffer (Sartorius) was then added. Binding kinetics were tested in 1× kinetics buffer and allowed to associate for 300 seconds followed by dissociation for 600 seconds. The sensor chip was regenerated with 10 mM glycine pH 1.7. Data generated was referenced by subtracting a blank or parallel buffer blank, baseline aligned to the y-axis, step-by-step correction by alignment to dissociation was performed, and data was smoothed by a Savitzky-Golay filter in the data analysis software (v9.0.0.14). As a measure of fitting accuracy, R 2 Or X 2 The processed data was fitted using a 1:1 Langmuir binding model using:
[0431] Results and Conclusions The results (summarized in Table 7) demonstrated that phage selection led to the isolation of several antibodies that displayed specific binding to human CEACAM5. In particular, antibodies AC_05059, AC_05060, AC_05061, AC_05062, AC_05064 showed promising binding profiles with selective binding to human CEACAM5 as demonstrated by both ELISA (for CEACAM5, CEACAM1, CEACAM6, CEACAM7, and CEACAM8) and FACS (on cells expressing CEACAM5, CEACAM1, or CEACAM1 / 5 chimeras).
[0432] In addition, the results also show that the clones selected using next-generation screening also generated clones with specific binding to human CEACAM5, as demonstrated by ELISA tests for CEACAM5 and CEACAM1 (Table 8 and Figure 1). Specifically, antibodies AC_05079, AC_05081, AC_05088, AC_05089, AC_05090, AC_05091, AC_05093, AC_05094, AC_05096, and AC_05097 show selective binding to human CEACAM5.
[0433] Affinity measurements using Octet demonstrated that the antibodies analyzed displayed a wide range of different affinities for CEACAM5 (Table 9). [Table 19] [Table 20] [Table 21]
[0434] Example 3 - Generation and manufacturability of bispecific antibodies targeting CD40 and CEACAM5 Background and Objectives Bispecific antibodies (bsAbs) were generated by combining the CEACEAM5-targeting antibodies evaluated above with either CD40 agonist antibodies 1132, G12, or "G12_mut" in the RUBY™ format. Briefly, bispecific antibodies in the RUBY™ format are generated by appending the antigen-binding fragment (Fab) of an antibody to the c-terminal portion of the heavy chain of an IgG via a short peptide linker. A selected set of bsAbs were further transferred to variants in the RUBY™ format with optimized properties. The generated RUBY™ bsAbs are listed in Table 10. The manufacturability of the listed bsAbs targeting CD40 and CEACAM5 was evaluated in terms of production yield and purity after Protein A purification.
[0435] Materials and Methods RUBY™, as listed in Table 10, as well as the expression control monoclonal antibody 1188, were transiently expressed using Expi293HEK (Life Technologies) cells in volumes ranging from 600 μl to 30 mL according to the manufacturer's protocol. Cells were transfected with three different vectors, each encoding one of the three polypeptide chains of the RUBY™ bsAb (i.e., immunoglobulin heavy chain (chain H1), immunoglobulin light chain (chain L1), and Fab heavy chain (chain H2) linked to a linker and a Fab light chain). Purification of antibodies from the supernatant was performed with Protein A using the NGC system (BioRad) or Predictor MabSelectSure 50 μl 96-well plates (GE Healthcare). Different transfection ratios of the three vectors were tested. Aggregation was measured using SE-HPLC on a 1260 InfinityII system (Agilent Technologies) using a TSK gel Super SW mAB HTP 4 μm, 4.6 × 150 mm column (TOSOH Bioscience) and 100 mM sodium phosphate, pH 6.8, 300 mM NaCl as the mobile phase at ambient temperature and a flow rate of 0.35 ml / min.
[0436] Results and Conclusions Bispecific antibodies can be produced in the RUBY™ format by combining CD40 and CEACAM5 targeting antibodies. Table 11 shows the production yields from high-throughput transient cultures and monomer fractions measured by SE-HPLC after Protein A high-throughput purification. Generally good productivity and quality were observed. In conclusion, it is possible to generate and produce highly pure RUBY™ bsAbs targeting CD40 and CEA. [Table 22-1] [Table 22-2] [Table 23-1] [Table 23-2]
[0437] Example 4 - Dual antigen binding of CD40 and CEACAM5 targeting bsAb and binding to CEACAM variants by ELISA the purpose The objective of the study was to evaluate the ability of selected RUBY™ bsAbs targeting CD40 and CEACAM5 to bind both of their targets simultaneously, as well as their potential cross-reactivity with additional members of the CEA protein family by ELISA.
[0438] Materials and Methods 96-well plates were coated with 0.5 μg / mL of antigen, hCEACAM-1 (2244-CM-050, R&D Systems), hCEACAM-5 (4128-CM-050, R&D Systems), hCEACAM-6 (3934-CM-050, R&D Systems), or CEACAM-8 (9639-CM-050, R&D Systems) in PBS overnight at 4° C. After washing with PBS / 0.05% Tween 20 (PBST), plates were blocked with PBST, 2% BSA for at least 30 minutes at room temperature, followed by a second round of washing. RUBY bsAb diluted in PBST, 0.5% BSA was then added and allowed to bind for at least 1 hour at room temperature. After washing, the plates were incubated with either 50 μl of detection antibody (0.5 μg / ml HRP-conjugated goat anti-human kappa light chain, #STAR127P, AbD Serotec) for analysis of binding to CEACAM protein family proteins, or 0.5 μg / ml biotinylated hCD40-muIg (504-030, Ancell) followed by HRP-conjugated streptavidin (21126, Pierce) for confirmation of dual antigen binding. Finally, a final round of washing was performed and bound complexes were detected using SuperSignal Pico Luminescent as substrate and luminescent signal was measured using a Fluostar Optima.
[0439] Results and Conclusions All RUBY™ bsAbs evaluated were indeed able to bind both CD40 and human CEACAM5 simultaneously (Figure 2), but with varying titers. In general, bsAbs with 1132 as the CD40-binding antibody (Multi46-Multi49) showed lower titers in the dual-target ELISA compared to bsAbs with G12_mut. Multi38 also showed reduced dual-target binding compared to other G12_mut-based bsAbs, which may be due to lower CEACAM5 binding of Fab6 than the other evaluated CEACAM5-binding antibodies.
[0440] As can be seen in Figure 3, the majority of the CD40 and CEACAM5 targeted RUBY™ bsAbs evaluated did not cross-react with any of the other CEA family members evaluated. However, a limited number...
Claims
1. A bispecific polypeptide comprising a first binding domain, designated B1, capable of specifically binding to CD40, and a second binding domain, designated B2, capable of specifically binding to carcinoembryonic antigen (CEA).
2. 2. The bispecific polypeptide of claim 1 , wherein the first and / or second binding domain is selected from the group consisting of an antibody and an antigen-binding fragment thereof, and a CD40 ligand.
3. 3. The bispecific polypeptide of claim 2, wherein the antigen-binding fragment is selected from the group consisting of an Fv fragment (such as a single chain Fv fragment or a disulfide-linked Fv fragment), a Fab-like fragment (such as a Fab fragment, a Fab' fragment or an F(ab)2 fragment), and a domain antibody.
4. 10. The bispecific polypeptide of claim 1 , wherein the polypeptide is a bispecific antibody.
5. (a) binding domain B1 and / or binding domain B2 are intact IgG antibodies; (b) binding domain B1 and / or binding domain B2 are Fv fragments; (c) binding domain B1 and / or binding domain B2 are Fab fragments, and / or (d) The bispecific polypeptide according to any one of the preceding claims, wherein binding domain B1 and / or binding domain B2 is a single domain antibody.
6. 6. The bispecific polypeptide of claim 5, wherein the bispecific antibody comprises a human Fc region or a variant of said region, said region being an IgG1 region, an IgG2 region, an IgG3 region, or an IgG4 region, preferably an IgG1 region or an IgG4 region.
7. The bispecific polypeptide of claim 6 , wherein the Fc exhibits no or very low affinity for FcγR.
8. The Fc region comprises the following positions:
8. The bispecific polypeptide of claim 7, which is a variant of a human IgG1 Fc region comprising mutations at one or more of L234, L235, P239, D265, N297, and / or P329.
9. 9. The bispecific polypeptide of claim 8, wherein an alanine is present at the mutated position(s).
10. 10. The bispecific polypeptide of claim 9, wherein the Fc region is a variant of a human IgG1 Fc region comprising the double mutation L234A and L235A.
11. The bispecific antibody comprises: (a) bivalent bispecific antibodies, such as IgG-scFv bispecific antibodies (e.g., B1 is an intact IgG and B2 is an scFv linked to B1 at the N-terminus of the light chain and / or the C-terminus of the light chain and / or the N-terminus of the heavy chain and / or the C-terminus of the heavy chain of said IgG, or vice versa); (b) monovalent bispecific antibodies such as DuoBody® or “knobs-in-holes” bispecific antibodies (e.g., scFv-KIH, scFv-KIHr, BiTE-KIH, or BiTE-KIHr); (c) scFv2-Fc bispecific antibodies (e.g., ADAPTIR™ bispecific antibodies); (d) BiTE / scFv2 bispecific antibody, (e) DVD-Ig bispecific antibody, (f) DART-based bispecific antibodies (e.g., DART2-Fc or DART); (g) DNL-Fab3 bispecific antibody, and (h) a bispecific antibody, a scFv-HSA-scFv bispecific antibody,
12. The bispecific polypeptide of claim 11, wherein the bispecific antibody is an IgG-scFv bispecific antibody.
13. 10. The bispecific polypeptide according to any one of the preceding claims, wherein binding domain B1 and binding domain B2 are directly fused to each other.
14. 10. The bispecific polypeptide according to any one of the preceding claims, wherein binding domain B1 and binding domain B2 are linked via a polypeptide linker.
15. 15. The bispecific polypeptide of claim 14, wherein the linker is selected from the group consisting of the amino acid sequences SGGGGSGGGGS (SEQ ID NO: 337), SGGGGSGGGGGSAP (SEQ ID NO: 338), NFSQP (SEQ ID NO: 339), KRTVA (SEQ ID NO: 340), GGGSGGG (SEQ ID NO: 341), GGGGSGGGGGS (SEQ ID NO: 342), GGGGSGGGGSGGGGS (SEQ ID NO: 343), GSTSGSGKPGSGEGSTKG (SEQ ID NO: 344), THTCPPCPEPKSSDK (SEQ ID NO: 345), GGGS (SEQ ID NO: 346), EAAKEAAKGGGGS (SEQ ID NO: 347), EAAKEAAK (SEQ ID NO: 348), or (SG)m, where m=1-7.
16. 10. The bispecific polypeptide of claim 9, wherein one of B1 or B2 is an immunoglobulin molecule and one of B1 or B2 is a Fab fragment, said Fab fragment being fused to the C-terminus of the heavy chain of an immunoglobulin via the light chain of the Fab fragment.
17. 10. The bispecific polypeptide of any one of the preceding claims, wherein the bispecific polypeptide comprises one or more mutations to facilitate association of a heavy chain polypeptide of the immunoglobulin with a light chain polypeptide of the immunoglobulin and / or to facilitate association of the heavy chain polypeptide of the Fab with the light chain polypeptide of the Fab.
18. 18. The bispecific polypeptide of claim 17, wherein the one or more mutations prevent the formation of aggregates and Fab by-products.
19. 19. The bispecific polypeptide of claim 17 or 18, wherein the mutations prevent the formation of aggregates and Fab by-products by creating steric hindrance and / or charge incompatibility.
20. 20. The bispecific polypeptide of any one of claims 17 to 19, wherein the polypeptide comprises one or more pairs of mutations, each pair comprising two functionally compatible mutations.
21. 10. The bispecific polypeptide according to any one of the preceding claims, wherein said polypeptide is capable of modulating the activity of myeloid cells and / or is capable of activating myeloid cells.
22. 10. The bispecific polypeptide of any one of the preceding claims, wherein the polypeptide is not capable of inducing antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and / or complement-dependent cytotoxicity (CDC).
23. 10. The bispecific polypeptide of any one of the preceding claims, wherein the polypeptide is capable of inducing tumor immunity.
24. The polypeptide, (a) tumor-specific immune activation, and / or (b) dendritic cell activation, and / or (c) internalization of associated tumor debris and / or extracellular vesicles containing the CEA antigen as well as tumor neo-antigens; and / or (d) cross-presentation of peptides derived from internalized tumor antigens at MHC; and / or (e) priming and activation of effector T cells; and / or 5. The bispecific polypeptide of any one of the preceding claims, which is capable of inducing a direct tumoricidal effect selected from the list consisting of apoptosis, necroptosis, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).
25. The bispecific polypeptide (a) activation of B cells in the presence of CEA; and / or (b) activating dendritic cells in the presence of CEA; and / or (c) enabling increased dendritic cell cross-presentation of neo-antigens; and / or 9. The bispecific polypeptide according to any one of the preceding claims, which is capable of (d) inducing the proliferation of neo-antigen-specific T cells.
26. 10. The bispecific polypeptide of any one of the preceding claims, wherein the bispecific polypeptide promotes uptake of tumor-derived material derived from tumor cells that overexpress CEA.
27. 2. The bispecific polypeptide of any one of the preceding claims, wherein B cell activation is characterized by CD86 upregulation.
28. Binding domain B1 binds human CD40 at 2 × 10 -7 Less than M or 1.5 x 10 -7 Less than M or 8.5 x 10 -8 Less than M or 8 x 10 -8 Less than M or 7.5 x 10 -8 Less than M or 7 x 10 -8 Less than M or 9 x 10 -8 Less than M or 9 x 10 -9 Less than M or 5 x 10 -10 Less than M or 3 x 10 -10 Less than M, preferably 8.5 x 10 -8 Less than M, more preferably 5×10 -10 Less than M or 3 x 10 -10 K less than M D 6. The bispecific polypeptide of claim 1 , wherein the bispecific polypeptide binds
29. 10. The bispecific polypeptide according to any one of the preceding claims, wherein binding domain B1 comprises one or more heavy chain CDR sequences selected from those in Table C(1) and / or binding domain B1 comprises one or more light chain CDR sequences selected from those in Table C(2).
30. 10. The bispecific polypeptide according to any one of the preceding claims, wherein binding domain B1 comprises one, two or three light chain CDR sequences from a particular row for an individual antibody reference in Table C(2) and / or one, two or three heavy chain CDR sequences from the corresponding row for said antibody with the same reference in Table C(1).
31. 10. The bispecific polypeptide according to any one of the preceding claims, wherein binding domain B1 comprises all three heavy chain CDR sequences of a particular antibody reference shown in Table C(1) and / or all three light chain CDR sequences of an antibody reference shown in Table C(2), or wherein binding domain B1 comprises a heavy chain VH sequence and / or a light chain VL sequence shown in Table A.
32. B1 is independently selected from the following: (a) a heavy chain CDR1 sequence consisting of the sequence "G,F,T,F,S,S,Y,A", (b) a heavy chain CDR2 sequence that is 8 amino acids in length and contains the consensus sequence: "I, G / S, S / G, Y / S, G / S, G / S, G / Y / S, T"; (c) a heavy chain CDR3 sequence that is 9-12 amino acids in length and includes the consensus sequence of "A, R, Y / R / G, Y / P / V / -, N / S / V, F / Y / W, G / H / S, - / S, - / V, M / F, D, Y"; (d) a light chain CDR1 sequence consisting of the sequence: Q, S, I, S, S, Y; (e) a light chain CDR2 sequence consisting of the sequence: A, A, S; (f) a light chain CDR3 sequence that is 9 amino acids in length and comprises the consensus sequence: "Q, Q, Y / S, G / Y, R / S / V, N / A / Y / T, P, P / F / Y, T".
33. Binding domain B1, (a) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 1132 / 1133 (SEQ ID NOs: 73, 74, and 75, and / or 90, 91, and 92); or (b) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 1107 / 1108 (SEQ ID NOs: 73, 78, and 80, and / or SEQ ID NOs: 90, 91, and 95); or (c) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 1150 / 1151 (SEQ ID NOs: 73, 76, and 77, and / or SEQ ID NOs: 90, 91, and 93); or (d) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 1140 / 1135 (SEQ ID NOs: 73, 78, and 79, and / or SEQ ID NOs: 90, 91, and 94); or (e) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody G12 or G12_mut or ffAC_05337 (SEQ ID NOs: 81, 82, 83, and / or SEQ ID NOs: 96, 97, and 98); or (f) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody APX005 (SEQ ID NOs: 84, 85, and 86, and / or SEQ ID NOs: 99, 100, and 101); or (g) A bispecific polypeptide according to any one of the preceding claims, comprising the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody 21.4.1 (SEQ ID NOs: 87, 88, and 89, and / or SEQ ID NOs: 102, 103, and 104).
34. Binding domain B1, (a) the heavy chain variable region and / or the light chain variable region of antibody 1132 / 1133 (SEQ ID NOs: 3 and 1); or (b) the heavy chain variable region and / or the light chain variable region of antibody 1107 / 1108 (SEQ ID NOs: 15 and 13), or (c) the heavy chain variable region and / or the light chain variable region of antibody 1150 / 1151 (SEQ ID NOs: 7 and 5); or (d) the heavy chain variable region and / or the light chain variable region of antibody 1140 / 1135 (SEQ ID NOs: 11 and 9), or (e) the heavy chain variable region and / or the light chain variable region of antibody G12 (SEQ ID NOs: 19 and 17); or (f) the heavy chain variable region and / or the light chain variable region of antibody APX005 (SEQ ID NOs: 23 and 21); or (g) the heavy chain variable region and / or the light chain variable region of antibody 21.4 / 1 (SEQ ID NOs: 27 and 25), or (h) the heavy chain variable region and / or the light chain variable region of the antibody G12_mut (SEQ ID NOs: 29 and 17), or 5. The bispecific polypeptide according to any one of the preceding claims, comprising i) the heavy chain variable region and / or the light chain variable region of the antibody ffAC_05337 (SEQ ID NOs: 431 and 430).
35. 10. A bispecific polypeptide according to any one of the preceding claims, wherein binding domain B1 comprises the light chain of antibody 1132 / 1133 (SEQ ID NO: 372 or 379) and / or the heavy chain of antibody 1132 / 1133 (SEQ ID NO: 371 or 378).
36. 3. A bispecific polypeptide according to any one of the preceding claims, wherein binding domain B1 comprises the light chain of antibody G12 (SEQ ID NO: 381) and / or the heavy chain of antibody G12 (SEQ ID NO: 380) or the light chain of antibody G12_mut (SEQ ID NO: 383) and / or the heavy chain of antibody G12_mut (SEQ ID NO: 382).
37. 4. The bispecific polypeptide according to any one of the preceding claims, wherein binding domain B1 comprises the light chain of antibody ffAC_05337 (SEQ ID NO: 430) and / or the heavy chain of antibody ffAC_05337 (SEQ ID NO: 431).
38. 2. The bispecific polypeptide of any one of the preceding claims, wherein the CEA is tumor-associated CEA.
39. 10. The bispecific polypeptide of any one of the preceding claims, wherein the CEA is a carcinoembryonic antigen-related cell adhesion molecule (CEACAM).
40. 40. The bispecific polypeptide of claim 39, wherein the CEACAM is one or more selected from the list consisting of CEACAM1, CEACAM6, and CEACAM5.
41. The bispecific polypeptide of claim 40, wherein the CEACAM is CEACAM5.
42. 2. A bispecific polypeptide according to any one of the preceding claims, wherein B2 is capable of specifically binding to CEA on a target cell.
43. 43. The bispecific polypeptide of claim 42, wherein the target cell is a cancer cell and / or a tumor cell.
44. 44. The bispecific polypeptide of claim 43, wherein the CEA on the target cell is an intermediate level of CEA or a high level of CEA.
45. 45. The bispecific polypeptide of claim 44, wherein the intermediate level of CEA is characterized by the target cells expressing about 10,000 or more CEA receptors per target cell, preferably about 50,000 or more CEA receptors per target cell.
46. 45. The bispecific polypeptide of claim 44, wherein said high level of CEA is characterized by said target cells expressing more than about 200,000 CEA receptors per target cell, preferably more than about 300,000 CEA receptors per target cell.
47. Binding domain B2 binds human CEA at 2 × 10 -6 Less than M or 1.5 x 10 -8 Less than M or 2.5 x 10 -9 Less than M or 2 x 10 -9 Less than M or 1.5 x 10 -12 Less than M or 1 x 10 -12 Less than M, preferably 1.5×10 -8 Less than M or 2.5 x 10 -9 Less than M or 1.5 x 10 -12 K less than M D 6. The bispecific polypeptide of claim 1 , wherein the bispecific polypeptide binds
48. 10. The bispecific polypeptide according to any one of the preceding claims, wherein binding domain B2 preferentially binds to CEA on cells over soluble CEA.
49. 13. The bispecific polypeptide according to any one of the preceding claims, wherein binding domain B2 comprises one or more heavy chain CDR sequences selected from those in Table D(1a) and / or Table D(1b) and / or binding domain B2 comprises one or more light chain CDR sequences selected from those in Table D(2).
50. 13. A bispecific polypeptide according to any one of the preceding claims, wherein binding domain B2 comprises one, two or three light chain CDR sequences from a particular row for an individual antibody reference in Table D(2) and / or one, two or three heavy chain CDR sequences from the corresponding row for said antibody having the same reference in Table D(1a) and / or Table D(1b).
51. 10. A bispecific polypeptide according to any one of the preceding claims, wherein binding domain B2 comprises all three heavy chain CDR sequences of a particular antibody reference shown in Table D(1a) and / or Table D(1b) and / or all three light chain CDR sequences of an antibody reference shown in Table D(2), or binding domain B1 comprises a heavy chain VH sequence and / or a light chain VL sequence shown in Table B.
52. B2 is independently selected from the following: (a) a heavy chain CDR1 sequence consisting of the sequence: "G, F, T, F, S, S, S, Y" or comprising the consensus sequence of "G, F, T, F, G / S, S, Y, Y / A"; (b) a heavy chain CDR2 sequence consisting of the sequence: "I, G, S, G, S, Y, S, T" or comprising the consensus sequence of "I, S, G, Y / S, G, Y / G, S, T"; (c) a heavy chain CDR3 sequence that comprises the consensus sequence of "A, R, Y, P, S, V, P / L, F, P, Q, S, P / H / L, H / P / L, L / F / V / W, D, Y" or that comprises the consensus sequence of "A, R, H / Y, G, Y, G / S / T, V / H, L / F, D, Y"; (d) a light chain CDR1 sequence consisting of the sequence: Q, S, I, S, S, Y, or comprising the consensus sequence Q, S, I, R / S, S, Y; (e) a light chain CDR2 sequence consisting of the sequence: A, A, S; (f) a light chain CDR3 sequence consisting of the sequence: "Q, Q, A, G, N, P, H, T" or comprising the consensus sequence of "Q, Q, G / Y, T / P / A, W / -, Y / -, F / V, P, F / Y, T".
53. Binding domain B2 is (a) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05059 (SEQ ID NOs: 216, 217, and 218, or 280, 281, and 218, and / or SEQ ID NOs: 90, 91, and 311); (b) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05060 (SEQ ID NOs: 219, 220, and 221, or 282, 283, and 221, and / or SEQ ID NOs: 312, 91, and 313); (c) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05061 (SEQ ID NOs: 222, 223, and 224, or 284, 285, and 224, and / or SEQ ID NOs: 90, 91, and 314); (d) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05062 (SEQ ID NOs: 222, 223, and 225, or 284, 285, and 225, and / or SEQ ID NOs: 315, 316, and 94); (e) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05064 (SEQ ID NOs: 222, 223, and 226, or 284, 285, and 226, and / or SEQ ID NOs: 90, 91, and 317); (f) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05079 (SEQ ID NOs: 216, 217, and 227, or 280, 281, and 227, and / or SEQ ID NOs: 90, 91, and 311); (g) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05080 (SEQ ID NOs: 216, 217, and 228, or 280, 281, and 228, and / or SEQ ID NOs: 90, 91, and 311); (h) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05081 (SEQ ID NOs: 216, 217, and 229, or 280, 281, and 229, and / or SEQ ID NOs: 90, 91, and 311); (i) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05082 (SEQ ID NOs: 222, 223, and 230, or 284, 285, and 230, and / or SEQ ID NOs: 90, 91, and 311); (j) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05083 (SEQ ID NOs: 222, 223, and 231 or 284, 285, and 231, and / or SEQ ID NOs: 318, 91, and 319); (k) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05084 (SEQ ID NOs: 222, 223, and 232, or 284, 285, and 232, and / or SEQ ID NOs: 90, 91, and 320); (l) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05085 (SEQ ID NOs: 219, 233, and 234, or 286, 287, and 234, and / or SEQ ID NOs: 90, 91, and 311); (m) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05086 (SEQ ID NOs: 216, 217, and 235, or 280, 281, and 235, and / or SEQ ID NOs: 90, 91, and 311); (n) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05087 (SEQ ID NOs: 216, 217, and 236, or 280, 281, and 236, and / or SEQ ID NOs: 90, 91, and 311); (o) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05088 (SEQ ID NOs: 216, 217, and 237, or 280, 281, and 237, and / or SEQ ID NOs: 90, 91, and 311); (p) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05089 (SEQ ID NOs: 216, 217, and 238, or 280, 281, and 238, and / or SEQ ID NOs: 90, 91, and 311); (q) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05090 or ffAC_05337 (SEQ ID NOs: 216, 217, and 239, or 280, 281, and 239, and / or SEQ ID NOs: 90, 91, and 311); (r) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05091 (SEQ ID NOs: 216, 217, and 240, or 280, 281, and 240, and / or SEQ ID NOs: 90, 91, and 311); (s) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05092 (SEQ ID NOs: 216, 217, and 218, or 280, 281, and 218, and / or SEQ ID NOs: 321, 91, and 311); (t) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05093 (SEQ ID NOs: 216, 217, and 241 or 280, 281, and 241, and / or SEQ ID NOs: 90, 91, and 311); (u) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05094 (SEQ ID NOs: 216, 217, and 242, or 280, 281, and 242, and / or SEQ ID NOs: 90, 91, and 311); (v) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05095 (SEQ ID NOs: 216, 217, and 243, or 280, 281, and 243, and / or SEQ ID NOs: 90, 91, and 311); (w) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05096 (SEQ ID NOs: 216, 217, and 244, or 280, 281, and 244, and / or SEQ ID NOs: 90, 91, and 311); (x) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05097 (SEQ ID NOs: 217, 216, and 245, or 280, 281, and 245, and / or SEQ ID NOs: 90, 91, and 311); (y) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05098 (SEQ ID NOs: 219, 220, and 246, or 282, 283, and 246, and / or SEQ ID NOs: 312, 91, and 313); (z) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05099 (SEQ ID NOs: 222, 223, and 224, or 288, 285, and 224, and / or SEQ ID NOs: 90, 91, and 311); (aa) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody AC_05100 (SEQ ID NOs: 222, 223, and 247, or 288, 285, and 247, and / or SEQ ID NOs: 90, 91, and 311); (ab) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab1 (SEQ ID NOs: 248, 249, and 250, or 289, 290, and 250, and / or SEQ ID NOs: 90, 91, and 322); (ac) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab2 (SEQ ID NOs: 251, 252, and 253, or 291, 292, and 253, and / or SEQ ID NOs: 90, 91, and 323); (ad) the three CDRs of the heavy chain and / or the three CDRs of the light chain of the antibody Fab3 (SEQ ID NOs: 254, 255, and 256, or 293, 294, and 256, and / or SEQ ID NOs: 324, 325, and 326); (ae) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab4 (SEQ ID NOs: 257, 258, and 259, or 295, 296, and 259, and / or SEQ ID NOs: 90, 91, and 327); (af) the three CDRs of the heavy chain and / or the three CDRs of the light chain of the antibody Fab5 (SEQ ID NOs: 260, 261, and 262, or 297, 298, and 262, and / or SEQ ID NOs: 324, 325, and 328); (ag) the three CDRs of the heavy chain and / or the three CDRs of the light chain of the antibody Fab6 (SEQ ID NOs: 263, 264, and 265, or 299, 300, and 265, and / or SEQ ID NOs: 324, 325, and 329); (ah) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab7 (SEQ ID NOs: 266, 267, and 268, or 301, 302, and 268, and / or SEQ ID NOs: 90, 91, and 330); (ai) the three CDRs of the heavy chain and / or the three CDRs of the light chain of antibody Fab8 (SEQ ID NOs: 269, 270, and 271, or 303, 304, and 271, and / or SEQ ID NOs: 90, 91, and 331); (aj) the three CDRs of the heavy chain and / or the three CDRs of the light chain of the antibody Fab9 (SEQ ID NOs: 272, 335, and 273, or 305, 306, and 273, and / or SEQ ID NOs: 90, 91, and 332); (ak) the three CDRs of the heavy chain and / or the three CDRs of the light chain of the antibody Fab10 (SEQ ID NOs: 274, 275, and 276, or 307, 308, and 276, and / or SEQ ID NOs: 90, 91, and 333); and / or (al) A bispecific polypeptide according to any one of the preceding claims, comprising the three CDRs of the heavy chain and / or the three CDRs of the light chain of the antibody Fab11 (SEQ ID NOs: 277, 278, and 279, or 309, 310, and 279, and / or SEQ ID NOs: 324, 325, and 334).
54. Binding domain B2 is (a) the heavy chain variable region and / or the light chain variable region of antibody AC_05059 (SEQ ID NO: 33 and / or SEQ ID NO: 31) (b) the heavy chain variable region and / or the light chain variable region of antibody AC_05060 (SEQ ID NO: 37 and / or SEQ ID NO: 35) (c) the heavy chain variable region and / or the light chain variable region of antibody AC_05061 (SEQ ID NO: 41 and / or SEQ ID NO: 39) (d) the heavy chain variable region and / or light chain variable region of antibody AC_05062 (SEQ ID NO: 45 and / or SEQ ID NO: 43) (e) the heavy chain variable region and / or the light chain variable region of antibody AC_05064 (SEQ ID NO: 49 and / or SEQ ID NO: 47) (f) the heavy chain variable region and / or light chain variable region of antibody AC_05079 (SEQ ID NO: 53 and / or SEQ ID NO: 51) (g) the heavy chain variable region and / or the light chain variable region of antibody AC_05080 (SEQ ID NO: 57 and / or SEQ ID NO: 55) (h) the heavy chain variable region and / or the light chain variable region of antibody AC_05081 (SEQ ID NO: 61 and / or SEQ ID NO: 59) (i) the heavy chain variable region and / or the light chain variable region of antibody AC_05082 (SEQ ID NO: 65 and / or SEQ ID NO: 63) (j) the heavy chain variable region and / or the light chain variable region of antibody AC_05083 (SEQ ID NO: 69 and / or SEQ ID NO: 67) (k) the heavy chain variable region and / or light chain variable region of antibody AC_05084 (SEQ ID NO: 106 and / or SEQ ID NO: 71) (l) the heavy chain variable region and / or light chain variable region of antibody AC_05085 (SEQ ID NO: 110 and / or SEQ ID NO: 108) (m) the heavy chain variable region and / or light chain variable region of antibody AC_05086 (SEQ ID NO: 114 and / or SEQ ID NO: 112) (n) the heavy chain variable region and / or light chain variable region of antibody AC_05087 (SEQ ID NO: 118 and / or SEQ ID NO: 116) (o) the heavy chain variable region and / or the light chain variable region of antibody AC_05088 (SEQ ID NO: 122 and / or SEQ ID NO: 120) (p) the heavy chain variable region and / or light chain variable region of antibody AC_05089 (SEQ ID NO: 126 and / or SEQ ID NO: 124) (q) the heavy chain variable region and / or light chain variable region of antibody AC_05090 (SEQ ID NO: 130 and / or SEQ ID NO: 128) (r) the heavy chain variable region and / or light chain variable region of antibody AC_05091 (SEQ ID NO: 134 and / or SEQ ID NO: 132) (s) the heavy chain variable region and / or light chain variable region of antibody AC_05092 (SEQ ID NO: 138 and / or SEQ ID NO: 136) (t) the heavy chain variable region and / or light chain variable region of antibody AC_05093 (SEQ ID NO: 142 and / or SEQ ID NO: 140) (u) the heavy chain variable region and / or light chain variable region of antibody AC_05094 (SEQ ID NO: 146 and / or SEQ ID NO: 144) (v) the heavy chain variable region and / or light chain variable region of antibody AC_05095 (SEQ ID NO: 150 and / or SEQ ID NO: 148) (w) the heavy chain variable region and / or light chain variable region of antibody AC_05096 (SEQ ID NO: 154 and / or SEQ ID NO: 152) (x) the heavy chain variable region and / or light chain variable region of antibody AC_05097 (SEQ ID NO: 158 and / or SEQ ID NO: 156) (y) the heavy chain variable region and / or light chain variable region of antibody AC_05098 (SEQ ID NO: 162 and / or SEQ ID NO: 160) (z) the heavy chain variable region and / or light chain variable region of antibody AC_05099 (SEQ ID NO: 166 and / or SEQ ID NO: 164) (aa) heavy chain variable region and / or light chain variable region of antibody AC_05100 (SEQ ID NO: 170 and / or SEQ ID NO: 168) (ab) heavy chain variable region and / or light chain variable region of antibody Fab1 (SEQ ID NO: 174 and / or SEQ ID NO: 172) (ac) the heavy chain variable region and / or light chain variable region of antibody Fab2 (SEQ ID NO: 178 and / or SEQ ID NO: 176) (ad) the heavy chain variable region and / or light chain variable region of antibody Fab3 (SEQ ID NO: 182 and / or SEQ ID NO: 180) (ae) the heavy chain variable region and / or light chain variable region of antibody Fab4 (SEQ ID NO: 186 and / or SEQ ID NO: 184) (af) the heavy chain variable region and / or the light chain variable region of antibody Fab5 (SEQ ID NO: 190 and / or SEQ ID NO: 188) (ag) heavy chain variable region and / or light chain variable region of antibody Fab6 (SEQ ID NO: 194 and / or SEQ ID NO: 192) (ah) the heavy chain variable region and / or light chain variable region of antibody Fab7 (SEQ ID NO: 198 and / or SEQ ID NO: 196) (ai) the heavy chain variable region and / or light chain variable region of antibody Fab8 (SEQ ID NO: 202 and / or SEQ ID NO: 200) (aj) the heavy chain variable region and / or the light chain variable region of antibody Fab9 (SEQ ID NO: 206 and / or SEQ ID NO: 204) (ak) the heavy chain variable region and / or light chain variable region of antibody Fab10 (SEQ ID NO: 210 and / or SEQ ID NO: 208) (a1) the heavy chain variable region and / or the light chain variable region of antibody Fab11 (SEQ ID NO: 214 and / or SEQ ID NO: 212) (am) the heavy chain variable region and / or the light chain variable region of the antibody mAb2 (SEQ ID NO: 387 and / or SEQ ID NO: 385); and / or (an) The bispecific polypeptide of any one of the preceding claims, comprising the heavy chain variable region and / or the light chain variable region of antibody ffAC_05337 (SEQ ID NO: 433 and / or SEQ ID NO: 432).
55. Binding domain B2 is (a) the light chain and / or the heavy chain of antibody AC_05059 (SEQ ID NO: 388 and / or SEQ ID NO: 389) (b) the light chain and / or the heavy chain of antibody AC_05060 (SEQ ID NO: 390 and / or SEQ ID NO: 391) (c) the light chain and / or the heavy chain of antibody AC_05061 (SEQ ID NO: 392 and / or (SEQ ID NO: 393) (d) the light chain and / or the heavy chain of antibody AC_05062 (SEQ ID NO: 394 and / or SEQ ID NO: 395) (e) the light chain and / or the heavy chain of antibody AC_05064 (SEQ ID NO: 396 and / or SEQ ID NO: 397) (f) the light chain and / or the heavy chain of antibody AC_05079 (SEQ ID NO: 398 and / or SEQ ID NO: 399) (g) the light chain and / or the heavy chain of antibody AC_05081 (SEQ ID NO: 400 and / or SEQ ID NO: 401) (h) the light chain and / or the heavy chain of antibody AC_05088 (SEQ ID NO: 402 and / or SEQ ID NO: 403) (i) the light chain and / or the heavy chain of antibody AC_05089 (SEQ ID NO: 404 and / or SEQ ID NO: 405) (j) the light chain and / or the heavy chain of antibody AC_05090 (SEQ ID NO: 406 and / or SEQ ID NO: 407) (k) the light chain and / or the heavy chain of antibody AC_05091 (SEQ ID NO: 408 and / or SEQ ID NO: 409) (l) light chain and / or heavy chain of antibody AC_05093 (SEQ ID NO: 410 and / or SEQ ID NO: 411) (m) the light chain and / or the heavy chain of antibody AC_05094 (SEQ ID NO: 412 and / or SEQ ID NO: 413) (n) the light chain and / or the heavy chain of antibody AC_05096 (SEQ ID NO: 414 and / or SEQ ID NO: 415) (o) the light chain and / or the heavy chain of antibody AC_05097 (SEQ ID NO: 416 and / or SEQ ID NO: 417) (p) the light chain and / or the heavy chain of the antibody Fab1 (SEQ ID NO: 418 and / or SEQ ID NO: 419) (q) the bispecific polypeptide of any one of the preceding claims, comprising a light chain and / or a heavy chain of the antibody Fab3 (SEQ ID NO: 420 and / or (SEQ ID NO: 421).
56. The bispecific polypeptide - comprising a chain H1 comprising a sequence selected from the list consisting of SEQ ID NO: 359, SEQ ID NO: 362, SEQ ID NO: 365, and / or SEQ ID NO: 367; and / or - comprising a chain L1 comprising a sequence selected from the list consisting of SEQ ID NO: 360, SEQ ID NO: 363, SEQ ID NO: 372, and / or SEQ ID NO: 368; and / or - The bispecific polypeptide according to any one of the preceding claims, comprising chain H2 comprising a sequence selected from the list consisting of SEQ ID NO: 361, SEQ ID NO: 364, SEQ ID NO: 366, and / or SEQ ID NO:
369.
57. 57. A polypeptide comprising a binding domain designated B2 as defined in any one of claims 1 to 56, said polypeptide being capable of specifically binding to CEA.
58. 58. A bispecific polypeptide comprising a first binding domain, designated B3, capable of specifically binding to a target antigen which is not CD40, and a second binding domain, designated B2, as defined in any one of claims 1 to 57, capable of specifically binding to CEA.
59. 58. An isolated nucleic acid molecule encoding a bispecific polypeptide according to any one of claims 1 to 56 or 58, or a polypeptide according to claim 57, or their constituent polypeptide chains.
60. 60. The nucleic acid molecule of claim 59, wherein the molecule is a cDNA molecule.
61. 61. The nucleic acid molecule of claim 59 or 60, encoding an antibody heavy chain or a variable region thereof.
62. 62. The nucleic acid molecule according to any one of claims 59 to 61, encoding an antibody light chain or a variable region thereof.
63. A vector comprising a nucleic acid molecule according to any one of claims 59 to 62.
64. 64. The vector of claim 63, wherein the vector is an expression vector.
65. A recombinant host cell comprising a nucleic acid molecule according to any one of claims 59 to 62, or a vector according to claim 63 or 64.
66. 66. The host cell of claim 65, wherein the host cell is a bacterial cell.
67. 66. The host cell of claim 65, wherein the host cell is a mammalian cell.
68. 68. The host cell of claim 67, wherein the host cell is a human cell.
69. 68. A method for producing a bispecific polypeptide according to any one of claims 1 to 56 or 58, or a polypeptide according to claim 57, said method comprising culturing a host cell as defined in any one of claims 65 to 68 under conditions allowing expression of said bispecific polypeptide or its constituent polypeptide chains.
70. 60. A pharmaceutical composition comprising an effective amount of a bispecific polypeptide according to any one of claims 1 to 56 or 58, or an effective amount of the polypeptide according to claim 59, and a pharma- ceutically acceptable diluent, carrier or excipient.
71. 71. The pharmaceutical composition of claim 70 adapted for parenteral delivery.
72. 71. The pharmaceutical composition of claim 70 adapted for intravenous delivery.
73. A bispecific polypeptide according to any one of claims 1 to 56 or 58, or a polypeptide according to claim 57, for use in medicine.
74. 58. A bispecific polypeptide according to any one of claims 1 to 56 or 58, or the polypeptide according to claim 57, for use in treating cancer and / or a tumour and / or a non-cancerous condition in a subject.
75. 58. Use of a bispecific polypeptide according to any one of claims 1 to 56 or 58, or a polypeptide according to claim 57, in the preparation of a medicament for treating cancer and / or a tumour and / or a non-cancerous condition in a subject.
76. 76. The bispecific polypeptide or polypeptide for use according to claim 74, or the use according to claim 75, wherein the polypeptide is for use in combination with one or more additional therapeutic agents.
77. 77. The bispecific polypeptide or polypeptide for use according to claim 76, or the use according to claim 76, wherein the one or more additional therapeutic agents are immunotherapeutic agents that bind to a target selected from the group consisting of PD-1 / PD-L1, VGFR, EGFR, HER2, CTLA-4, CD137, OX40, GITR, LAG3, TIM3, CD27, VISTA, and KIR.
78. 78. A bispecific polypeptide or polypeptide for use according to any one of claims 74, 76 or 77, or the use according to any one of claims 75 to 77, for systemic administration.
79. 57. A method for the treatment and / or diagnosis of cancer and / or tumors and / or non-cancerous conditions in a subject, comprising the step of administering to said subject an effective amount of a bispecific polypeptide according to any one of claims 1 to 56 or 58, or a polypeptide according to claim 57.
80. 80. The method of claim 79, wherein the method comprises administering the bispecific polypeptide systemically or the polypeptide systemically.
81. 81. The method of claim 79 or 80, further comprising administering to the subject one or more additional therapeutic agents.
82. 82. The method of claim 81, wherein the one or more additional therapeutic agents are immunotherapeutic agents that bind to a target selected from the group consisting of PD-1 / PD-L1, VGFR, EGFR, HER2, CTLA-4, CD137, OX40, GITR, LAG3, TIM3, CD27, and KIR.
83. 84. The bispecific polypeptide or polypeptide for use according to any one of claims 74 or 76 to 78, the use according to any one of claims 75 to 78, or the method according to any one of claims 80 to 83, wherein the cancer and / or the tumour comprises target cells which comprise expression of CEA.
84. 84. The bispecific polypeptide or polypeptide for use according to claim 83, the use according to claim 83, or the method according to claim 83, wherein the expression of CEA is an intermediate level of CEA expression or a high level of CEA expression.
85. 85. The bispecific polypeptide or polypeptide for use according to claim 84, the use according to claim 84, or the method according to claim 84, wherein said intermediate level of CEA expression is characterized by said target cells expressing about 10,000 or more CEA receptors per target cell, preferably about 50,000 or more CEA receptors per target cell.
86. 85. The bispecific polypeptide or polypeptide for use according to claim 84, the use according to claim 84, or the method according to claim 84, wherein said high level of CEA expression is characterized by said target cells expressing more than about 200,000 CEA receptors per target cell, preferably more than about 300,000 CEA receptors per target cell.
87. 87. The bispecific polypeptide or polypeptide for use according to any one of claims 74 or 76 to 86, the use according to any one of claims 75 to 86, or the method according to any one of claims 79 to 86, wherein said cancer and / or tumor is one or more cancers and / or tumors selected from the list consisting of prostate cancer and / or prostate tumors, breast cancer and / or breast tumors, lung cancer and / or lung tumors, colorectal cancer and / or colorectal tumors, melanoma, bladder cancer and / or bladder tumors, brain / CNS cancer and / or brain / CNS tumors, cervical cancer and / or cervical tumors, esophageal cancer and / or esophageal tumors, gastric cancer and / or gastric tumors, head and neck cancer and / or head and neck tumors, renal cancer and / or renal tumors, liver cancer and / or liver tumors, carcinoma, leukemia, lymphoma, ovarian cancer and / or ovarian tumors, pancreatic cancer and / or pancreatic tumors, tonsil cancer and / or tonsil tumors, and sarcoma.
88. 88. The bispecific polypeptide or polypeptide for use according to claim 87, the use according to claim 87, or the method according to claim 87, wherein the one or more cancers and / or tumors are selected from the list consisting of breast cancer and / or breast tumors, lung cancer and / or lung tumors, colorectal cancer and / or colorectal tumors, gastric cancer and / or gastric tumors, and / or pancreatic cancer and / or pancreatic tumors.
89. 89. The bispecific polypeptide or polypeptide for use according to any one of claims 74 or 76 to 88, the use according to any one of claims 75 to 88, or the method according to any one of claims 79 to 88, wherein the tumor is a solid tumor.
90. 82. The bispecific polypeptide or polypeptide for use according to any one of claims 74 or 76 to 78, the use according to any one of claims 75 to 78, or the method according to any one of claims 79 to 82, wherein the one or more non-cancerous conditions are selected from the list consisting of ulcerative colitis, pancreatitis, cirrhosis of the liver, COPD, Crohn's disease and / or hypothyroidism.
91. 91. The bispecific polypeptide or polypeptide for use according to any one of claims 74 or 76 to 90, the use according to any one of claims 75 to 90, or the method according to any one of claims 79 to 90, wherein the subject is a human.
92. 13. A bispecific polypeptide substantially as herein described with reference to the description and drawings.
93. 2. A polypeptide substantially as herein described with reference to the description and drawings.
94. 2. A polynucleotide substantially as herein described with reference to the description and drawings.
95. 13. A pharmaceutical composition substantially as herein described with reference to the description and drawings.
96. 3. A bispecific polypeptide for use or a polypeptide for use substantially as herein described with reference to the description and drawings.
97. 23. Use of a bispecific polypeptide substantially as herein described with reference to the description and drawings.
98. 23. A method of treatment substantially as herein described with reference to the description and drawings.
Citation Information
Patent Citations
Anti-CD40 antibody, use, and method
JP2014531201A
Anti-CD40 binding molecules and bi-specific antibodies comprising such
WO2021081303A1
